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Abstract
Background: Huntington’s disease (HD) is a rare, neurodegenerative disease caused by an
expanded cytosine-adenine-guanine (CAG) sequence in the Huntingtin gene, resulting in the
production of an aberrant protein, mutant huntingtin (mHTT). The mHTT protein exhibits a
toxic loss and gain in function, leading to degeneration of neurons in the brain. Consequently,
the classic triad of motor, cognitive and mood features of the disease develop. Among the
earliest features of HD are circadian rhythm and sleep disturbances. These anomalies present
many years prior to formal clinical diagnosis of HD and, while it has been postulated that these
disturbances arise as a result of hypothalamic pathology, the neurobiological mechanisms
underpinning these sleep disturbances have not yet been robustly investigated.
The hypothalamus of the brain contains several key nuclei that are essential in maintaining
circadian rhythm and sleep/wake cycles. Hypothalamic pathology and dysregulation of
neuroendocrine factors that mediate the sleep/wake cycle have been reported in HD, as early
as the premanifest stage. It is not known however if hypothalamic pathology precedes
neuroendocrine dysregulation. Identification of mechanisms underpinning sleep and circadian
rhythm disturbances will enable the development of therapeutic strategies aimed at mitigating
sleep and circadian rhythm anomalies. To date, no therapies exist to combat pathological
changes in sleep architecture and circadian rhythm.
Evidence from mouse models of HD shows that the circadian rhythm and sleep-wake cycle are
amenable to environmental interventions, including exercise, bright light therapy and
temporally scheduled feeding. Furthermore, previous studies in HD of multidisciplinary
rehabilitation- a construct of exercise and cognitive training, along with social interaction have
been shown to increase grey matter volume in the caudate tail and dorsolateral prefrontal cortex
in manifest HD, with accompanying improvements in verbal learning and memory. It is
postulated that this intervention paradigm could also improve sleep outcomes in HD. Studies
iv

in Parkinson’s disease have shown that multidisciplinary rehabilitation improves sleep quality,
however, the effects of multidisciplinary rehabilitation on circadian rhythm and sleep outcomes
have not yet been investigated in HD and particularly not in premanifest HD when the effects
of intervention would be most beneficial.
Aims: The initial aim of this thesis was to determine, through a review of the literature, the
potential neurobiological mechanisms associated with circadian rhythm and sleep disturbances
in individuals with premanifest HD. This was used to inform the next study, which was to
determine whether hypothalamic pathology was associated with circadian rhythm and habitual
sleep disturbances in individuals with premanifest HD. The next aim was to then determine if
nine-months of multidisciplinary rehabilitation could impact on circadian rhythm and habitual
sleep outcomes and associated hypothalamic volume in individuals with premanifest HD. The
aim of the final study was to explore the effects of a nine-month multidisciplinary rehabilitation
program on sleep architecture in individuals with premanifest HD.
Methods: For the study presented in Chapter 3 (aim 2), 32 individuals with premanifest HD
and 29 healthy age- and gender-matched controls underwent magnetic resonance imaging scans
to evaluate hypothalamic volume. Circadian rhythm and habitual sleep were assessed via
measurement of morning and evening cortisol and melatonin levels, wrist-worn actigraphy, the
Consensus Sleep Diary and sleep questionnaires. Information on mood, physical activity levels
and body composition were also collected.
In the study presented in Chapter 4 (aim 3) 18 individuals with HD (ten premanifest and eight
prodromal) undertook a nine-month multidisciplinary rehabilitation intervention (intervention
group) and were compared to a community sample of 11 individuals with premanifest HD
receiving standard care (control group). Hypothalamic volume, blood-based BDNF, salivary
cortisol and melatonin concentrations, subjective sleep quality, daytime somnolence, habitual
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sleep-wake patterns and stress, anxiety and depression symptomatology were all evaluated
prior to and following the intervention. Sixteen of these individuals also underwent
polysomnography and sleep-dependent memory consolidation prior to and following the ninemonth intervention to assess sleep architecture and sleep-dependent memory consolidation
(Chapters 4 and 5).
Results: Here in Chapter 2, a review of the literature revealed the hypothalamus as a potential
modulator of circadian rhythm and sleep disturbances in HD. Chapter 3 shows that
hypothalamic grey matter volume in premanifest HD individuals is reduced compared to ageand gender-matched healthy controls. We also observed reduced sleep quality and an increased
number of awakenings in premanifest HD individuals compared to healthy controls. Contrary
to expectation, there were no strong associations between sleep outcomes and hypothalamic
volume. There were, however, differences in the associations between hypothalamic volume
and neuroendocrine factors in premanifest HD individuals compared to healthy controls.
Following nine months of multidisciplinary rehabilitation, a reduced rate of loss of grey matter
volume in the hypothalamus was observed in the premanifest HD intervention group compared
to the premanifest HD standard care group (Chapter 4). This was accompanied by a
maintenance of brain-derived neurotrophic factor (BDNF) levels in the intervention compared
to the control group. No robust changes were observed in the release of circadian-regulated
hormones or in habitual sleep outcomes; however, exploratory data revealed changes in sleep
architecture, particularly in REM percentage and latency, following the nine-month
intervention (Chapter 5).
Conclusion: Data presented in this thesis suggests that, although hypothalamic volume is
reduced in individuals with premanifest HD, circadian rhythm is maintained, perhaps via neural
compensation. Moreover, we provide, for the first time, preliminary data suggesting that
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multidisciplinary rehabilitation is useful in reducing the loss of volume of the hypothalamus
and, while no robust effects on circadian rhythm were observed, improvements in sleep
architecture were observed in individuals with premanifest HD. Further randomised controlled
studies in a larger cohort of individuals with premanifest and manifest HD are required to
confirm and extend on these preliminary findings.

vii

Acknowledgements
First and foremost, I would like to thank my supervisors, Mel and Travis. Thank you for
believing in me and for your ongoing support, guidance and friendship over the years. You
have taught me many invaluable lessons and provided me with the opportunity to accomplish
such a great achievement and for that, I am sincerely thankful.
To the study participants, who have taught me the true meaning of commitment and
determination. Thank you for placing your trust in us- without you, the research presented in
this thesis would not have been possible.
To the members of the ECU Huntington’s disease and Melanoma Research teams, the staff at
ECU and my office buddies, thank you for your help and friendship over the years and for
making it an enjoyable experience to come into work every day. To our many collaborators,
thank you for your continued guidance and advice.
To my friends, Pauline, Leslie, Travis, Aaron, Dani and Charlene, thank you for your
understanding and continued support and for sticking around when things got tough.
Finally, to my family. Tim, Mum, Dad, Ashleigh, Matt, Mitchell, Nanna, Grandad, Aunty Liz,
Uncle Jon, Kath, Iain, Alison and the rest of my extended family, words cannot describe how
much your unconditional love, support and understanding helped me throughout this process.
Tim, thank you for putting up with me through the bad times, as well as the good, and for your
unwavering patience, love and support.

viii

This thesis is submitted as a series of papers.
As a result of the work performed for this thesis, one paper has been published, one paper
has been accepted for publication and two papers are ready for submission for publication:

Neuroendocrine and Neurotrophic Signaling in Huntington’s Disease: Implications for
Pathogenic Mechanisms and Treatment Strategies
Danielle M. Bartlett, Travis M. Cruickshank, Anthony J. Hannan, Peter R. Eastwood, Alpar
S. Lazar, Mel R. Ziman.
Published: Neuroscience and Biobehavioral Reviews, 2016, Volume 71, Pages 444-454.

Mechanisms Associated with Sleep Disturbances in Premanifest Huntington’s Disease
Danielle M. Bartlett*, Juan F. Domínguez D*, Alvaro Reyes, Pauline Zaenker, Kirk W.
Feindel, Robert U. Newton, Anthony J. Hannan, James A. Slater, Peter R. Eastwood, Alpar S.
Lazar, Mel Ziman, Travis Cruickshank.
*Danielle M. Bartlett and Juan F. Dominguez D contributed equally to the manuscript
Published: Neurobiology of Sleep and Circadian Rhythms

Multidisciplinary Rehabilitation Reduces Hypothalamic Grey Matter Volume Loss in
Individuals with Premanifest Huntington’s Disease: An Exploratory Study
Danielle Bartlett, Juan Dominguez, Alpar Lazar, Catarina Kordsachia, Tim Rankin, Brian
Power, Amit Lampit, Peter Eastwood, Travis Cruickshank, Mel Ziman.

ix

The Effects of Multidisciplinary Rehabilitation on Sleep and Sleep-Dependent Memory
Consolidation Outcomes in Individuals with Premanifest Huntington’s Disease: An
Exploratory Study
Danielle Bartlett, Juan F. Dominguez D, Kathleen Maddison, Robert Newton, Peter
Eastwood, Alpar Lazar, Govinda Poudel, Mel Ziman, Travis Cruickshank.

x

Statement of Contribution Towards Publications
While this thesis was part of a larger research program, the project presented herein was devised
by me in collaboration with my supervisors specifically for this thesis. For the article presented
in Chapter 2, I conceptualised, wrote and edited the manuscript with the assistance of the coauthors. For the article presented in Chapter 3, and for which I am equal first author, I
contributed to the study design. I collected all the samples and I performed all the biochemical
measures and analyses of results for all salivary samples. I also collected and analysed all of
the actigraphy and sleep, mood and physical activity questionnaires. Dr Juan Dominguez, who
is equal first author on this manuscript, was responsible for analysing brain images and running
association analyses between hypothalamic volume and cortisol, melatonin and sleep
outcomes. For the study presented in Chapters 4, I contributed to the study design, I collected
all the blood samples and I performed all the biochemical analyses of salivary and blood
samples. I collected and analysed all of the sleep, mood and physical activity questionnaires
and I played a key role in the delivery of the cognitive training component of the nine-month
intervention. For the study presented in Chapter 5, I conducted the cognitive training
component of the nine-month intervention, I collected data for memory consolidation analysis
and I completed the statistical analyses of the sleep and memory consolidation data. I wrote all
manuscripts presented in this thesis and edited each manuscript with assistance from coauthors.

xi

Table of Contents
Use of Thesis..............................................................................................................................ii
Declaration ............................................................................................................................... iii
Abstract ..................................................................................................................................... iv
Acknowledgements ................................................................................................................ viii
Statement of Contribution Towards Publications ..................................................................... xi
List of Figures .......................................................................................................................... xv
List of Tables .......................................................................................................................... xvi
List of Abbreviations .............................................................................................................xvii
Chapter 1 .................................................................................................................................... 1
General Introduction .............................................................................................................. 1
1.1 Overview ...................................................................................................................... 1
1.2 The Genetics of Huntington’s Disease ......................................................................... 1
1.3 Features of Huntington’s Disease ................................................................................. 2
1.4 The Hypothalamus ........................................................................................................ 4
1.5 The Role of Sleep ......................................................................................................... 6
1.6 The Regulation of the Circadian Rhythm and Sleep/Wake Cycle ............................... 8
1.7 The Circadian Regulation of Cortisol and Melatonin ................................................ 14
1.8 Circadian Rhythm and Sleep Disturbances in HD ..................................................... 19
1.9 The Pathological Effects of Sleep and Circadian Rhythm Disturbances in Huntington’s
Disease .............................................................................................................................. 20
1.10 Potential Pathological Mechanisms Underpinning Sleep Disturbances in
Huntington’s Disease ........................................................................................................ 22
1.11 Therapies for Huntington’s Disease ......................................................................... 22
1.12 Multidisciplinary Rehabilitation as a Non-Pharmaceutical Strategy for Sleep and
Circadian Rhythm Disturbances ....................................................................................... 25
1.13 Theoretical Framework.......................................................................................... 27
1.14 Hypothesis and Aims ............................................................................................. 29
Chapter 2 .................................................................................................................................. 30
Neuroendocrine and Neurotrophic Signaling in Huntington’s Disease: Implications for
Pathogenic Mechanisms and Treatment Strategies .............................................................. 30
2.1 Abstract ....................................................................................................................... 31
2.2 Introduction ................................................................................................................ 31
2.3 Normal Function of the HPA-Axis and the SCN ....................................................... 34
2.4 Stress and the Role of Cortisol ................................................................................... 37
2.5 Pathological Effects of Chronic Glucocorticoid Release ........................................... 38
xii

2.6 Effects of Glucocorticoids on BDNF ......................................................................... 39
2.7 Pathologies of the HPA-Axis and SCN in HD ........................................................... 40
2.8 Circadian Rhythm Disruption in HD .......................................................................... 41
2.9 Melatonin and Sleep Disturbance in HD .................................................................... 43
2.10 Environmental Enrichment: A Comprehensive Non-Pharmaceutical Strategy to
Reduce the Impact of Circadian Rhythm Disturbances and HPA-Axis Dysfunction in HD
.......................................................................................................................................... 45
2.11 Effects of Multidisciplinary Therapy on Brain Volume and Potential Biomarkers of
HD in Humans .................................................................................................................. 48
2.12 Conclusion ................................................................................................................ 51
2.13 Acknowledgements .................................................................................................. 51
Chapter 3 .................................................................................................................................. 52
Mechanisms Associated with Sleep Disturbances in Premanifest Huntington’s Disease ... 52
3.1 Abstract ....................................................................................................................... 53
3.2 Introduction ................................................................................................................ 54
3.3 Materials and Methods ............................................................................................... 55
3.4 Results ........................................................................................................................ 60
3.5 Discussion ................................................................................................................... 67
3.6 Acknowledgements .................................................................................................... 72
3.7 Sources of Funding ..................................................................................................... 72
3.8 Conflicts of Interest .................................................................................................... 72
3.9 Author Contributions .................................................................................................. 72
3.10 Supplementary Data ................................................................................................. 73
Chapter 4 .................................................................................................................................. 82
Multidisciplinary Rehabilitation Reduces Hypothalamic Grey Matter Volume Loss in
Individuals with Premanifest Huntington’s Disease: An Exploratory Study ....................... 82
4.1 Abstract ....................................................................................................................... 83
4.2 Introduction ................................................................................................................ 84
4.3 Materials and Methods ............................................................................................... 86
4.4 Results ........................................................................................................................ 91
4.5 Discussion ................................................................................................................... 99
4.6 Supplementary Data ................................................................................................. 103
Chapter 5 ................................................................................................................................ 107
The Effects of Multidisciplinary Rehabilitation on Sleep and Sleep-Dependent Memory
Consolidation Outcomes in Individuals with Premanifest Huntington’s Disease: An
Exploratory Study .............................................................................................................. 107
xiii

5.1 Abstract ..................................................................................................................... 108
5.2 Introduction .............................................................................................................. 109
5.3 Materials and Methods ............................................................................................. 110
5.4 Results ...................................................................................................................... 112
5.5 Discussion ................................................................................................................. 115
Chapter 6 ................................................................................................................................ 118
6.1 General Discussion ....................................................................................................... 118
6.2 Future Directions .......................................................................................................... 126
6.3 Conclusion.................................................................................................................... 129
References .............................................................................................................................. 130
Appendix 1: Information Letter and Consent Form for Individuals with HD ....................... 157
Appendix 2: Information Letter and Consent Form for Healthy Controls ............................ 168
Appendix 3: Salivary Sampling Instructions for Participants................................................ 174
Appendix 4: Saliva Sampling Questionnaire ......................................................................... 180

xiv

List of Figures
Figure 1.1. Organisation of the hypothalamus. .......................................................................... 5
Figure 1.2. The neurological circuitry of the circadian system. ................................................ 9
Figure 1.3. The components of the ascending arousal system involved in the maintenance of
wakefulness. ............................................................................................................................. 12
Figure 1.4. The hypothalamic-pituitary-adrenal (HPA) axis. .................................................. 16
Figure 1.5. The neural pathway of melatonin release. ............................................................. 18
Figure 2.1. The interrelated consequences of HPA-axis and circadian rhythm disruption on
BDNF expression and sleep and the implications on neurobiology. ....................................... 35
Figure 3.1. Hypothalamic volume in its association with cortisol and melatonin output. ....... 61
Figure S3.2. Hypothalamus mask (in red). Slice labels are displayed on top. L, left .............. 75
Figure S3.3. Volume measurements for three participants scanned twice at each site. .......... 76
Figure S3.4. Average within and between sites differences across volume measurements. ... 77
Figure S3.5. VBM analysis of striatal grey matter volume ..................................................... 78
Figure 4.1. Effects of nine months of multidisciplinary therapy on hypothalamic grey matter
(GM) volume. .......................................................................................................................... 93

xv

List of Tables
Table 1.1. Frequencies, waveforms and characteristics of stages of sleep. ............................ 10
Table 2.1. Summary of HD pathologies relevant to this review article .................................. 33
Table 3.1. Demographic and clinical characteristics of premanifest Huntington’s disease and
healthy control participants. ..................................................................................................... 63
Table 3.2. Cortisol and melatonin values, subjective and objective sleep outcomes and stress,
anxiety and depression questionnaire scores for premanifest Huntington’s disease and healthy
control participants................................................................................................................... 65
Table 3.3. Association analyses between hypothalamic volume and CAPs, cortisol and
melatonin.................................................................................................................................. 67
Table 4.1. Demographic and clinical characteristics of premanifest plus prodromal HD
intervention group and control group at baseline .................................................................... 92
Table 4.2. Results from voxel-based morphometry analysis. ................................................. 93
Table 4.3. Mean salivary cortisol and melatonin concentrations, subjective sleep outcomes and
affective symptomatology outcomes in the premanifest HD intervention and control groups.
.................................................................................................................................................. 95
Table S4.4. Demographic and clinical characteristics of premanifest HD and prodromal HD
intervention groups and premanifest HD control group at baseline ...................................... 104
Table S4.5. Mean salivary cortisol and melatonin concentrations, subjective sleep outcomes
................................................................................................................................................ 105
Table S4.6. Results from voxel-based morphometry analysis. ............................................. 106
Table 5.1. Demographic and clinical characteristics of premanifest HD participants (n=16)
................................................................................................................................................ 113
Table 5.2. Sleep and memory consolidation outcomes following a nine-month
multidisciplinary rehabilitation intervention (n=16). ............................................................. 114

xvi

List of Abbreviations
AUCG

Area under the curve with respect to ground

BDNF

Brain-derived neurotrophic factor

BMI

Body mass index

CAG

Cytosine-adenine-guanine

CAPs

Cytosine-adenine-guanine age product score

CSD

Consensus Sleep Diary

DARTEL

Diffeomorphic Anatomical Registration through Exponentiated Lie

DBS

Disease burden score

EEG

Electroencephalography

ELISA

Enzyme-linked immunosorbent assay

ESS

Epworth Sleepiness Scale

HADS

Hospital anxiety and depression scale

HD

Huntington’s disease

HPA

Hypothalamic-pituitary-adrenal

MET

Metabolic equivalents

MNI

Montreal Neurological Institute

MRI

Magnetic resonance imaging

NREM

Non-rapid eye movement

PET

Positron emission tomography
xvii

PLM

Periodic limb movement

PQSI

Pittsburgh Sleep Quality Index

PSG

Polysomnography

PSS

Perceived Stress Scale

REM

Rapid eye movement

RMR

Resting metabolic rate

SCN

Suprachiasmatic nucleus

SOL

Sleep onset latency

SWS

Slow wave sleep

TIB

Time in bed

TST

Total sleep time

UHDRS-TMS

Unified Huntington’s Disease Rating Scale-Total Motor Score

WASO

Wake after sleep onset

xviii

Chapter 1
General Introduction
1.1 Overview
Huntington’s disease (HD) is a rare, progressive neurodegenerative disorder affecting 2.71 per
100,000 people worldwide (Pringsheim et al., 2012). The classic triad of features by which the
disease is clinically diagnosed include motor impairment, cognitive dysfunction and mood
disturbances (Bates et al., 2015). However, it is becoming increasingly evident that sleep and
circadian rhythm disturbances are common and debilitating features that present early in the
disease process and progressively worsen as the disease course lengthens (Lazar et al., 2015;
Morton, 2013; Morton et al., 2005). Sleep disturbances have the potential to exacerbate the
severity of clinical features of the disease and hasten neurodegeneration (Musiek & Holtzman,
2016; Wulff, Gatti, Wettstein, & Foster, 2010). It is therefore pivotal to understand the
mechanisms underpinning sleep and circadian rhythm disturbances in HD in order to develop
suitable therapeutic strategies.
1.2 The Genetics of Huntington’s Disease
George Huntington was the first to officially describe the inheritance pattern of HD in his first
and only publication (Huntington, 1872). The account of the inheritance pattern of “hereditary
chorea”, as it was termed, was vividly described as autosomal dominant. Despite this
description, it was not until 1993 that the causative gene region for HD was identified on
chromosome 4p16.3 (The Huntington's Disease Collaborative Research Group, 1993). It was
discovered that the mutant variant of the HTT gene, termed mutant huntingtin (mHTT),
contained an expanded cytosine-adenine-guanine (CAG) repeat sequence in exon 1, translating
to an aberrant protein. Identification of the disease causing gene has allowed for genetic testing
to determine if an individual will indeed develop HD based on the number of CAG repeats
(CAGn). For example, an individual possessing less than 36 CAG repeats will not develop HD,
1

whereas an individual with greater than 40 CAG repeats will show near complete penetrance
and will develop HD within their lifespan (Kremer et al., 1994). Individuals with 36 to 39 CAG
repeats exhibit incomplete penetrance and may or may not develop HD later in life (Brinkman,
Mezei, Theilmann, Almqvist, & Hayden, 1997; Rubinsztein et al., 1996). Although individuals
with 27 to 35 CAG repeats are themselves unaffected, genetic anticipation can result in these
individuals passing in excess of 35 CAG repeats on to their offspring and consequently, these
offspring will be at risk of developing HD (Ranen et al., 1995).
A relationship has been identified between the number of CAG repeats and the age at onset of
HD, with the number of CAG repeats accounting for 47% to 72% of variability in the age at
onset (Andrew et al., 1993; Brinkman et al., 1997; Craufurd & Dodge, 1993; Lee et al., 2012;
Ranen et al., 1995; Rosenblatt et al., 2001). Of the remainder of the variability in age of onset,
environmental factors have been suggested to account for 60%, with several studies, including
those on HD gene positive monozygotic twins, identifying lifestyle as a key factor (BonnerJackson et al., 2013; Trembath et al., 2010; Wexler & The US–Venezuela Collaborative
Research Project, 2004). Identification of the disease-causing gene has also allowed for the
development of the CAG-age product score (CAP score) quotient (Zhang et al., 2011), which
is a product of the individual’s CAG repeat number and age and allows for classification of
individuals based on estimated proximity to diagnosis of manifest disease, indicated by onset
of motor features.
1.3 Features of Huntington’s Disease
The classic triad of clinical HD features include motor, cognitive and mood disturbances. HD
gene carriers typically transition from asymptomatic, to displaying subtle clinical signs
(premanifest HD), to overt progressive extrapyramidal motor signs of HD (manifest HD)
(Bates et al., 2015). Although cognitive and mood features typically arise during the
premanifest stage, diagnosis of manifest disease is based on the presence of unmistakable
2

extrapyramidal motor signs identified by a qualified clinician using the Unified Huntington’s
Disease Rating Scale (UHDRS) (The Huntington Study Group, 1996).
Progressive neuronal dysfunction and death are thought to give rise to the clinical features of
HD. The exact cause of neuronal degeneration in HD is not known; however, a myriad of
cellular processes have been implicated. The huntingtin protein is vital in transcription
regulation, protein trafficking, vesicle transport, post-synaptic signalling and apoptosis (Gil &
Rego, 2008). Expression of the mutated huntingtin protein results in a loss of normal function,
as well as a potential gain in toxic function, including excitotoxicity, mitochondrial
dysfunction, metabolic impairment, oxidative stress and autophagy (Guedes-Dias et al., 2016;
Schapira, Olanow, Greenamyre, & Bezard, 2014). The loss of normal function and toxic gain
in function of the protein is thought to lead to the early, selective loss of GABAergic medium
spiny neurons that is observed in the striatum of HD gene-positive individuals, with greater
loss of cortical neurons and interneurons occurring as the disease progresses (Aylward et al.,
1997; de la Monte, Vonsattel, & Richardson, 1988; Kim et al., 2014; Tabrizi et al., 2012;
Thieben et al., 2002; Thu et al., 2010). These microscopic changes are evident at the
macroscopic level using magnetic resonance imaging (MRI). Neuroimaging studies have
shown significant levels of atrophy of the caudate and putamen, areas which play vital roles in
learning and memory, planning and the regulation of voluntary motor movements, in
individuals with premanifest HD (Domínguez D et al., 2013; Georgiou-Karistianis et al., 2013;
Tabrizi et al., 2011; van den Bogaard et al., 2011). Several studies have reported the rates of
caudate and putamen atrophy to be 1.1% to 2.4% and 2.3% per year, respectively, in
premanifest HD individuals compared to healthy controls (Aylward et al., 2000; Hobbs et al.,
2009; Tabrizi et al., 2011; Weir, Sturrock, & Leavitt, 2011).
These neuropathological changes give rise to the motor, cognitive and mood features observed
in HD. Motor disturbances in HD manifest as involuntary movements, such as chorea, and loss
3

of control of voluntary movements, leading to problems with balance, mobility, speech and
swallowing. In some individuals however, cognitive and mood disturbances occur prior to the
onset of overt motor features (Roos, 2010). Individuals with HD have a predominant reduction
in capacity for memory storage, encoding of verbal learning, cognitive flexibility, processing
speed, planning and problem solving and attention, as well as impairments in social cognition,
which arise as early as nine to fifteen years before clinical diagnosis of HD (during the
premanifest stages) and worsen as the disease progresses (Eddy & Rickards, 2015; Lemiere,
Decruyenaere, Evers-Kiebooms, Vandenbussche, & Dom, 2004; Lundervold, Reinvang, &
Lundervold, 1994; Massman, Delis, Butters, Levin, & Salmon, 1990; Robins Wahlin, Lundin,
& Dear, 2007; Rosenberg, Sorensen, & Christensen, 1995; Stout et al., 2011). In addition,
premanifest HD individuals also experience neuropsychiatric changes, such as anxiety,
depression, irritability and apathy. Beyond the classic triad of clinical features, it is becoming
increasingly evident that individuals with HD suffer from circadian rhythm and sleep
disturbances, presumably as result of hypothalamic degeneration (Petersén et al., 2005; Politis
et al., 2008; Soneson et al., 2010).
1.4 The Hypothalamus
The hypothalamus is located below the thalamus within the diencephalon of the brain. It is
bound by the optic chiasm in the anterior, the optic tracts laterally and the mammillary body
posteriorly (Figure 1.1). The hypothalamus contains distinct nuclei arranged in three
longitudinally oriented regions: the preoptic area, the tuberal hypothalamus and the posterior
hypothalamus (Saper & Lowell, 2014). Each of these areas contains specific nuclei that mediate
endocrine, autonomic and behavioural functions.
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Figure 1.1. Organisation of the hypothalamus.
The hypothalamus contains distinct nuclei that are vital in endocrine, autonomic and
behavioural functions, including circadian rhythm, sleep/wake regulation,
thermoregulation, metabolism, feeding and sexual behaviour (image adapted from
Kelly (2016)).

The preoptic area of the hypothalamus contains the suprachiasmatic nucleus (SCN) and the
ventrolateral and median preoptic nuclei (Saper & Lowell, 2014). The SCN and ventrolateral
preoptic nucleus are responsible for the neural regulation of the circadian rhythm and
sleep/wake cycle, respectively, while the median preoptic nucleus regulates body fluid
electrolyte balance and temperature though the release of vasopressin (antidiuretic hormone;
ADH) (Boulant, 2000).
The tuberal hypothalamus contains the paraventricular nucleus (PVN), lateral hypothalamic
area, dorsomedial and ventromedial nuclei, supraoptic nucleus and arcuate nucleus. The PVN
contains sub-divisions of parvocellular and mangocellular neurons. Parvocellular neurons
express corticotropin-releasing factor (CRF), which initiates the cascade leading to the release
of cortisol (see Section 1.7.1), while magnocellular neurons secrete oxytocin or vasopressin.
The dorsomedial nucleus is also responsible for regulating the circadian rhythm, while also
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functioning alongside the lateral hypothalamic area, ventromedial nucleus and arcuate nucleus
to regulate food intake and body weight through the actions of neuropeptide Y (Ahima &
Antwi, 2008).
The posterior hypothalamus consists of the posterior hypothalamic nucleus and the
tuberomammillary and supramammillary bodies. The posterior hypothalamic nucleus
maintains wakefulness through the release of orexin following innervation by the SCN
(Abrahamson, Leak, & Moore, 2001). The tubero- and supramammillary bodies are also
involved in the maintenance of wakefulness, predominantly through histaminergic and
glutamatergic innervation of the cerebral cortex, basal forebrain and hippocampus, promoting
arousal (Blandina, Munari, Provensi, & Passani, 2012; Pedersen et al., 2017; Saper & Lowell,
2014).
Given its multi-faceted role in the regulation of circadian rhythm and the sleep/wake cycle,
pathological changes in the hypothalamus have been suggested to drive the disruption of the
circadian rhythm and sleep/wake changes in individuals with HD. Emerging evidence suggests
that detectable changes in the hypothalamus (Politis et al., 2008; Soneson et al., 2010) and
circadian rhythm and sleep disturbances arise prior to the manifestation of motor, cognitive
and mood disturbances. Changes in circadian rhythm and the sleep/wake cycle have been
purported to exacerbate the clinical severity of the disease and accelerate neurodegeneration
(Musiek & Holtzman, 2016; Wulff et al., 2010).
1.5 The Role of Sleep
A lack of consensus exists on the function of sleep (Krueger, Frank, Wisor, & Roy, 2016).
However, sleep is theorised to play a pivotal role in several physiological processes, including
memory consolidation, neural development and plasticity, repletion of energy and clearance of
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toxins and cellular waste products (Krueger et al., 2016; Schmidt, 2014; Telzer, Goldenberg,
Fuligni, Lieberman, & Gálvan, 2015; Tononi & Cirelli, 2014).
Sleep has been suggested to facilitate learning and memory, particularly procedural memories
such as skill acquisition, via modulation of long term potentiation (Hobson & Pace-Schott,
2002; Stickgold, LaTanya, & Hobson, 2000). For example, improvements following training
on a motor sequence task, motor adaptation task and visual texture discrimination task have
been observed in individuals following a night of sleep, but not following a wake period of
equal duration (Fischer, Hallschmid, Elsner, & Born, 2002; Huber, Ghilardi, Massimini, &
Tononi, 2004; Walker, Brakefield, Morgan, Hobson, & Stickgold, 2002). Furthermore,
individuals with partial or total sleep deprivation did not experience the same improvements,
indicating that sleep is essential for the reinforcement of memories.
Sleep has been reported to be a vital mediator of the clearance of metabolites from the brain.
Clearance of metabolites from the brain during sleep has been demonstrated to be defective in
Alzheimer’s disease mouse models, suggesting an involvement of sleep in the maintenance of
metabolic homeostasis by removal of potential neurotoxins (Xie et al., 2013).
Disruption of sleep has considerable consequences, both short- and long-term. In the shortterm, sleep disruption results in increased responsivity to stress, mood disturbances, emotional
distress and deficits in cognition and memory. Long-term adverse effects of sleep disruption
include metabolic syndrome, hypertension and cardiovascular disease and dyslipidaemia
(Cedernaes, Schioth, & Benedict, 2015; McCoy & Strecker, 2011; Medic, Wille, & Hemels,
2017; Meisinger, Heier, Löwel, Schneider, & Döring, 2007). Given that sleep quality and
architecture have been shown to be perturbed in HD, it is possible that sleep disturbances could
exacerbate the cognitive, motor and mood features of the disease. Furthermore, disturbances in
sleep may impair metabolite removal and energy repletion processes in the brain, further
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contributing to neurodegenerative processes in HD. It is therefore necessary to understand the
pathological mechanisms underpinning these changes in order to develop therapies aimed at
ameliorating these changes to reduce the impact of the disease.

1.6 Regulation of the Circadian Rhythm and Sleep/Wake Cycle
1.6.1 The Regulation of the Circadian Rhythm
The hypothalamus contains several key nuclei that are central to regulating the circadian
rhythm and sleep/wake cycles (Figure 1.2). In particular, situated directly above the optic
chiasm is the master circadian oscillator, the SCN, which is responsible for synchronising the
circadian rhythm of endogenous clocks existing in all cells of the body (Moore, 2013; Moore
& Eichler, 1972). The SCN is entrained to the light/dark cycle by receiving photic stimuli from
the retinohypothalamic tract. This information is then relayed from the SCN to the dorsal and
ventral subparaventricular zones. The neurons of the dorsal and ventral subparaventricular
zones provide outputs to the dorsomedial nucleus of the hypothalamus, which integrates these
inputs and projects information via excitatory and inhibitory neurotransmitters to the
ventrolateral preoptic nucleus to promote sleep, to the lateral hypothalamus to induce
wakefulness and regulate feeding patterns and to the paraventricular nucleus to induce the
cascades leading to the release of cortisol and melatonin (Moruzzi & Magoun, 1949; Saper,
Scammell, & Lu, 2005; Sherin, Shiromani, McCarley, & Saper, 1996; Starzl, Taylor, &
Magoun, 1951).
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Figure 1.2. The neurological circuitry of the circadian system.
The SCN of the hypothalamus controls various behavioural and physiological
processes, including sleep and wakefulness, corticosteroid release and
thermoregulation, through indirect neuronal connections with other key hypothalamic
nuclei (image from Saper et al., 2005).

1.6.2 The Stages of Sleep
Sleep is classified into two stages: non-rapid eye movement (NREM) sleep and REM sleep.
NREM is further categorised as stages N1, N2 and N3, characterised by specific cortical neuron
oscillations,

of

which

the

resultant

electrophysiology

can

be

measured

using

electroencephalography (EEG). These stages can be distinguished from one another by EEG
waveforms (see Table 1.1), as well as other physiological phenomena, such as eye and muscle
movements, measured using electrooculography and electromyography, respectively (Berry et
al., 2015; Rechtschaffen & Kales, 1968).
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Stage N1 is characterised by drowsiness and the onset of sleep. This then transitions into the
light sleep stage, N2, which is characterised by EEG signatures known as spindles and kcomplexes. The exact physiological roles for these spindles and k-complexes are not yet
understood, however, they are thought to be involved in sleep-dependent memory
consolidation, particularly motor memory, and the maintenance of sleep (Clemens, Fabo, &
Halasz, 2005; Schabus et al., 2004). Stage N3, also known as slow wave sleep (SWS), is the
deepest stage of NREM sleep, and is thought to modulate memory consolidation and formation.
This is generally followed by REM sleep which, as the name suggests, is characterised by rapid
movement of the eyes, as well as muscle atonia and an EEG tracing similar to that of wake and
is indicative of dreaming (Peigneux, Urbain, & Schmitz, 2012). REM sleep is purported to play
a role in the reorganisation and consolidation memory, particularly emotional memory (Genzel,
Spoormaker, Konrad, & Dresler, 2015; W. Li, Ma, Yang, & Gan, 2017; Peever & Fuller, 2017).

Table 1.1. Frequencies, waveforms and characteristics of stages of sleep.
Stage

Frequency

N1

3-7 Hz

N2

11-16 Hz

N3

0.5-2 Hz

Delta waves. The deepest sleep stage, also
known as slow wave sleep. 20-25% of TST.

15-30 Hz

Desynchronised waves close to that of wake
(low
amplitude,
mixed
frequency).
Accompanied by eye movements and muscle
atonia. 20-25% of TST.

REM

Waveform

Characteristics
Theta waves. The transition from wake to
sleep. Little or no body movement, slowing of
the breathing rate, slow oscillating eye
movements. 5-10% of TST.
Sigma waves with occasional spindles and kcomplexes. The light stage of sleep. Body
temperature and heart rate decrease, cessation
of eye movements. 45-55% of TST.

N1= stage 1 of non-rapid eye movement sleep (NREM), N2= stage 2 of NREM, N3= stage 3 of NREM,
REM= rapid eye movement, Hz= Hertz, TST= total sleep time. Images adapted from Virk and Kotecha
(2016).

10

Under normal conditions, individuals will transition through these sleep stages five times per
night, with each cycle lasting 90 to 110 minutes. During normal sleep, 75% to 80% of the total
sleep time is spent in NREM, with the remaining 20% to 25% of total sleep time spent in REM
sleep (Berry et al., 2015). Deprivation of the quantity of each sleep stage, perhaps due to
multiple awakenings, alcohol or caffeine consumption or the use of opioid-based drugs, will
result in an increase in the percentage of that sleep stage over the following night, also known
as “rebound” (Garcia & Salloum, 2015). For example, a reduction in the quantity of REM sleep
will result in REM rebound the following night, such that the percentage of the total sleep time
spent in REM will increase, indicating the presence of a homeostatic sleep drive to regulate the
duration of each sleep stage (Achermann & Borbély, 2003; Schwartz & Roth, 2008).
1.6.3 The Regulation of Wakefulness
Sleep/wake cycles are tightly regulated by the secretion of excitatory and inhibitory
neurotransmitters from several brain regions, resulting in the “switching” between wake and
sleep states (Schwartz & Roth, 2008). Wakefulness is maintained by an ascending arousal
system that originates in the rostral pons and continues through the reticular formation of the
midbrain and is facilitated by monoamine neurotransmitters, including noradrenaline (NA) and
dopamine (DA), as well as acetylcholine (Ach) and orexin (ORX). The maintenance of
wakefulness involves two main pathways: an ascending pathway to the thalamus and an
ascending pathway that bypasses the thalamus, activating the lateral hypothalamus and basal
forebrain (Figure 1.3) (Saper et al., 2005).
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Figure 1.3. The components of the ascending arousal system involved in the
maintenance of wakefulness.
The yellow pathway depicts the ascending pathway to the thalamus and the red pathway
indicates the ascending pathway that bypasses the thalamus, activating the
hypothalamus and basal forebrain. Both pathways activate the cerebral cortex,
maintaining wakefulness (image from Saper et al., 2005).

The ascending pathway to the thalamus originates in the pedunculopontine and laterodorsal
tegmental nuclei and is driven by acetylcholine. These nuclei provide inputs to the thalamicrelay nuclei and reticular nucleus of the thalamus. Input from the pedunculopontine and
laterodorsal tegmental nuclei to the reticular nucleus acts as a gateway mechanism that blocks
neural transmission between the thalamic relay nuclei and the cerebral cortex; allowing the
innervation of the cerebral cortex by the thalamic relay nuclei induces a state of wakefulness
(McCormick, 1989; Saper et al., 2005). Maintenance of cortical arousal is also thought to be
partly regulated by the intralaminar and midline nuclei (Krout, Belzer, & Loewy, 2002).
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The second pathway, which bypasses the thalamus, is initiated by release of a number of
neurotransmitters in the upper brainstem and caudal hypothalamus, including the locus
coeruleus (noradrenergic), dorsal and median raphe nuclei (serotonergic), ventral periaqueduct
(dopaminergic) and tuberomammillary (histaminergic) neurons (Saper, 1985; Saper, Chou, &
Scammell, 2001). Lateral hypothalamic neurons containing melanin-concentrating hormone or
orexin and cholinergic or gamma-aminobutyric acid (GABA) basal forebrain neurons enhance
the input of the upper brainstem and caudal hypothalamic neurons to the cerebral cortex (Saper
et al., 2005).
1.6.4 The Regulation of Sleep
The promotion of sleep originates at the ventrolateral preoptic nucleus. Neurons of the
ventrolateral preoptic nucleus project to key nuclei that are responsible for arousal in the
hypothalamus and brainstem (Sherin et al., 1996). These neurons contain the inhibitory
neurotransmitters GABA and galanin. Activation of these neurons results in inhibition of the
ascending arousal system, thereby promoting sleep (Gaus, Strecker, Tate, Parker, & Saper,
2002; Sherin, Elmquist, Torrealba, & Saper, 1998; Szymusiak, Alam, Steininger, & McGinty,
1998).
Historical studies into the regulation of REM sleep implicated the switching between inhibition
of cholinergic and serotonergic neurons of the raphe nuclei, with the noradrenergic neurons of
the locus coeruleus of the pons (Hobson, McCarley, & Wyzinski, 1975; Pace-Schott & Hobson,
2002). However, emerging evidence suggests that regulation of REM sleep is controlled by
GABAergic and glutamatergic neurons of the brain stem (Boissard, Fort, Gervasoni, Barbagli,
& Luppi, 2003; Sapin et al., 2009; Verret, Fort, Gervasoni, Leger, & Luppi, 2006), which
project to the basal forebrain to regulate cortical neuron oscillations and to the medulla and
spinal cord to regulate atonia during REM sleep (J. Lu, Sherman, Devor, & Saper, 2006), as
well as by neurons outside the brainstem, particularly those of the anterior and lateral
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hypothalamus (Clement et al., 2012; Jego et al., 2013; Ju. Lu et al., 2002; Sapin et al., 2010;
Weber et al., 2018).
In general, sleep itself is thought to be regulated by homeostatic and circadian drives
(Achermann & Borbély, 2003; Saper et al., 2005). The homeostatic drive is believed to be
initiated as a result of prolonged wakefulness, where the accumulation of a substrate, for
example adenosine, results in an increased drive to sleep (Radulovacki, Virus, DjuricicNedelson, & Green, 1984; Strecker et al., 2000). The circadian sleep drive is regulated by an
autoregulatory transcription-translation feedback loop that originates within the SCN. This
molecular clock relies on the heterodimerisation of the transcription factors clock circadian
regulator (CLOCK) and brain and muscle Arnt-like 1 (BMAL1) in order to activate period
circadian regulator 1 (PERIOD), Cryptochrome Circadian Clock 1 (CRYPTOCHROME) and
Nuclear Receptor Subfamily 1 Group D Member 1 (REV-ERBα) expression (Gekakis et al.,
1998). These factors work in positive and negative feedback loops to produce the clock
machinery of the cell. The SCN innervates the dorsomedial nucleus both directly and indirectly,
which, via GABAergic neuronal projections, innervates the VLPO and lateral hypothalamic
area to control the sleep/wake cycle (Aston-Jones, Chen, Zhu, & Oshinsky, 2001; Chou et al.,
2002; Chou et al., 2003; Deurveilher & Semba, 2005; Yoshida, McCormack, España, Crocker,
& Scammell, 2006). On a 24-hour basis, the functional output of the SCN is reset by light
stimuli transmitted from the retina, via the retino-hypothalamic tract, to the SCN during
daylight hours and melatonin secretion from the pineal gland during the night.
1.7 The Circadian Regulation of Cortisol and Melatonin
The circadian release of cortisol and melatonin is mediated by the connection between the SCN
and paraventricular nucleus. The circadian rhythm generated at the SCN is transmitted to the
paraventricular nucleus via projections of the subparaventricular zone and dorsomedial nucleus
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of the hypothalamus, which then initiates the cascades leading to the release of cortisol and
melatonin.
1.7.1 The Regulation of Cortisol Release
The PVN releases corticotrophin releasing factor into the hypophyseal portal system, which
comes into direct contact with the anterior of the pituitary gland, stimulating the corticotropes
to release adrenocorticotropic hormone (Figure 1.4). Once in the systemic circulation, this
hormone stimulates the release of cortisol from the adrenal cortex. The physiological effects of
cortisol include increasing blood pressure and glucose uptake, maintaining blood calcium
levels, metabolising fat and decreasing inflammation (Golden, Wand, Malhotra, Kamel, &
Horton, 2011). In the brain, cortisol has been shown to impact on memory, particularly longterm and primed burst potentiation, by interacting with mineralocorticoid and glucocorticoid
receptors in a dose-dependent manner (D. M. Diamond, Bennett, Fleshner, & Rose, 1992;
McEwen, 2007; Pavlides, Kimura, Magarinos, & McEwen, 1994; Pavlides, Watanabe,
Magarin, & McEwen, 1995). For example, long-term potentiation occurs efficiently in the
presence of low levels of cortisol, however high levels of cortisol have been reported to impair
long-term potentiation (and therefore impact on memory formation and retrieval) (Joëls, 2006).
Cortisol also binds to glucocorticoid receptors in the paraventricular nucleus and pituitary,
inhibiting further release of corticotropin releasing factor and adrenocorticotropic hormone in
a negative feedback loop (Hyman, 2009; Keller-Wood & Dallman, 1984).
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Figure 1.4. The hypothalamic-pituitary-adrenal (HPA) axis.
Structures of the HPA axis include the hypothalamus, pituitary and adrenal glands. The
paraventricular nuclei release corticotrophin releasing factor, which stimulates the
release of adrenocorticotropic hormone from the anterior pituitary. Adrenocorticotropic
hormone then stimulates the release of glucocorticoids (cortisol) from the cortex of the
adrenal glands, which regulates responses to stress in both the central and peripheral
systems. Glucocorticoids provide a negative feedback loop, inhibiting further release
of corticotrophin releasing factor and adrenocorticotropic hormone. This axis becomes
dysfunctional in premanifest HD, leading to alterations in cortisol release (image from
Hyman, 2009).

There is a large circadian variation in blood cortisol concentrations between individuals,
however, the phenomenon known as the cortisol awakening response (CAR) is relatively stable
intra-individually (Clow, Thorn, Evans, & Hucklebridge, 2004; Stone et al., 2001). The CAR
occurs within the first 30 minutes following awakening and is represented by a 75% surge in
cortisol release (Pruessner et al., 1997). While the role of the CAR is not yet known, it is
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thought to be a biochemical response to awakening that facilitates the activation of memory to
allow individuals to orient themselves in anticipation of the day ahead (Fries, Dettenborn, &
Kirschbaum, 2009). Following this spike in cortisol, concentrations then gradually decrease
across the day, reaching a nadir around midnight, which coincides with the rise in melatonin
levels (Brzezinski, 1997; Chan & Debono, 2010).
1.7.2 Regulation of Melatonin Release
The regulation of melatonin release involves the neural projections of the paraventricular
nucleus to the intermediolateral cell column (of the spinal cord). This then provides input to
the superior cervical ganglion, which then directly innervates the pinealocytes to synthesise
melatonin from tryptophan molecules according to the following pathway (Axelrod &
Weissbach, 1960; Coon et al., 1995; Rath et al., 2016):

The release of melatonin from the pineal gland is thought to stabilise and reinforce the circadian
rhythm in all cells of the body, in addition to initiating the thermoregulatory cascade. Melatonin
regulates body temperature via the activation of MT1 or MT2 receptors to induce
vasoconstriction or vasodilation, respectively, in the vascular beds of the extremities. This
differentially effects the flow of blood to ensure the optimal internal body temperature to
promote the onset of sleep (Brzezinski, 1997; Cajochen, Kräuchi, & Wirz‐Justice, 2003; Cook,
Sauder, & Ray, 2010; Krauchi, Cajochen, Werth, & Wirz-Justice, 1999, 2000).
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Figure 1.5. The neural pathway of melatonin release.
Melatonin is secreted via a multi-step pathway beginning at the SCN, which is
synchronised to the day/night cycle by photic stimuli received via the
retinohypothalamic tract. The SCN then projects to the dorsomedial nucleus, which
controls the release of melatonin via projections to the intermediolateral cell column.
The Intermediolateral cell column innervates the superior cervical ganglion, which
directly stimulates the pineal gland to synthesise and release melatonin (image from
Cardinali and Pevet, 1998).

Ultimately, the SCN and other key nuclei of the hypothalamus are responsible for the
sleep/wake cycle and circadian regulation of cortisol and melatonin release. It is plausible that
hypothalamic pathology in HD could affect these nuclei, influencing the regulation of sleep,
circadian rhythm and neuroendocrine output.
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1.8 Circadian Rhythm and Sleep Disturbances in HD
Circadian rhythm and sleep disturbances have been reported in both HD mouse models and
humans (Kudo et al., 2011; Lazar et al., 2015; Morton, 2013). These circadian changes appear
to commence during the premanifest stages of HD and worsen as the course of the disease
lengthens. In particular, early changes in the circadian regulation of cortisol and melatonin and
a sleep phase delay have been noted in individuals with premanifest HD (Aziz, Anguelova,
Marinus, Lammers, & Roos, 2010; Aziz, Pijl, Frölich, Schroder-van der Elst, et al., 2009; Aziz,
Pijl, Frölich, van der Graaf, et al., 2009; Kalliolia et al., 2014; van Duijn et al., 2010).
The CAR is a characteristic of the circadian rhythm of cortisol (Clow, Hucklebridge, Stalder,
Evans, & Thorn, 2010; Clow et al., 2004). Due to its stability across days, the CAR can be used
to measure changes in cortisol circadian regulation. Compared to mutation-negative healthy
controls (from HD families), premanifest HD individuals exhibit increased salivary cortisol
within the hour following awakening when measuring the CAR (van Duijn et al., 2010).
Furthermore, Hubers et al. (2015) reported an increase in the total salivary cortisol output
during the CAR, using area under the curve with respect to increase (AUCi) analysis in
individuals with premanifest compared to manifest HD, indicating perturbations in cortisol
release in premanifest HD individuals.
Alterations in melatonin secretion have also been reported in HD. Recent work by Kalliolia et
al. (2014) described a decrease in levels and a greater temporal spread in melatonin, indicating
a temporal shift in melatonin release in HD. Given that melatonin is released in a circadian
manner and modulated by the SCN, this shift in melatonin release could indicate a disruption
of the circadian rhythm. Furthermore, as melatonin is vital in promoting the onset of sleep, the
disruption of melatonin release could result in delayed sleep onset, a feature that has been
observed in HD (Lewy, Ahmed, Jackson, & Sack, 1992).
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In addition to the dysregulation of circadian-regulated hormone, altered rest-activity profiles
have also been reported in HD. Studies in the R6/2 HD mouse model have revealed altered
night-day activity ratios that worsen as the disease progresses (Kudo et al., 2011; Maywood et
al., 2010; Morton et al., 2005). Furthermore, dysregulation of clock gene expression has been
reported, particularly within the SCN, in HD mouse models (Morton et al., 2005). While it is
not possible to directly measure the functioning of the SCN, it is believed that the circadian
rhythm dysfunction present in mouse models is recapitulated in humans with HD. For example,
similar to that in HD mouse models, altered night-day activity has been reported in individuals
with manifest HD (Morton et al., 2005), which has also been reported to be accompanied by
altered sleep-wake timing (Hurelbrink, Lewis, & Barker, 2005), potentially leading to the sleep
disturbances observed in HD.
Recent findings by Lazar and colleagues (2015) show that sleep disturbances are an early
feature of HD. In particular, premanifest HD individuals are known to experience sleep
fragmentation, indicated by an increase in the number of awakenings throughout the night.
These sleep disturbances worsen as the disease progresses and include reduced sleep efficiency,
excessive daytime sleepiness, increased sleep onset latency, reduced slow wave sleep and REM
sleep, increased REM latency, increased sleep spindles and delayed awakenings (Arnulf et al.,
2008; Piano et al., 2015; Piano et al., 2017). Given that disturbances in circadian rhythm and
sleep arise during the premanifest stage of HD and worsen as the disease progresses,
identification of potential mechanisms and early treatments aimed at reducing or ameliorating
circadian rhythm and habitual sleep disturbances are warranted.
1.9 The Pathological Effects of Sleep and Circadian Rhythm Disturbances in
Huntington’s Disease
Sleep disturbances have been reported to impair cognitive function and can induce
psychological features, such as depression, anxiety and stress (Ferrie et al., 2011; Harrison &
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Horne, 2000; Kribbs & Dinges, 1994). Studies in animal models have shown that sleep deficits
can impact on hippocampal function, leading to impairments in consolidation of memory
(Prince & Abel, 2013; Tartar et al., 2006). This is thought to occur due to disruption of synaptic
plasticity (long-term potentiation) and reduced N-Methyl-D-Aspartate (NMDA) and α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor signalling, as well as
fluctuations in glutamate (Campbell, Guinan, & Horowitz, 2002; Disbrow & Ruth, 1984;
McDermott et al., 2003; Ravassard et al., 2009). Furthermore, sleep deficits have been shown
to negatively impact executive functions associated with the prefrontal cortex, although the
molecular events leading to this phenomenon are yet to be confirmed (Blagrove, Alexander, &
Horne, 1995; Boonstra, Stins, Daffertshofer, & Beek, 2007; Dahl, 1996; Harrison & Horne,
1997, 1998; Horne, 1988; Lo et al., 2012; Muzur, Pace-Schott, & Hobson, 2002). Furthermore,
disrupted or restricted sleep leads to increased activity of the HPA axis (Buckley & Schatzberg,
2005; Meerlo, Sgoifo, & Suchecki, 2008) and increased sympathetic activation demonstrated
by increases in heart rate and blood pressure (Zhong et al., 2005).
Morton et al (2005) reported that premanifest HD individuals show a disrupted circadian
profile, which worsens as the disease progresses. Disruption of the circadian rhythm can result
in altered release of cortisol and melatonin and decreased sleep quality and can exacerbate
impairments in cognition, including attention and executive function, glucose metabolism,
motor control and mood (Briançon-Marjollet et al., 2015; Ju, Lucey, & Holtzman, 2014;
Scullin & Bliwise, 2015; Videnovic, Lazar, Barker, & Overeem, 2014; Wirz-Justice et al.,
1981; Wulff et al., 2010). Ultimately, alterations in circadian rhythm are likely to potentiate
pathological mechanisms that are already present in HD individuals.
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1.10 Potential Pathological Mechanisms Underpinning Sleep Disturbances in
Huntington’s Disease
Several studies have reported hypothalamic pathology in HD as early as 10 years prior to
estimated clinical onset (Politis et al., 2008; Soneson et al., 2010). Significant hypothalamic
nuclear atrophy and hypothalamic neuronal loss have also been reported in HD mouse models
(Björkqvist et al., 2006; Du et al., 2012; Du & Pang, 2015) and in patients (Douaud et al., 2006;
Gabery et al., 2010; Kassubek et al., 2004; Kremer, Roos, Dingjan, Marani, & Bots, 1990;
Soneson et al., 2010; Timmers, Swaab, van de Nes, & Kremer, 1996). These findings suggest
that hypothalamic pathology is a key feature of HD. Post-mortem investigations reveal
significant neuronal loss in the nucleus tuberalis lateralis and lateral hypothalamus (Kremer et
al., 1991; Kremer et al., 1990; Petersén & Björkqvist, 2006; Petersén et al., 2005; Timmers et
al., 1996; Vogt, 1952). Furthermore, a significant loss of orexin-releasing neurons in the lateral
hypothalamus has been reported in HD (Petersén et al., 2005). Hypothalamic atrophy has also
been reported in individuals with manifest and premanifest HD using voxel based
morphometry (VBM) (Douaud et al., 2006; Kassubek et al., 2004; Soneson et al., 2010).
Considering the importance of the hypothalamic nuclei in maintaining circadian rhythm and
other behavioural processes, it is plausible that changes in the hypothalamus alters the circadian
release of neuroendocrine factors, particularly cortisol and melatonin, adversely impacting on
sleep/wake behaviour.
1.11 Therapies for Huntington’s Disease
Despite intense efforts, there are currently no proven disease modifying strategies for HD.
Many promising pharmaceutical candidates are currently under investigation (Frank, 2014),
however many of these candidates will fail due to futility and tolerability issues. Successful
pharmaceutical candidates may also take up to a decade to become available to HD sufferers
(Bates, Tabrizi, & Jones, 2014). There is, therefore, a fundamental need to identify non22

pharmaceutical strategies that can positively impact on the clinical and pathological
progression of HD. Lifestyle strategies such as multidisciplinary rehabilitation, which
encompass exercise and cognitive training, appear to be a particularly promising therapeutic
approach that is safe and can be trialled immediately in premanifest HD individuals, prior to
severe neuronal loss and manifestation of clinical features.
Long-standing evidence shows that lifestyle factors, such as sedentary behaviour, poor
education and excessive calorie intake, impact on disease onset, symptomatology and
progression (Bonner-Jackson et al., 2013; López‐Sendón et al., 2011; Trembath et al., 2010;
Wexler & The US–Venezuela Collaborative Research Project, 2004). Sleep disturbances may
be an environmental modifier that contributes to disease related pathology (Musiek, 2015).
Emerging evidence suggests that treatment of circadian rhythm and sleep disturbances may
lead to improvements in symptoms of HD (H.-B. Wang et al., 2018; H.-B. Wang et al., 2017).
A study by Cuesta and colleagues demonstrated that behavioural manipulation prevents the
emergence of circadian abnormalities in HD animal models (Cuesta, Aungier, & Morton,
2014). This study explored the individual and synchronistic effects of bright light therapy and
free or restricted wheel running, two behavioural interventions known to modulate the
circadian output of the SCN, on circadian behaviour in the R6/2 mouse model, a transgenic
model of HD with a rapidly progressive phenotype. Results from this study suggest that
incremental exposure to light and exercise, together and in unison, have the potential to entrain
the circadian rhythm in HD.
Further evidence from other clinical and healthy populations also supports the use of nonpharmaceutical interventions, such as exercise and cognitive training, for treating circadian
rhythm and sleep disturbances in HD. Several studies have reported that exercise favourably
modulates circadian rhythm and improves sleep outcomes in healthy populations (Edwards,
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Reilly, & Waterhouse, 2009; Yamanaka et al., 2006; Youngstedt et al., 2016). Exercise has
also been reported to improve sleep in other neurodegenerative populations, including
Parkinson’s disease and Alzheimer’s disease, as well as individuals with sleep disorders such
as insomnia (Nascimento et al., 2014; Passos et al., 2011; Reid et al., 2010).
Frazitta et al. (2015) reported an improvement in sleep quality, motor symptoms and daytime
somnolence using the Parkinson’s Disease Sleep Scale after a four week intensive
multidisciplinary rehabilitation intervention encompassing stretching, functional training and
aerobic exercise. In another study by Silva-Batista et al. (2017), twelve weeks of resistance
training was found to significantly improve Pittsburgh Sleep Quality Index values in
Parkinson’s disease patients, indicating an improvement in sleep quality. Finally, Nascimento
et al. (2014), reported an attenuation of sleep disturbances in Parkinson’s and Alzheimer’s
disease patients following six months of aerobic and resistance training exercise.
In older adults with insomnia, improvements in sleep quality have been observed following an
eight-week computerised cognitive training intervention (Haimov & Shatil, 2013).
Additionally, Diamond and colleagues (2015) reported improvements in subjective sleep
quality following seven weeks of the Healthy Brain Ageing Cognitive Training (HBA-CT)
program in older adults. Taken together, these results suggest that cognitive training can
improve subjective sleep quality in older populations with and without insomnia.
Despite many studies documenting the positive effects of environmental interventions on
circadian rhythm and sleep outcomes in HD mouse models and subjective sleep outcomes in
other clinical populations, no studies to date have assessed the effects of these therapies on
circadian rhythm and subjective or objective sleep outcomes in HD patients.
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1.12 Multidisciplinary Rehabilitation as a Non-Pharmaceutical Strategy for Sleep and
Circadian Rhythm Disturbances
Emerging evidence indicates that multidisciplinary therapy is feasible, well tolerated and
associated with positive clinical and physiological benefits in HD (Cruickshank et al., 2015;
Piira et al., 2013; Thompson et al., 2013; Veenhuizen et al., 2011; Zinzi et al., 2007).
Zinzi et al. (2007) were the first to document significant improvements in motor performance
and activities of daily living in individuals with manifest HD after an eighteen-month
individualised intervention comprising three-weekly intensive cognitive, physical, respiratory
and vocational exercises up to three times per year. Subsequently, a study by Veenhuizen et al.
(2011) reported that eighteen months of individualised outpatient multidisciplinary care
provided by a specialised multidisciplinary team was perceived as beneficial and appreciated
by the twenty individuals with manifest HD that participated in the study, as well as their carers
and the health care workers involved. Following this, Piira et al. (2013) demonstrated that
intensive (five days per week for eight hours, for three weeks, three times per year) inpatient
multidisciplinary rehabilitation, comprising physiotherapy, occupational therapy, speech
therapy, resistance exercises and hydrotherapy, improved balance, gait and physical quality of
life, as well as reduced symptoms of depression and anxiety in individuals with manifest HD.
This data was reinforced by research from our team indicating that nine-months of
multidisciplinary rehabilitation, comprising once-weekly supervised group aerobic and
resistance training sessions in an exercise clinic, fortnightly occupational therapy sessions and
an individualised home-based exercise program, reduces deterioration of motor and postural
stability, significantly improves strength and fat-free mass and, to a smaller extent, improves
cognition, depression and quality of life (Thompson et al., 2013).
More recently, data from our team has demonstrated, for the first time, that multidisciplinary
therapy can increase grey matter volume in the dorsolateral prefrontal cortex and the right
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caudate of patients with manifest HD, and that such increases are strongly associated with a
preserved performance in verbal learning and memory (Cruickshank et al., 2015). In addition
to studies in individuals with HD, lifestyle and multidisciplinary rehabilitation interventions
have been reported to positively impact on pathological disease burden and clinical outcomes
in other neurodegenerative diseases, such as Parkinson’s disease (Ellis et al., 2008; Frazzitta,
Bertotti, et al., 2013; 2015; Trend, Kaye, Gage, Owen, & Wade, 2002; van der Marck, Bloem,
et al., 2013; van der Marck, Munneke, et al., 2013; Wade et al., 2003) and multiple sclerosis
(Asano, Raszewski, & Finlayson, 2014; Khan, Turner-Stokes, Ng, & Kilpatrick, 2007;
Rietberg, van Wegen, Eyssen, Kwakkel, & the MS study group, 2014; Salhofer-Polanyi et al.,
2013). Taken together, these studies suggest that multidisciplinary rehabilitation paradigms are
feasible, well-tolerated and have the potential to improve the clinical aspects of HD. It remains
to be determined, however, whether multidisciplinary rehabilitation positively impacts on
circadian rhythm and sleep outcomes in HD.
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1.13

Theoretical Framework

Sleep and circadian rhythm disturbances are common features of HD that arise during the
premanifest stage of the disease and worsen as the disease progresses. Emerging evidence from
animal models and investigations in other neurodegenerative populations shows that circadian
rhythm and sleep disturbances contribute to age-and disease-related atrophy of the brain and
exacerbates disease features. Despite this knowledge of the impact of circadian rhythm and
sleep disruption on disease progression and symptomatology, there is a paucity of data
investigating the mechanisms underpinning circadian rhythm and sleep disturbances in HD.
Furthermore, no treatments exist to combat circadian rhythm and sleep disturbances in HD.
The circadian rhythm and sleep/wake cycle are tightly regulated by the interaction between key
nuclei in the hypothalamus. These nuclei also mediate the release of neuroendocrine factors,
particularly cortisol and melatonin, which further mediate the sleep/wake cycle. As the release
of cortisol and melatonin are regulated by the circadian rhythm, changes in the temporal release
of these hormones can indicate changes in the circadian rhythm. Hypothalamic pathology and
disruption of the circadian release of neuroendocrine factors has been reported in premanifest
HD. It is not known however, if this is the contributing pathological factor for the reported
disturbances in circadian rhythm and sleep observed in HD.
The regulation of the circadian rhythm and sleep/wake cycle is coordinated by the SCN, which
responds to environmental cues, known as zeitgebers. Physical activity and cognitive training
are known zeitgebers that act to entrain the circadian rhythm and sleep/wake cycle. The
combined effects of physical exercise and cognitive training, in the form of multidisciplinary
rehabilitation, have been shown to be beneficial and feasible in HD, as well as in other
neurodegenerative populations, such as Parkinson’s disease and Alzheimer’s disease.
Furthermore, multidisciplinary rehabilitation has been reported to improve subjective sleep
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quality in patients with Parkinson’s disease. The effects of multidisciplinary rehabilitation on
circadian rhythm and sleep outcomes is yet to be investigated in HD.
Therefore, the overall aim of this thesis was to investigate the neurobiological mechanisms
underpinning circadian rhythm and sleep disturbances in premanifest HD, with particular focus
on the hypothalamus. This thesis also aimed to investigate, for the first time, the effects of
multidisciplinary rehabilitation on measures of circadian rhythmicity, as well as subjective and
objective sleep in individuals with premanifest HD. The studies presented in this thesis
focussed on individuals with premanifest HD, the stage of the disease when an intervention
would be most beneficial, as at this stage the disease can be ameliorated more effectively prior
to severe, irreversible neuronal loss.
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1.14

Hypothesis and Aims

The overarching hypothesis of this thesis is that multidisciplinary rehabilitation improves
circadian rhythm and sleep outcomes by preserving hypothalamic volume in premanifest HD.
Aim 1:
To perform a thorough literature investigation of the potential neurobiological
mechanisms associated with circadian rhythm and sleep architecture in individuals with
Huntington’s disease.
Aim 2:
To determine the extent to which hypothalamic volume is associated with circadian
rhythm and habitual sleep outcomes in individuals with premanifest Huntington’s
disease.
Aim 3:
To assess the effects of a nine-month multidisciplinary therapy program on measures
of circadian rhythm and habitual sleep and associated hypothalamic volume in
individuals with premanifest Huntington’s disease.
Aim 4:
To explore the effects of a nine-month multidisciplinary therapy program on sleep
architecture in individuals with premanifest Huntington’s disease.
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2.1 Abstract
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by an extended
polyglutamine tract in the huntingtin protein. Circadian, sleep and hypothalamic-pituitaryadrenal (HPA) axis disturbances are observed in HD as early as 15 years before clinical disease
onset. Disturbances in these key processes result in increased cortisol and altered melatonin
release which may negatively impact on brain-derived neurotrophic factor (BDNF) expression
and contribute to documented neuropathological and clinical disease features. This review
describes the normal interactions between neurotrophic factors, the HPA-axis and circadian
rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these
intricately balanced networks in HD. We also discuss the implications of these alterations on
the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep
pathologies. Measurable alterations in these pathways provide targets that, if treated early, may
reduce degeneration of brain structures. We therefore focus here on the means by which
multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the
balance of these pathways.
2.2 Introduction
Huntington’s disease (HD) is a fatal autosomal dominant neurodegenerative disease caused by
an expanded cytosine-adenine-guanine (CAG) repeat sequence in exon 1 of the Huntingtin
gene (HTT) (The Huntington's Disease Collaborative Research Group, 1993). This expanded
sequence encodes a mutant version of the protein, huntingtin (mHTT), which is associated with
ubiquitous molecular and cellular anomalies, widespread neuronal dysfunction and cell loss
(Kim et al., 2014) and the presentation of motor and non-motor features, including progressive
impairments in motor control, cognitive function and mood (Tabrizi et al., 2013). Evidence
also indicates that individuals suffer from sleep disturbances (Arnulf et al., 2008; Hansotia,
Wall, & Berendes, 1985; Lazar et al., 2015; Morton, 2013; Piano et al., 2015; Wiegand, Moller,
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Schreiber, Lauer, & Krieg, 1991), autonomic abnormalities (e.g. hyperhidrosis, micturition
disturbances, swallowing difficulties, sexual dysfunction, altered heart rate variability)
(Andrich et al., 2002; Kobal et al., 2010) and metabolic irregularities (Browne et al., 1997;
Mazziotta et al., 1987), with some non-motor features, such as cognitive and sleep
abnormalities, emerging years before the onset of motor signs (Lazar et al., 2015; Tabrizi et
al., 2011).
Although the pathophysiology underlying the development and progression of these clinical
features is complex, the accompanying alterations in neuroendocrine signalling, including
cortisol (Aziz, Pijl, Frölich, van der Graaf, et al., 2009; Hubers et al., 2015) and melatonin
(Aziz, Pijl, Frölich, Schroder-van der Elst, et al., 2009; Kalliolia et al., 2014) release, and
changes in circadian rhythmicity (Aziz et al., 2010; Morton et al., 2005) suggest that the activity
of the hypothalamic-pituitary-adrenal (HPA) axis and the suprachiasmatic nucleus (SCN) are
impaired in HD (see Table 2.1 for a summary of pathologies relevant to this review).
Neuropathological changes including volume loss, the loss of orexin-releasing neurons and
decreased protein levels of vasoactive intestinal peptide (VIP) and arginine vasopressin (AVP)
in the hypothalamus support this supposition (Petersén et al., 2005; Politis et al., 2008; Soneson
et al., 2010).
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Table 2.1. Summary of HD pathologies relevant to this review article
Pathologies
in HD
HPA-axis
and SCN
pathologies

Evidence

References

Increased
cortisol
levels

Mouse models:
 Hypothalamic degeneration, pituitary and adrenal
pathologies
 Loss of orexin-releasing neurons
Premanifest HD:
 Hypothalamic volume loss (shown by voxel-based
morphometry)
Manifest HD:
 Hypothalamic volume loss (shown by voxel-based
morphometry)
 Loss of neurons in the nucleus tuberalis lateralis (NTL)
and lateral hypothalamus (at post-mortem)
 Loss of orexin-releasing neurons (at post-mortem)
 Decreased protein levels of vasoactive intestinal peptide
(VIP) and arginine vasopressin (AVP) (at post-mortem)
Premanifest HD:
 Increases in the cortisol awakening response (CAR)
 Increased daily cortisol output

Decreased
BDNF

Mouse models:
 Decreased brain BDNF levels

Circadian
rhythm
disturbances

Alterations
in melatonin
release

Sleep
disturbances

(Björkqvist et al., 2006; Du et al., 2012;
Petersén et al., 2005; Sathasivam et al.,
1999)
(Soneson et al., 2010)

(Aziz et al., 2008; Douaud et al., 2006;
Gabery et al., 2010; Kassubek et al., 2004;
Kremer et al., 1991; 1990; van Wamelen et
al., 2013)

(Hubers et al., 2015; van Duijn et al.,
2010)
(Pang, Stam, Nithianantharajah, Howard,
& Hannan, 2006; Zuccato et al., 2005)

Manifest HD:
 Reduction of between 53-82% of BDNF in the caudate
and putamen (at post-mortem)
Mouse models:
 Breakdown in rest-activity cycle
 Dysregulation of circadian gene expression, particularly
in the SCN
 Reduced circadian rhythm of spontaneous electrical
activity in SCN neurons
Manifest HD:
 Disturbances in rest-activity profiles
 Abnormal day-night ratios
 Altered sleep-wake timing
Premanifest HD:
 Temporal spread of melatonin rise
Manifest HD:
 Decreased mean and acrophase melatonin levels
 Temporal spread of melatonin rise
 Delayed rise phase
Premanifest HD:
 Fragmented sleep profile
 Decreased theta power during REM sleep
Manifest HD:
 Insomnia
 Decreased REM
 Decreased slow wave sleep (SWS)
 Decreased sleep efficiency
 Advanced sleep phase
 Frequent nocturnal awakenings
 Increased periodic leg movements (PLMs)

(Ferrer, Goutan, Marin, Rey, & Ribalta,
2000)
(Kudo et al., 2011; Maywood et al., 2010;
Morton et al., 2005)

(Hurelbrink et al., 2005; Morton et al.,
2005)

(Kalliolia et al., 2014)
(Aziz, Pijl, Frölich, Schroder-van der Elst,
et al., 2009; Kalliolia et al., 2014)

(Lazar et al., 2015)

(Arnulf et al., 2008; Hansotia et al., 1985;
Morton, 2013; Morton et al., 2005; Neutel
et al., 2015; Piano et al., 2015; Wiegand,
Möller, et al., 1991)

Premanifest HD= individuals carrying the gene for Huntington’s disease who do not yet display overt motor signs, however may exhibit mild
cognitive decline and mood disturbances; Manifest HD= individuals carrying the Huntington’s disease gene who display overt motor signs of
disease, cognitive decline and mood disturbances; HD= Huntington’s disease; HPA-axis= hypothalamic-pituitary-adrenal axis; BDNF= brainderived neurotrophic factor; SCN= suprachiasmatic nucleus; REM= rapid eye movement
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The HPA-axis is central to neuroendocrine signalling. Indeed, an intricate balance exists
between neuroendocrine signalling and expression of neurotrophic factors, particularly brainderived neurotrophic factor (BDNF) (Issa, Wilson, Terry Jr, & Pillai, 2010; Smith, Makino,
Kvetnansky, & Post, 1995). In this review, we present for the first time the biological impact
of HPA-axis dysfunction on circadian rhythm, neuroendocrine signalling, and neurotrophic
factor support in HD (for a diagrammatic view, see Figure 2.1). We also draw on existing
evidence in animal models and patients with HD and other disorders to review nonpharmaceutical treatment strategies, particularly multidisciplinary therapy, exercise, cognitive
therapy and social interaction, which may positively impact on HPA-axis dysfunction and
potential downstream mechanisms and thereby delay disease onset in individuals with
premanifest HD. Since candidate pharmaceutical treatment strategies for HD have been
reviewed recently (Ross et al., 2014), here we detail non-pharmaceutical multidisciplinary
approaches as they have been reported to exert beneficial effects on HPA-axis function,
circadian rhythm and BDNF, are of minimal cost and can be implemented throughout life with
few side effects.
2.3 Normal Function of the HPA-Axis and the SCN
The structures of the HPA-axis, including the hypothalamus, pituitary and adrenal glands,
function in a tightly regulated manner to control responses to physiological and psychological
stress, autonomic and immune functions and sleep-wake behaviour through the release of
hormones, such as cortisol, in a circadian manner (Steiger, 2002; Ulrich-Lai & Herman, 2009;
Webster Marketon & Glaser, 2008).
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Figure 2.1. The interrelated consequences of HPA-axis and circadian rhythm
disruption on BDNF expression and sleep and the implications on neurobiology.
Disruption of the HPA-axis and circadian rhythmicity as a result of hypothalamic
dysfunction facilitates alterations in cortisol release and disrupted sleep architecture.
Conversely, disrupted sleep can lead to increased cortisol and negatively effect the
circadian rhythm. Increased cortisol can also disrupt sleep architecture and the circadian
rhythm. Circadian rhythm abnormalities and increased cortisol can negatively effect the
release of BDNF and this, in turn, can induce cognitive deficits, disrupt sleep
architecture and reduce neuronal support which can facilitate the loss of brain volume.
Multidisciplinary therapy has the potential to favourably affect this mechanism at
several levels. HPA axis= hypothalamic-pituitary-adrenal axis; SCN= suprachiasmatic
nucleus; NTL= nucleus tuberalis lateralis; REM= rapid eye movement; SWS= slow
wave sleep; PLMs= periodic leg movements; BDNF= brain-derived neurotrophic
factor.

The paraventricular nucleus (PVN) releases corticotrophin releasing factor (CRF) into the
hypophyseal portal system, where it stimulates the release of adrenocorticotrophic hormone
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(ACTH) from the corticotropes of the anterior pituitary (Rivier & Vale, 1983). ACTH is
released into the systemic circulation and stimulates the adrenal cortex to release
glucocorticoids, such as corticosterone in mice and cortisol in humans, which regulate
responses to stress in central and peripheral systems. These glucocorticoids then provide
negative feedback, inhibiting further release of CRF and ACTH by binding to glucocorticoid
receptors (GRs) at the PVN and pituitary level, inhibiting further HPA-axis activation via
glucocorticoid response elements (GREs) (Keller-Wood & Dallman, 1984).
Glucocorticoid release is subject to inputs from other brain regions, particularly the amygdala,
stria terminalis and hippocampus, which are all regions fundamentally involved in emotional
regulation and memory (Hauger & Dautzenberg, 2000). However, the basal circadian release
of glucocorticoids is facilitated by the connection between the PVN and SCN.
The SCN is located in the anterior hypothalamus and functions as the central circadian clock
that is the principle site of circadian rhythm coordination in mammals (Nishino, Koizumi, &
Brooks, 1976). The SCN receives information from the retina and other brain regions and
synchronises the circadian rhythms of the organism emerging at cellular, physiological and
behavioural levels to various zeitgebers, the most important of which is ambient light.
Synchronization is mediated through neural and humoral signals. On a molecular level the
circadian rhythm in mammals is based on an autoregulatory transcriptional-translational
feedback mechanism involving CLOCK and BMAL1 transcription factors and PERIOD
(PER1, 2 and 3) and CRYPTOCHROME (CRY 1 and 2) core clock genes (Gekakis et al.,
1998). This molecular clock regulates a considerable proportion of the human genome.
Importantly, through its connections with the PVN and mediation of the HPA-axis, the SCN
controls daily variations in melatonin and cortisol release which are involved, amongst other
things, in sleep-wake behaviour and autonomic arousal regulation.
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More specifically, activity of the SCN is synchronised to the environmental light-dark cycle
directly through the retinal-hypothalamic tract and indirectly through the retinogeniculate
pathways and conveys this information to other hypothalamic nuclei, the reticular formation
and the pineal gland, coordinating the diurnal activities of these brain regions (Brzezinski,
1997). Melatonin coordinates circadian rhythms in response to the day-night cycle and initiates
the thermoregulatory cascade, decreasing core body temperature to induce sleepiness
(Brzezinski, 1997; Krauchi et al., 2000). The circadian variation of core body temperature is
also associated with the internal structure of sleep, particularly with the circadian rhythm of
REM (Dijk & Czeisler, 1995).
2.4 Stress and the Role of Cortisol
Cortisol secretion follows a circadian rhythm in individuals with normal sleep-wake cycles.
Within the first 30 minutes of awakening, cortisol levels increase by up to 75% (Pruessner et
al., 1997). Cortisol levels then tend to plateau and around midnight reach their nadir. There is
large variation in circadian cortisol levels between individuals, however morning cortisol levels
are relatively stable intra-individually, allowing for measurement of the cortisol awakening
response (CAR), which serves as an indication of HPA-axis function and circadian rhythmicity
(Stone et al., 2001).
In addition to its natural circadian rhythm, cortisol is released in response to physiological and
psychological stress (Staufenbiel, Penninx, Spijker, Elzinga, & van Rossum, 2013). Stress has
many contributing factors and occurs when environmental demands surpass the individual’s
coping abilities (Fink, 2010). The response to stress, particularly adaptation, varies among
individuals and is influenced by an individual’s resilience (Russo, Murrough, Han, Charney,
& Nestler, 2012). The biological processes that occur in order to allow the individual to adapt
to environmental stressors are collectively termed allostasis and involve the release of cortisol
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and adrenalin among many other chemical mediators (Juster, McEwen, & Lupien, 2010;
Sterling & Eyer, 1988).
Cortisol acts to maintain blood pressure, mobilise energy resources and decrease inflammation
(Fraser et al., 1999; Peckett, Wright, & Riddell, 2011; Petrovsky, McNair, & Harrison, 1998).
Although individuals have the ability to adapt to these biological effects of cortisol, excessive
or insufficient activation of the HPA-axis can contribute to maladaptive consequences, leading
to pathology (McEwen & Stellar, 1993).
2.5 Pathological Effects of Chronic Glucocorticoid Release
Significant increases in the CAR and daily cortisol output have been documented in
premanifest HD (preHD) compared to healthy controls and manifest HD (Hubers et al., 2015;
Shirbin et al., 2013; van Duijn et al., 2010), which implies disruption of the circadian rhythm
and therefore of the HPA-axis (Aziz, Pijl, Frölich, van der Graaf, et al., 2009; Politis et al.,
2008).
Disruption of the HPA-axis leads to altered circadian release of cortisol (Saper et al., 2005).
Severe alterations in glucocorticoids have been shown to exacerbate excitotoxic processes in
neurons, predominantly those of the hippocampus (Crochemore et al., 2005; Sapolsky, Packan,
& Vale, 1988; Sorrells, Munhoz, Manley, Yen, & Sapolsky, 2014; Stein-Behrens, Mattson,
Chang, Yeh, & Sapolsky, 1994). Chronic exposure to glucocorticoids decreases neurogenesis,
arborisation of dendrites and density of synapses in the hippocampus and prefrontal cortex
(PFC) (Crochemore et al., 2005; Tata, Marciano, & Anderson, 2006) and results in
abnormalities of the caudate, putamen and amygdala in animal models (Delgado y Palacios,
Verhoye, Henningsen, Wiborg, & Van der Linden, 2014). Chronic stress has been shown to
modulate the onset and progression of disease features in the R6/1 HD mouse model (Mo,
Pang, et al., 2014; Mo, Renoir, & Hannan, 2014). Higher glucocorticoid levels, such as those
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seen in post-traumatic stress disorder (PTSD), have also been linked to a loss of volume in the
PFC and striatum and associated impairments in cognitive function and sleep homoeostasis,
which suggests that exacerbated cortisol levels, such as those observed in preHD, may
accelerate the onset and progression of disease features, particularly cognitive and mood
disturbances (Sapolsky, 1999; Staufenbiel et al., 2013). Chronically elevated cortisol levels
have also been associated with reduced levels of BDNF in wild-type and schizophrenia rodent
models and in humans in other clinical populations, including schizophrenia and major
depressive disorder (Issa et al., 2010; Smith, Makino, Kvetňanský, & Post, 1995). This
reduction in BDNF could further exacerbate loss of volume in striatal and extra-striatal
structures and further disrupt melatonin release and HPA-axis function. Such an association
between chronic cortisol release and reduced BDNF requires further investigation in preHD
for treatment strategies.
2.6 Effects of Glucocorticoids on BDNF
BDNF is essential for survival, differentiation and outgrowth of neurons in the central and
peripheral nervous systems and protects neurons from excitotoxin-induced degeneration
(Bemelmans et al., 1999; Husson et al., 2005). BDNF is synthesised in cortical neurons and
delivered to the striatum via axonal transport of vesicles (Altar et al., 1997; L. J. Goodman et
al., 1996). BDNF deficits have been documented in cell lines expressing mHTT and in brains
of HD mouse models and patients at post-mortem (Ferrer et al., 2000; Gauthier et al., 2004;
Zuccato et al., 2001; Zuccato et al., 2005). Analyses of post-mortem brain tissue of four HD
subjects indicated regional BDNF deficits of between 53% and 82% in the caudate and
putamen compared to age-matched controls (Ferrer et al., 2000; Gauthier et al., 2004),
suggesting that volume loss in these regions may, at least in part, be mediated by a lack of
neurotrophic factor support.
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Significantly elevated glucocorticoids have been reported to decrease the expression of BDNF
in animal models and other clinical populations (Issa et al., 2010; Smith, Makino, Kvetňanský,
et al., 1995). Chronic stress in rodents induced by repeated restraint results in a negative
correlation between plasma glucocorticoid levels and hippocampal BDNF mRNA expression
(Murakami, Imbe, Morikawa, Kubo, & Senba, 2005; Smith, Makino, Kvetnansky, et al., 1995).
Furthermore, exogenous administration of glucocorticoids is associated with a transient, dosedependent reduction in BDNF mRNA and protein in the hippocampus of adrenalectomized
(ADX) rodent models (Hansson et al., 2006; Schaaf, de Jong, de Kloet, & Vreugdenhil, 1998).
However, five days of oral corticosterone treatment in the R6/1 HD mouse model did not
significantly affect hippocampal BDNF expression, emphasising the need to characterise the
effects of chronic elevated stress on BDNF levels in HD animal models and patients. It is
conceivable that elevated glucocorticoid levels, as observed in preHD, contribute to decreased
BDNF expression, thereby potentiating neuronal dysfunction and cell loss in cortical and subcortical brain structures.
In addition to supporting normal neuronal functioning, BDNF is thought to be integral in the
homeostatic regulation of sleep (Datta, Knapp, Koul-Tiwari, & Barnes, 2015). Alterations in
BDNF signalling as a result of irregular cortisol regulation may potentiate sleep deficits, which
are evident early in HD. The interplay between glucocorticoids, neurotrophic factor support
and sleep are not well understood but are likely to be important considerations in better
understanding the interaction of the HPA-axis and circadian rhythm disruption as features of
HD.
2.7 Pathologies of the HPA-Axis and SCN in HD
mHTT causes progressive neuronal dysfunction and cell loss in striatal and extra-striatal
regions, including the hypothalamic nuclei (H. Li, Li, Johnston, Shelbourne, & Li, 2000;
Tabrizi et al., 2011). Studies in mouse models report significant degeneration of the
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hypothalamus, as well as pituitary and adrenal pathologies (Björkqvist et al., 2006; Du et al.,
2012; Petersén & Björkqvist, 2006; Sathasivam et al., 1999). Post-mortem and structural
imaging studies in HD mutation carriers have reported volume loss in the hypothalamus, with
significant hypothalamic nuclear atrophy, neuronal loss (particularly that of the nucleus
tuberalis lateralis (NTL) and lateral hypothalamus (Kremer et al., 1991; Kremer et al., 1990))
and microglial activation (Douaud et al., 2006; Gabery et al., 2010; Kassubek et al., 2004;
Politis et al., 2008). Post-mortem studies have also reported loss of orexin-releasing neurons,
responsible for innervating the SCN, in the hypothalamus in HD (Aziz et al., 2008; Petersén et
al., 2005). Loss of this neuronal population is thought to contribute to circadian rhythm
disturbances, HPA-axis dysfunction and subsequent alterations in cortisol release (Petersén et
al., 2005). Moreover, HPA-axis dysregulation has been proposed as a contributing factor to comorbid depression in neurodegenerative diseases, including HD (for a comprehensive review,
see Du & Pang, 2015).
Hypothalamic atrophy has also been reported in preHD individuals using voxel-based
morphometry (VBM) (Soneson et al., 2010). This may, at least in part, explain the observed
alterations in cortisol release in preHD. A recent study, however, reported no hypothalamic
volume loss in preHD individuals at a 12 month follow-up scan (Gabery et al., 2015). These
conflicting findings reinforce the need to better characterise hypothalamic and other regional
volumetric changes in preHD, and determine whether such changes mediate or contribute to
circadian rhythm disturbances and clinical features in HD.
2.8 Circadian Rhythm Disruption in HD
Circadian rhythmicity is progressively disrupted in HD, suggesting a possible bi-directional
relationship with the neurodegenerative disease process (for a review see Videnovic et al.,
2014). Support for this notion comes from transgenic animal models of HD, such as in the
R6/2, R6/1 and BACHD mice, which have shown that circadian disruption precedes the
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presentation of disease features (Kudo et al., 2011; Maywood et al., 2010; Morton et al., 2005).
Furthermore, humans with manifest HD also display circadian rhythm abnormalities, with
disturbances in rest-activity profiles and abnormal day-night ratios, as well as alterations in
sleep-wake timing and melatonin and cortisol profiles (Hurelbrink et al., 2005; Morton et al.,
2005; Videnovic et al., 2014). The neurobiology underlying these changes has yet to be
clarified.
Several studies point to alterations in the SCN as being central to circadian disruptions in HD.
For example, in the R6/2 mouse model of HD the rhythmic transcription of core clock genes
in the SCN and other brain regions is disrupted in vivo, but then rescued when assessed in in
vitro explants, suggesting that circadian deficits are due to alterations of the intrinsic circuitry
of the SCN (Maywood et al., 2010; Morton et al., 2005). This is supported by a reduced
circadian rhythm in spontaneous electrical activity in SCN neurons in BACHD transgenic mice
(Kudo et al., 2011). Histopathological studies reveal reduced protein levels of VIP and AVP
within the SCN of HD patients at post-mortem (van Wamelen et al., 2013). In transgenic animal
models of HD, the decrease in VIP levels is associated with circadian disruption (Fahrenkrug,
Popovic, Georg, Brundin, & Hannibal, 2007). Recent evidence from Alzheimer’s disease (AD)
patients indicates that the number of VIP-expressing SCN neurons in the post-mortem brain
correlates with circadian rhythm amplitude of motor activity (J. L. Wang et al., 2015).
Disruption of circadian rhythmicity has the potential to affect a broad range of molecular,
cellular and physiological processes, most noticeably sleep (Archer et al., 2014; Lazar et al.,
2015). Disturbances in sleep are known to have multiple negative consequences on human
physiology, including neuronal dysfunction and loss of brain volume (Joo et al., 2013),
metabolic disturbances (Schmid, Hallschmid, & Schultes, 2015), immune dysregulation (Irwin,
2002), impaired cardiovascular function (Zhong et al., 2005), cognitive impairments (Lo et al.,
2012) and mood disturbances (Dinges et al., 1997). Sleep disturbance can, by itself, cause
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further disruption to circadian rhythmicity (Moller-Levet et al., 2013). It is highly likely that
sleep and circadian disturbances are interrelated in HD.
2.9 Melatonin and Sleep Disturbance in HD
Melatonin promotes the onset of sleep by inducing the thermoregulatory cascade (Krauchi et
al., 2000). Significant decreases in mean and acrophase (times of peak rhythm) melatonin
levels have been reported in manifest HD, with trends towards decreased melatonin levels in
preHD (Kalliolia et al., 2014). A temporal shift in melatonin release has also been documented
in HD mutation carriers, which could explain documented sleep disturbances (Kalliolia et al.,
2014). The morning rise phase of melatonin has also been shown to be delayed in HD
individuals (Aziz, Pijl, Frölich, Schroder-van der Elst, et al., 2009), which provides a
mechanism underlying the delayed sleep-wake timing reported to occur in these patients (Aziz
et al., 2010; A. O. Goodman, Morton, & Barker, 2010). The precise mechanism responsible for
the decrease or delayed melatonin levels observed in HD is unclear, but could potentially be
attributed to the progressive neuronal dysfunction in the SCN (Kalliolia et al., 2014; van
Wamelen et al., 2013).
Disrupted or restricted sleep leads to increased activity of the HPA-axis (Meerlo et al., 2008).
Acute sleep deprivation is associated with increased sympathetic activation, reflected by
increases in heart rate and blood pressure (Zhong et al., 2005) and has been described as a
chronic stressor that can elevate glucocorticoids and exacerbate disease pathways, such as
neuronal dysfunction and degeneration (Leproult, Copinschi, Buxton, & Van Cauter, 1997;
McEwen, 2006). It is also important to note that disturbances in sleep, particularly disruption
of slow wave sleep and decreased sleep duration, result in declines in cognitive and motor
performance, as well as altered mood (Ferrie et al., 2011; Mander et al., 2015; Mander, Rao,
Lu, Saletin, Ancoli-Israel, et al., 2013; Mander, Rao, Lu, Saletin, Lindquist, et al., 2013).
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Studies in animal models have shown that sleep deficits can negatively affect hippocampal
function, and can lead to impaired synaptic plasticity (long-term potentiation) and changes in
N-Methyl-D-Aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor signalling and fluctuations in levels of glutamate, a ligand for these receptors
(Kopp, Longordo, Nicholson, & Lüthi, 2006; Ravassard et al., 2009). Sleep has been reported
to promote the formation of branch-specific dendritic spines following motor learning in mice,
with disruption of non-REM (NREM) sleep preventing the formation of branch-specific
dendritic spines (Yang et al., 2014). Furthermore, sleep has been shown to drive clearance of
neurotoxic waste from the central nervous system in mice and disruption of sleep could
potentially facilitate accumulation of these substances (Xie et al., 2013). Sleep deficits have
also been shown to negatively affect executive functions associated with the PFC, such as
working memory and lateral thinking, likely due to the differential activation of adenosine
receptors and disruption of synaptic homeostasis (Florian, Vecsey, Halassa, Haydon, & Abel,
2011; Harrison & Horne, 1998; Lo et al., 2012). Loss of volume of the frontal, temporal and
parietal cortices are associated with sleep deficits (Sexton, Storsve, Walhovd, Johansen-Berg,
& Fjell, 2014) and could also affect executive functions associated with these regions.
Sleep disturbances have been reported in manifest HD, with several studies reporting insomnia,
decreased REM, slow wave sleep and sleep efficiency, advanced sleep phase, frequent
nocturnal awakenings and increased periodic leg movements (PLMs) (Arnulf et al., 2008;
Hansotia et al., 1985; Morton et al., 2005; Neutel et al., 2015; Piano et al., 2015; Wiegand,
Möller, et al., 1991). Furthermore, a recent study by Lazar et al (2015) showed that sleep
disruption is evident in preHD, characterised by a fragmented sleep profile and a decrease in
theta power during REM sleep (Lazar et al., 2015). These features were associated with disease
burden score. It is notable that sleep deficits seem to appear at a time when cognitive
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impairments also start to emerge, indicating a potential relationship between these disease
features.
Sleep deficits are of particular interest in HD, as cognitive functions associated with both the
hippocampus and PFC are affected in this population before disease onset (Tabrizi et al., 2011),
and can be negatively impacted by sleep disturbances, as well as increased glucocorticoids
(Belanoff, Gross, Yager, & Schatzberg, 2001; Blagrove et al., 1995; Oei, Everaerd, Elzinga,
van Well, & Bermond, 2006). Ultimately, alterations in circadian rhythm marked by changes
in the molecular clock and facilitated by hypothalamic and SCN pathologies, could result in
changes in melatonin release and increased cortisol levels, with resultant sleep disturbances,
which are likely to potentiate neurodegeneration and associated changes in cognitive and motor
deficits and mood disturbances in HD.
2.10 Environmental Enrichment: A Comprehensive Non-Pharmaceutical Strategy to
Reduce the Impact of Circadian Rhythm Disturbances and HPA-Axis Dysfunction in HD
Several non-pharmaceutical strategies have been employed to ameliorate circadian and HPAaxis dysfunctions in mouse models of HD, including bright light and behavioural therapy
(Cuesta et al., 2014) and environmental enrichment (EE). EE is an experimental approach
reported to change intrinsic and behavioural rest-activity circadian rhythmicity and
glucocorticoid release and has been widely studied in transgenic and drug-induced AD,
Parkinson’s disease (PD) and HD mouse models (reviewed in Nithianantharajah & Hannan,
2006). EE employs exercise, cognitive and sensory stimulation to promote neurogenesis and
improve cognitive and behavioural function, motor features and overall pathological processes
underpinning these clinical features (Hannan, 2014; Lazic et al., 2006; Nithianantharajah &
Hannan, 2006).
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The first demonstration that EE could be beneficial in a genetic animal model involved HD
mice (van Dellen, Blakemore, Deacon, York, & Hannan, 2000) and demonstrated that EE could
delay disease onset and progression displayed by improved motor function and preserved
peristriatal brain structures. Ensuing investigations revealed that EE has cognitive and body
composition benefits in R6/2 (Hockly et al., 2002) and N171 HD mice (Schilling et al., 2004),
while also ameliorating cognitive deficits (Nithianantharajah, Barkus, Murphy, & Hannan,
2008) and affective (depressive-like) abnormalities in R6/1 mice (Pang, Du, Zajac, Howard, &
Hannan, 2009; Renoir et al., 2013). Considering the more rapid disease progression of the R6/2
model compared to R6/1, this demonstrates that EE is effective in both rapid and more
prolonged disease progression phenotypes.
EE has been reported to increase the length of neuronal dendrites in the dorsomedial nucleus
of the hypothalamus, which is thought to play a role in the circadian control of sleep and waking
behaviours (Chou et al., 2003), and alter stress reactivity in outbred rats (Francis, Diorio,
Plotsky, & Meaney, 2002; Mitra & Sapolsky, 2012), and in the female R6/1 mouse model, EE
modulates HPA-axis activity (Du et al., 2012). Furthermore, circadian rhythm disturbances
have also been ameliorated through bright light therapy and exercise in the R6/2 mouse model
(Cuesta et al., 2014). This demonstrates that environmental interventions have the potential to
modulate functions of the HPA-axis and the SCN in mouse models of HD and warrants further
investigation into whether this can be recapitulated in the human HD population.
Moreover, EE in HD mice has been shown to rescue BDNF protein levels in the striatum and
hippocampus (Spires et al., 2004), with associated delays in disease onset, including a reduction
in cognitive decline (Nithianantharajah et al., 2008). These studies suggest that modulation of
HPA-axis function and circadian rhythm facilitated by EE may, at least in part, rescue BDNF
levels, ultimately contributing to neuroprotection and neurogenesis (Mattson, 2012).
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Evidence suggests that physical activity in itself can be beneficial in delaying the progression
of HD in mouse models. Pang et al. (2006) demonstrated that voluntary wheel running delayed
onset of rear paw clasping, a feature of HD in mouse models, ameliorated cognitive deficits
and also normalised rearing behaviour (Pang et al., 2006). Additionally, wheel running from a
juvenile age (4 weeks) delayed onset of rear paw clasping and of deficits in motor coordination
and rescued locomotor activity and exploratory behaviour (van Dellen, Cordery, Spires,
Blakemore, & Hannan, 2008). It has been suggested that some of the behavioural
improvements resulting from voluntary physical activity are modulated by the upregulation of
monoamines, such as serotonin, dopamine and nor-adrenaline, across several brain regions
(Renoir, Chevarin, Lanfumey, & Hannan, 2011). Interestingly, wheel running is associated
with sex-dependent increases in BDNF expression, with only female HD mice exhibiting
increases in BDNF following physical activity alone and male HD mice showing increases in
BDNF only following EE (Zajac et al., 2010). This indicates that voluntary physical activity
can up-regulate key molecules that modulate cognitive and behavioural changes in mouse
models of HD in a sex-dependent manner.
Studies in several animal disease models have demonstrated the importance of social
interaction in mediating the benefits of EE. For example, co-housed AD APP/PS1 mouse
models exhibit amelioration of memory deficits facilitated by increased BDNF-dependent
neurogenesis in the hippocampus (Hsiao, Hung, Chen, & Gean, 2014). Transgenic HD sheep
exhibit circadian abnormalities when housed only with other HD flock, with circadian
abnormalities absent in those HD gene positive sheep housed with wild-type sheep (Morton et
al., 2014). Although physical activity and co-housing, when assessed alone, can produce
positive outcomes in mouse models of HD, greater beneficial effects are observed when used
in conjunction with other components of EE. Such findings demonstrate that environmental

47

interventions have a positive impact on disease processes in animal models of HD and warrant
further investigation into the translation of these programs into the human HD population.
2.11 Effects of Multidisciplinary Therapy on Brain Volume and Potential Biomarkers of
HD in Humans
Preclinical studies show that EE has positive effects on the pathological and clinical course of
HD. However, translation of EE from the laboratory to the clinic has proven difficult due to
the strict parameters of the experimental model, such as diet and housing conditions. Several
research teams have, nevertheless, begun to address some of these translational gaps using
multidisciplinary therapy; a complex, interdisciplinary therapeutic approach comprising
physical activity, cognitive stimulation and social interaction.
Studies evaluating the utility of multidisciplinary therapy have documented significant changes
in grey matter volume, as well as improvements in memory, processing speed, balance and
gait, mood and quality of life in patients with manifest HD (Cruickshank et al., 2015; Piira et
al., 2013; Thompson et al., 2013; Veenhuizen et al., 2011). Recent data from our research
programme has shown, in particular, that multidisciplinary therapy increases grey matter
volume in the caudate tail and dorsolateral PFC in patients with manifest HD (Cruickshank et
al., 2015). This therapy has also been reported to improve cognitive function, quality of life
and depressive symptoms in patients with mild AD and cognitive impairment without dementia
(Santos et al., 2015) and in PD, multidisciplinary therapy has been reported to improve motor
performance, dyskinesias, balance and gait and slow disease progression (Frazzitta,
Abbruzzese, et al., 2013; Frazzitta et al., 2012; Frazzitta, Bertotti, et al., 2013). The molecular
mechanisms driving these neural and clinical changes are yet to be investigated. Several lines
of evidence suggest, however, that multidisciplinary therapy may restore normal HPA-axis
function, circadian rhythmicity and basal BDNF levels, promoting neural and clinical benefits
in HD.
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EE is capable of restoring normal HPA-axis function, circadian rhythmicity and basal BDNF
levels in HD mouse models (Cuesta et al., 2014; Du et al., 2012; Zajac et al., 2010), with
significant delays in peristriatal degeneration and cognitive and motor decline
(Nithianantharajah et al., 2008; Pang et al., 2006; van Dellen et al., 2008), which could be
facilitated by restoration of the HPA-axis and circadian rhythmicity and increases in BDNF
levels. While these positive molecular changes are yet to be reported in patients with HD,
evidence from other diseases suggests that multidisciplinary therapy may impact on the
neuropathological and clinical course of the disease in a similar fashion to EE. For example, in
PD multidisciplinary therapy has been reported to increase serum BDNF levels and lessen
clinical burden in the early stages of the disease (Frazzitta, Maestri, Bertotti, et al., 2015;
Frazzitta et al., 2014).
The effects of multidisciplinary therapy on HPA-axis function, stress reactivity and circadian
rhythmicity are yet to be investigated in any disease population. Furthermore, the effects of
this therapy on BDNF in HD are also yet to be reported. However, the benefits of EE on the
HPA-axis, BDNF levels and circadian rhythmicity in HD mouse models, both before disease
features appear and following onset, the increase in serum BDNF in PD patients and the
increase in brain volume in manifest HD patients following multidisciplinary therapy, highlight
the importance of assessing the effects of this therapy on HPA-axis function, circadian
rhythmicity and BDNF levels in HD. It is conceivable that multidisciplinary therapy could
regulate the HPA-axis, and possibly circadian rhythm, and increase BDNF levels, resulting in
the positive brain changes observed in HD individuals following this therapy. Rationale for
this can be seen in other populations when the effects of each of the components of
multidisciplinary therapy are evaluated individually.
Physical activity, cognitive training and social interaction have a range of benefits on striatal
and extra-striatal brain structures, HPA-axis function, circadian rhythm and BDNF levels.
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Higher physical activity levels are associated with increased hippocampal and PFC volume,
accompanying improvements in memory in healthy older adults (Colcombe et al., 2006;
Erickson et al., 2011) and increased BDNF levels (de Melo Coelho et al., 2014; Pereira et al.,
2013). The latter could be mediated by the continual induction and eventual down-regulation
of the stress response due to acute, transient increases in cortisol following exercise (Luger et
al., 1987), leading to an adaptive stress response. The regulation of circadian rhythmicity and
melatonin levels by exercise, indicated by shifts in onset and increases in peak melatonin
release (Buxton, Lee, L'Hermite-Baleriaux, Turek, & Van Cauter, 2003; Miyazaki, Hashimoto,
Masubuchi, Honma, & Honma, 2001), could also facilitate an increase in BDNF and regulation
of the HPA-axis, and lead to improvements in brain volume and associated functions.
Cognitive training has also been documented to increase grey matter volume in the cortex in
regions involved in episodic memory in individuals with subjective memory impairment, a
common risk factor for AD (Engvig et al., 2014). Furthermore, cognitive training has been
shown to reduce stress-related symptoms and improve sleep onset latency and efficiency in
individuals with stress-related exhaustion (Gavelin, Boraxbekk, Stenlund, Järvholm, & Neely,
2015) and in older adults with insomnia (Haimov & Shatil, 2013), respectively. The regulation
of stress symptoms and improved sleep efficiency could facilitate an increase in BDNF, which
has been reported following cognitive training in individuals with PD (Angelucci et al., 2015).
Lastly, social interaction has been shown to increase whole brain volume, with associated
improvements in visual attention and verbal learning (Mortimer et al., 2012). Social interaction
attenuates the cortisol response to stressful stimuli, likely through coping or resiliency
mechanisms (Kirschbaum, Klauer, Filipp, & Hellhammer, 1995), which is likely to facilitate
the increase in BDNF observed in AD mouse models following social interaction (Hsiao et al.,
2014).
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These findings collectively indicate that lifestyle interventions could favourably impact on
clinical and pathological aspects of HD. Indeed, evidence from animal models and human
studies indicate that multidisciplinary therapy has significant potential to treat many of the
clinical consequences of HPA-axis and circadian rhythm disturbances in HD. Such an approach
may even have the potential to reduce the rate and/or forestall neuropathological changes that
occur in individuals with preHD.
2.12 Conclusion
HD individuals exhibit a wide spectrum of clinical features indicative of degeneration in striatal
and extra-striatal structures, including the hypothalamus. Hypothalamic pathologies are likely
to result in HPA-axis dysfunction and circadian rhythm dysregulation, features which have
been reported in HD mouse models and gene-positive individuals. The consequent increase in
glucocorticoids and dysregulation of melatonin and sleep patterns are associated with
decreased BDNF levels and have the potential to contribute to, or even exacerbate, disease
processes. Much is still to be understood about the interaction between glucocorticoids, BDNF
and sleep. However, emerging evidence of potential strategies to ameliorate negative
downstream consequences of these interactions, suggest a positive role for multidisciplinary
therapy. Preliminary studies using such strategies have demonstrated favourable effects on
HPA-axis and circadian rhythm disturbances in animal models of HD, as well as other clinical
populations, however the effects of multidisciplinary therapy on HPA-axis dysfunction,
circadian rhythmicity and BDNF levels in HD gene-positive individuals are yet to be
investigated.
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3.1 Abstract
Objective: Pathological changes within the hypothalamus have been proposed to mediate
circadian rhythm and habitual sleep disturbances in individuals with Huntington’s disease
(HD). However, investigations examining the relationships between hypothalamic volume and
circadian rhythm and habitual sleep in individuals with HD are sparse. This study aimed to
comprehensively evaluate the relationships between hypothalamic pathology and circadian
rhythm and habitual sleep disturbances in individuals with premanifest HD.
Methods: Thirty-two individuals with premanifest HD and twenty-nine healthy age- and
gender-matched controls participated in this dual-site, cross-sectional study. Magnetic
resonance imaging scans were performed to evaluate hypothalamic volume. Circadian rhythm
and habitual sleep were assessed via measurement of morning and evening cortisol and
melatonin levels, wrist-worn actigraphy, the Consensus Sleep Diary and sleep questionnaires.
Information on mood, physical activity levels and body composition were also collected.
Results: Compared to healthy controls, individuals with premanifest HD displayed
significantly reduced grey matter volume in the hypothalamus, decreased habitual sleep
efficiency and increased awakenings; however, no alterations in morning cortisol or evening
melatonin release were noted in individuals with premanifest HD. While differences in the
associations between hypothalamic volume and cortisol and melatonin output existed in
individuals with premanifest HD compared to healthy controls, no consistent associations were
observed between hypothalamic volume and circadian rhythm or habitual sleep outcomes.
Conclusion: While significant differences in associations between hypothalamic volume and
cortisol and melatonin existed between individuals with premanifest HD and healthy controls,
no differences in circadian markers were observed between the groups. This suggests that
circadian regulation is maintained despite hypothalamic pathology, perhaps via neural
compensation. Longitudinal studies are required to further understand the relationships
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between the hypothalamus and circadian rhythm and habitual sleep disturbances in HD as the
disease course lengthens.

3.2 Introduction
Circadian rhythm and habitual sleep disturbances are common features of Huntington’s disease
(HD) that occur early in the disease course and exacerbate impairments in cognitive function,
metabolism, hormone regulation, mood and quality of life (Aziz et al., 2010; BriançonMarjollet et al., 2015; Lazar et al., 2015; Morton et al., 2005).
A number of studies have reported dysregulation of markers of circadian rhythm and habitual
sleep-wake outcomes in individuals with HD. In particular, increased morning cortisol output
has been reported in individuals with premanifest HD (Hubers et al., 2015; van Duijn et al.,
2010). Reduced mean and acrophase concentrations and a temporal spread of melatonin
release, indicating a potential phase shift in melatonin, have been reported in individuals with
premanifest HD (Kalliolia et al., 2014). Furthermore, studies have reported disruption of the
sleep-wake cycle and delayed sleep phase in individuals with HD (Aziz et al., 2010; Morton et
al., 2005). Despite these findings, the neurobiological origin of circadian rhythm and habitual
sleep-wake disturbances in individuals with HD has been poorly investigated and warrants
further exploration.
Pathological changes within the hypothalamus have been proposed to disrupt circadian rhythm
and sleep in individuals with HD (Aziz et al., 2010; Morton et al., 2005). Hypothalamic nuclei,
particularly the suprachiasmatic nucleus, are known to be integrally involved in the regulation
of circadian markers such cortisol and melatonin, as well as sleep (Saper et al., 2005; Steiger,
2002). Studies have reported grey matter volume loss and microglial activation within the
hypothalamus and circadian rhythm and sleep disturbances that arise concomitantly in
individuals with premanifest HD (Lazar et al., 2015; Morton et al., 2005; Politis et al., 2008;
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Soneson et al., 2010). Despite these findings, only one study has examined the potential link
between neural pathology and circadian rhythm and sleep disturbances in individuals with HD
(Baker et al., 2016). Baker et al (2016) reported an association between subjective sleep
disturbances and neural pathology in HD. However, authors did not use formalised sleep
questionnaires to examine sleep and did not evaluate markers of circadian rhythm relative to
neural pathology. There is, therefore, a need for subsequent research to investigate more closely
the potential relationships between hypothalamic pathology and circadian rhythm and sleep
disturbances in HD.
The purpose of this study was to evaluate whether hypothalamic pathology is associated with
the dysregulation of biological and clinical markers of circadian rhythm, particularly cortisol,
melatonin and sleep-wake timing, and habitual sleep in individuals with premanifest HD. We
hypothesized that hypothalamic pathology would be associated with dysregulation of circadian
rhythm and habitual sleep, as evidenced by significant alterations in cortisol and melatonin
release and habitual sleep-wake cycles in individuals with premanifest HD.
3.3 Materials and Methods
3.3.1 Participants
Thirty-five premanifest HD individuals and 31 age- and gender-matched healthy controls were
recruited from existing databases, HD clinics and media advertisements in Perth and
Melbourne. Inclusion criteria for premanifest HD individuals were a cytosine-adenine-guanine
(CAG) repeat length ≥ 40 and a diagnostic confidence score < 2 on the Unified Huntington’s
Disease Rating Scale Total Motor Score (UHDRS-TMS) (Reilmann, Leavitt, & Ross, 2014).
Exclusion criteria for all participants were, presence of known musculoskeletal, metabolic,
endocrine, cardiovascular or sleep disorders, recent or long-standing substance abuse, shift
work other neurological conditions and, for healthy controls, a family history of HD. Five
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participants withdrew from the study or contributed incomplete data and were excluded from
analyses, leading to a total of 32 premanifest HD and 29 healthy individuals.
All aspects of the study were conducted in accordance with the Declaration of Helsinki. Ethical
approval was granted by the Edith Cowan University and Monash University Human Research
Ethics Committees. All participants provided written informed consent.
3.3.2 Study Procedures
Testing procedures included 3T MRI scans for hypothalamic imaging, saliva sampling to
quantify morning cortisol and evening melatonin, wrist-worn actigraphy for monitoring sleep,
a sleep diary for monitoring habitual sleep patterns and questionnaires for monitoring sleep
quality, psychological stress, physical activity, anxiety and depression.
3.3.3 Acquisition and Pre-Processing of MRI Data
T1-weighted structural images of the brain were obtained from each participant in Perth or
Melbourne using a GE Healthcare Discovery and a Siemens Skyra 3T MRI scanner,
respectively. In Perth, images were acquired with a 24-channel head coil using an IR-SPGR
sequence (TA = 9 m 59 s, TR = 3 s, TE = Min, TI = 400 ms, flip angle = 11˚, field of view =
256 mm, image matrix = 256 x 256, 1 mm3 isotropic voxels). In Melbourne, acquisition took
place with a 32-channel head coil and an MP-RAGE sequence (TA = 9 m 14 s, TR = 2.3 s, TE
= 2.96 ms, TI = 900 ms, flip angle = 9˚, field of view = 256 mm, image matrix = 256 x 256).
Images were acquired consistently across both sites according to the Alzheimer’s Disease
Neuroimaging Initiative protocols for multi-site imaging (Jack et al., 2008). Pre-processing of
images was conducted according to the SPM12 pipeline (supplementary data, section 3.10).
3.3.4 Measurement of Biological Markers of Circadian Rhythm
Salivary cortisol and melatonin have previously been shown to be useful measures of circadian
rhythm (Dickmeis, 2009; Voultsios, Kennaway, & Dawson, 1997). Participants were given
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written and verbal instructions to collect saliva samples by passive drool into polypropylene
collection tubes (SSI Bio) at the same time on two consecutive days for determination of
morning cortisol and evening melatonin concentrations. Participants collected saliva samples
at four time points in the morning (15, 30, 45 and 60 minutes following awakening) for morning
cortisol analysis and four time points in the evening at one hour intervals from two hours before
their usual bedtime (T1) until one hour after their usual bedtime (T4) for melatonin analysis.
Saliva samples were collected according to criteria from previous studies (van Duijn et al.,
2010; Voultsios et al., 1997) to avoid contamination of samples (see supplementary files).
Based on these criteria, a questionnaire was devised to monitor participant compliance. Saliva
samples were stored at -80˚C until analysis using commercially available salivary cortisol and
melatonin ELISA kits (Salimetrics, USA) according to the manufacturer’s instructions.
3.3.5 Measures of Habitual Sleep-Wake Parameters
Actigraphy
At the commencement of the study, a convenience sample of individuals with premanifest HD
and healthy controls were given the opportunity to undertake habitual sleep monitoring using
actigraphy. Of the original cohort, 19 premanifest HD and 24 healthy individuals underwent
home-based actigraphy sleep measurement for seven consecutive nights to assess habitual
sleep-wake patterns. Actigraphy was recorded at 30 Hz using wrist-worn GT3X+ ActiGraph
monitors (ActiGraph, USA) on the non-dominant wrist. The start and end time of sleep periods
were recorded using the Consensus Sleep Diary (Carney et al., 2012).
Wrist-based actigraphy has been used previously to assess circadian rhythm via analysis of
habitual sleep-wake patterns in individuals with HD and in other populations (Ancoli-Israel,
Cole, et al., 2003; Morton et al., 2005). Therefore, here we similarly used ActiGraph monitors,
which were initialised, downloaded and analysed using the ActiLife software (version 6.8).
Data were scored with a low frequency extension filter in 60 second epochs as awake or sleep
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according to the Cole-Kripke algorithm (Cole, Kripke, Gruen, Mullaney, & Gillin, 1992). Total
sleep time, sleep onset latency, wake after sleep onset, number of awakenings and sleep
efficiency outcomes were calculated for each night and then averaged across the seven nights
to obtain single values for use in subsequent analyses.
Consensus Sleep Diary
Habitual sleep-wake timing was evaluated using the Consensus Sleep Diary (Carney et al.,
2012). Participants were required to document time in bed, time of awakening, time to sleep
onset, number of awakenings and sleep quality for seven nights in combination with actigraphy
assessment.
Subjective Sleep Quality and Daytime Somnolence
Sleep quality was assessed in all participants using the Pittsburgh Sleep Quality Index (PSQI)
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). Daytime somnolence was measured
using the Epworth Sleepiness Scale (ESS) (Johns, 1991).
3.3.6 Stress, Anxiety and Depression Symptomatology
The Perceived Stress Scale (Cohen, Kamarck, & Mermelstein, 1983) was used to measure
psychological stress in the previous month. The Perceived Stress Scale has been demonstrated
to be a valid measure of perceived psychological stress in individuals with HD (Downing et
al., 2011). Symptoms of anxiety and depression were measured using the Hospital Anxiety and
Depression Scale (HADS). This scale has been previously demonstrated to be valid and reliable
in HD (De Souza, Jones, & Rickards, 2010).
3.3.7 Physical Activity
Physical activity levels were recorded prior to and during saliva sampling days using the
Minnesota Leisure Time Physical Activity Questionnaire. Metabolic equivalents (METs) were
calculated using recorded physical activity levels, the Compendium of Physical Activities
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database and estimated resting metabolic rate (RMR) (Ainsworth et al., 2011). RMR was
calculated using the Harris-Benedict formula (see supplementary file) (Harris & Benedict,
1918).
3.3.8 Statistical Analysis
Hypothalamic Volume
A hypothalamus mask from the WFU Pick Atlas (http://fmri.wfubmc.edu/software/pickatlas),
dilated by 3mm, was used to restrict analysis to this area (Breen et al., 2016). Grey matter
images from individuals with premanifest HD and healthy controls were compared voxel-wise
using a two-sample t-test to evaluate group differences in the hypothalamus. Gender, site and
age were included as covariates of no interest. Next, we investigated group differences in the
association between hypothalamic volume and cortisol and/or melatonin output in individuals
with premanifest HD compared to healthy controls, using a categorical by continuous covariate
interaction model. The model included group regressors, one for each group, and regressors
modelling change in cortisol or melatonin output, one for each group. The following contrasts
were used to model the group by cortisol/melatonin output interaction effect: [0 0 1 -1] and [0
0 -1 1]. Gender, site, age, PSS, ESS, and PSQI were included as covariates of no interest. In
premanifest HD, we adjusted also for CAP score.
We also evaluated the relationship between hypothalamic volume and disease status (i.e. CAP
score). Given the exploratory nature of this study and our a priori interest in the hypothalamus,
the threshold for statistical significance for all analyses was set at α = 0.05.
Salivary Cortisol and Melatonin
Missing data points from saliva sampling (removed due to suspected blood contamination)
were imputed by calculating the average of the previous and subsequent values in the curve
(n= 2 of 504, 0.40%), unless the missing value was the first time point in each curve (n= 3 of
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504, 0.60%), in which case the group average was imputed to avoid removing the participant
from analyses and maintain sample size (van Duijn et al., 2010). Area under the curve with
respect to ground (AUCG) was calculated using the trapezoid rule for morning cortisol and
evening melatonin output on the two consecutive days (Dijk et al., 2012; van Duijn et al., 2010).
Normality assumptions for all variables were tested using a Shapiro-Wilk test. Between-group
differences were examined using a t-test for continuous variables and a two sample proportion
test for categorical variables. Spearman correlation coefficient was calculated to assess
relationships between cortisol AUCG, melatonin AUCG and Perceived Stress Scale, PSQI and
Consensus Sleep Diary scores. Statistical significance was set at p ≤ 0.05. Statistical analyses
were performed using STATA version 9.1.
3.4 Results
3.4.1 Participant Demographics and Clinical Characteristics
There were no significant differences for age or gender between premanifest HD patients and
healthy controls (p = 0.472 and 0.283, respectively; Table 3.1).
3.4.2 Hypothalamic Volume
A significant decrease in grey matter volume in the anterior-superior region of the left side of
the hypothalamus was observed in individuals with premanifest HD compared to healthy
controls (peak voxel at MNI -9 1 -4; t = 2.38; k = 22; see, Figure 3.1A). We also found a
significant negative association in premanifest HD between grey matter volume bilaterally in
the anterior-superior and anterior-inferior regions of the hypothalamus and CAP score (r = 0.42; see Table 3.3 and Figure 3.1B).
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Figure 3.1. Hypothalamic volume in its association with cortisol and melatonin output.
Results from voxel-based morphometry analyses showing overlap between maps of (A)
the hypothalamic volume group difference, (B) association between hypothalamus loss
and CAPs in premanifest HD, (C) group by cortisol output interaction and (D) group
by melatonin output interaction. (E) shows the map of group by cortisol output
interaction effect on hypothalamic volume (as per voxel-wise analysis) and a scatterplot
illustrating the interaction and (F) shows the map of group by melatonin output
interaction effect on hypothalamic grey matter volume and scatterplot illustrating the
interaction. The data points in the scatterplot correspond to the average intensity across
all voxels within the area exhibiting a significant interaction effect for each participant.
Slice labels are displayed on top. Cross-slices are shown. Crosshairs in (A), (B), (C),
and (D) are centred at MNI -9 1 -5. L= left; R= right.
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3.4.3 Biological Markers of Circadian Rhythm
No significant differences were observed between individuals with premanifest HD and healthy
control participants in the amplitude of morning cortisol or evening melatonin output at any of
the time points sampled (p > 0.05; Table 3.2). Furthermore, no differences were observed in
total morning cortisol (p = 0.357) or evening melatonin (p = 0.219) output when subject to area
under the curve analysis with respect to ground (AUCG; Table 3.2).
3.4.4 Habitual Sleep Outcomes
Actigraphy
Premanifest HD individuals exhibited a decreased sleep efficiency compared to healthy
controls (p = 0.012). A significant increase in the number of awakenings (p = 0.039) and time
spent awake after sleep onset (p = 0.028) were also observed in premanifest HD participants
compared to healthy controls (Table 3.2).
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Table 3.1. Demographic and clinical characteristics of premanifest Huntington’s disease and
healthy control participants.
Premanifest HD

Healthy

p-value

(n=32)

Controls (n=29)

44.5 ± 11.4

44.3 ± 10.8

0.472

11 (34.4)

8 (27.6)

0.283

42.8 ± 2.8

N/A

N/A

47.4 (44.9-55.7)

N/A

N/A

Diagnostic Confidence Level, mean ± SD

0.38 ± 0.70

N/A

N/A

UHDRS-TMS, mean ± SD

4.35 ± 7.24

N/A

N/A

Disease burden score, mean ± SD

305.0 ± 76.8

N/A

N/A

CAPs, mean ± SD

0.89 ± 0.18

N/A

N/A

BMI, mean ± SD

26.47 ± 4.5

26.75 ± 5.9

0.417

Smoker, n (%)

6 (18.8)

0 (0.0)

0.007*

High alcohol consumption, n (%)**

5 (15.6)

6 (20.7)

0.303

Psychotropic medication, n (%)

3 (9.4)

5 (17.2)

0.181

3278.0 ± 6272.5

7481.2 ± 9584.5

0.022*

168 ± 359.2

85.1 ± 211.8

0.141

Demographic Characteristics
Age, mean ± SD
Male, n (%)
Clinical Characteristics
CAGn, mean ± SD
Estimated age of onset, median (IQR)

Monthly METs, mean ± SD
METs (previous day), mean ± SD

Group differences were analysed using t-tests for continuous variables and two sample proportion tests
for categorical variables. Disease burden score was calculated using the formula: age x (CAGn – 35.5).
CAPs was calculated using the formula: (age x (CAGn - 33.66))/432.3326.
*Results are significant at p < 0.05
**High alcohol consumption equates to in excess of 14 alcoholic drinks per week
HD = Huntington’s disease; CAGn = number of cytosine-adenine-guanine repeats; UHDRS-TMS =
Unified Huntington’s Disease Rating Scale-Total Motor Score; CAPs = scaled CAG age product score;
BMI = body mass index; MET= metabolic equivalents; METs (previous day) refers to the METs
calculated for the day prior to saliva sampling; N/A = not applicable.
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Consensus Sleep Diary
No significant differences were observed in self-report sleep outcomes using the Consensus
Sleep Diary (Table 3.2).
Subjective Sleep Outcomes
There were no significant differences between premanifest HD individuals and healthy controls
in global PSQI score (p = 0.134). The average PSQI score in the premanifest HD group fell
above the cut-off of 5, suggesting a disruption in sleep quality. Although healthy controls
scored significantly higher than premanifest HD individuals on the ESS, scores for both groups
remained within the normative range (< 10) (Johns, 1991).
3.4.5 Stress, Anxiety and Depression Questionnaires
No significant differences were observed in stress (p = 0.062), anxiety (p = 0.164) or depression
(p = 0.427) symptomatology between premanifest HD and healthy individuals (Table 3.2).
Furthermore, values on the Perceived Stress Scale and HADS were considered below
threshold, indicating no clinically meaningful stress, anxiety or depressive symptomatology in
the premanifest HD and healthy control groups.
3.4.6 Physical Activity
The premanifest HD group reported significantly less monthly physical activity (METs) than
healthy controls (p = 0.022; Table 3.1). Physical activity on the day prior to saliva sampling
did not differ between the groups, negating any acute effects of physical activity on hormone
levels. Furthermore, there was no association between reported physical activity levels and
measures of sleep, cortisol and melatonin output and hypothalamic volume.
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Table 3.2. Cortisol and melatonin values, subjective and objective sleep outcomes and stress,
anxiety and depression questionnaire scores for premanifest Huntington’s disease and healthy
control participants.
Cortisol nmol/L (mean ± SD)
Time of awakening (hh:mm)
Time of sample relative to awakening:
+15 mins
+30 mins
+45 mins
+60 mins
AUCG
Melatonin (pg/mL)
Reported usual bedtime (hh:mm)
Time of sample relative to bedtime:
-2 hrs
-1 hr
+0 hrs
+1 hr
AUCG
Actigraphy measures:
Total time in bed (min)
Total sleep time (min)
Sleep onset latency (min)
Wake after sleep onset (min)
Number of awakenings
Average duration of awakenings (min)
Sleep efficiency (%)
PSQI global score
Epworth Sleepiness Scale Score
Consensus Sleep Diary:
Total time in bed (min)
Total sleep time (min)
Sleep onset latency (min)
Wake after sleep onset (min)
Sleep efficiency
Number of awakenings
Average duration of awakenings (min)
Restorative quality of sleep
Perceived Stress Scale
HADS:
Total score
Anxiety
Depression

Premanifest HD

Healthy Controls

p-value

6:06 ± 1:01

6:21 ± 0:45

0.141

11.08 ± 4.40
13.84 ± 4.59
13.69 ± 3.56
12.26 ± 3.47
38.17 ± 11.30

11.28 ± 3.32
13.42 ± 4.29
13.30 ± 4.41
11.62 ± 3.72
39.20 ± 10.61

0.421
0.357
0.352
0.244
0.357

22:05 ± 0:50

22:10 ± 0:31

0.322

10.87 ± 7.68
12.16 ± 7.07
17.10 ± 9.30
19.42 ± 12.02
49.20 ± 25.88

10.02 ± 6.19
13.71 ± 7.84
19.44 ± 11.10
22.07 ± 11.11
44.41 ± 21.77

0.319
0.210
0.187
0.188
0.219

464.28 ± 46.73
403.17 ± 45.20
7.10 ± 6.80
54.02 ± 25.97
18.47 ± 6.72
2.87 ± 0.64
86.98 ± 5.42
5.76 ± 3.02
4.69 ± 3.61

458.58 ± 43.10
415.12 ± 40.25
4.39 ± 3.77
39.07 ± 16.87
14.55 ± 5.33
2.75 ± 0.87
90.68 ± 3.75
4.97 ± 2.44
6.76 ± 3.37

0.680
0.365
0.106
0.028*
0.039*
0.625
0.012*
0.134
0.025*

430.42 ± 61.33
385.82 ± 53.90
16.65 ± 19.90
19.04 ± 25.37
90.52 ± 5.17
1.25 ± 1.47
10.18 ± 23.46
3.75 ± 0.81
17.12 ± 6.72

434.84 ± 68.48
387.92 ± 74.77
14.35 ± 13.92
16.93 ± 22.89
89.32 ± 9.96
1.75 ± 1.03
8.97 ± 11.11
3.80 ± 0.92
19.86 ± 6.85

0.372
0.453
0.303
0.412
0.487
0.057
0.059
0.411
0.062

7.54 ± 5.30
5.06 ± 3.48
2.49 ± 2.52

8.38 ± 5.69
6.00 ± 3.97
2.38 ± 2.14

0.276
0.164
0.427

Data are reported as mean and standard deviation, unless stated otherwise. Group differences were
analysed using t-tests. AUCG was calculated using the trapezoid rule for morning cortisol and evening
melatonin output using the curve generated from the average cortisol values and the average melatonin
values, respectively. Sleep efficiency was calculated using the formula: (total sleep time/total time in
bed) X 100. PSQI score greater than 5 indicates poor sleepers. The Consensus Sleep Diary- restorative
quality of sleep item is a Likert scale ranging from 1 (not restorative) to 5 (very restorative). Higher
Perceived Stress Scale scores indicate greater stress. HADS sub-scores greater than 7 indicate clinically
relevant anxiety and depression symptomatology. *Results are significant at p < 0.05.
HD= Huntington’s disease; AUCG= area under the curve with respect to ground; PSQI= Pittsburgh Sleep
Quality Index; HADS= Hospital Anxiety and Depression Scale.
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3.4.7 Associations Between Hypothalamic Volume, Circadian Markers and Disease Status
A significant negative association was revealed by voxel-wise analysis between grey matter
volume in the left hypothalamus and morning cortisol output in the premanifest HD group.
This association was found to be moderate (r = -0.39), indicating that lesser grey matter volume
in the left side of the hypothalamus is associated with greater morning cortisol output. No
significant association was observed in the healthy control group (Figure 3.1E and Table 3.3).
This group difference in the association between hypothalamic volume and morning cortisol
output was statistically significant, as shown by interaction analysis (Figure 3.1C, Figure 3.1E
and Table 3.3). The group by cortisol output interaction encompassed two separate areas – first,
the region spanning the posterior hypothalamus and the superior tuberal hypothalamus and
second, the anterior-inferior hypothalamic region.
A negative relationship between grey matter volume in the right side of the hypothalamus and
morning cortisol output was seen in healthy controls, but not in premanifest HD participants,
and the group by cortisol output interaction was significant (Table 3.3). However, the
association between right hypothalamic grey matter volume and morning cortisol output in
healthy controls was weak (r = -0.06), indicating a non-existent relationship in this case.
Grey matter volume in the left side of the hypothalamus was positively associated with evening
melatonin output in healthy controls (r = 0.36), but not in premanifest HD individuals (Figure
3.1F and Table 3.3). This group difference in the correlation between hypothalamic volume
and evening melatonin output was statistically significant (Figure 3.1D, Figure 3.1F and Table
3.3). The group by melatonin output interaction encompassed the region extending from the
superior tuberal hypothalamus to the anterior-inferior hypothalamus.
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Table 3.3. Association analyses between hypothalamic volume and CAPs, cortisol and
melatonin
Side

CAPs
Negative association
premanifest HD

with

CAPs

in

Cortisol
Negative association with cortisol output in
premanifest HD
Group by cortisol output interaction
Melatonin
Positive association with melatonin output
in healthy controls
Group by melatonin output interaction

k

Peak voxel
t score

MNI
coordinates

B

204

3.16

-3 2 -7

L

161

2.54

-10 1 -4

L

186

2.32

-10 1 -4

L

161

2.67

-10 1 -6

L

201

2.41

-6 2 -8

Group differences were analysed using two-sample t-tests.
*Results are significant at p < 0.05, uncorrected.
k = No. of voxels; MNI = Montreal Neurological Institute; HD = Huntington’s disease; B = bilateral; L
= left.

3.4.8 Associations Between Hypothalamic Volume and Habitual Sleep Outcomes
No reliable pattern of associations was observed between hypothalamic volume and measures
of subjective sleep quality, sleep onset latency, number of awakenings, sleep efficiency or
perceived stress in the premanifest HD or healthy cohorts.
3.5 Discussion
Hypothalamic pathology and disturbances in circadian rhythm and sleep arise during the
premanifest stages of HD. Despite the central role of the hypothalamus in mediating the
circadian rhythm and sleep-wake timing, only one study has attempted to discern the possible
relationship between hypothalamic pathology and sleep disturbances in individuals with HD
(Baker et al., 2016). In the absence of robust data, the aim of this study was to examine the
potential relationship between hypothalamic pathology and circadian rhythm and habitual sleep
disturbances in individuals with premanifest HD.
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Consistent with previous findings (Soneson et al., 2010), significantly reduced grey matter
volume was observed in the hypothalamus of individuals with premanifest HD compared to
healthy controls. Using normative parcellations of the hypothalamus that rely on visible
anatomic landmarks in MR images (Makris et al., 2013), this reduced grey matter volume can
be located to the anterior-superior region of the hypothalamus, a region comprising the
paraventricular nucleus (PVN), which mediates the release of cortisol and melatonin. Reduced
hypothalamic volume was found to be associated with CAP score, suggesting a relationship
between estimated time to disease onset and loss of hypothalamic grey matter volume.
Interestingly, degeneration within the hypothalamus was leftward biased. The reason for this
is unknown. Studies have reported a leftward-biased pattern of grey matter atrophy in the
striatum in individuals with manifest HD (Minkova et al., 2018; Mühlau et al., 2007), however,
this has not been reported in the striatum or the hypothalamus in individuals with premanifest
HD. Minkova et al. (2018) postulated that the earliest pathological changes in the hypothalamus
occur on the left side and become more apparent as individuals approach clinical onset,
however additional research is needed to support this supposition.
The pathological mechanisms responsible for reduced hypothalamic volume in individuals
with HD are not yet understood. Evidence from post-mortem investigations and studies in
mouse models provides insight into potential mechanisms by which hypothalamic changes
could occur, as well as mechanisms by which these changes could impact on circadian rhythm
and habitual sleep outcomes. For example, neuronal inclusions of mutant huntingtin in
suprachiasmatic nucleus (SCN) tissue at post-mortem (Aziz et al., 2008), may directly mediate
changes in the functioning of the SCN. Such neuronal inclusions of mutant huntingtin within
the SCN could reduce the number of vasoactive intestinal polypeptide and arginine vasopressin
expressing neurons, which are crucial in the regulation of SCN activity (Aton, Colwell,
Harmar, Waschek, & Herzog, 2005; Hofman & Swaab, 1994), as well as post-transcriptional
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changes in these neuropeptides, which have been reported in HD (van Wamelen et al., 2013).
These changes, together with a loss of orexin-releasing neurons in the lateral hypothalamus
which has been reported in individuals with HD at post-mortem and in mouse models of HD
(Aziz et al., 2008; Petersén et al., 2005), could result in impaired functioning of the
hypothalamic nuclei and lead to the disruption of the circadian rhythm and sleep-wake cycle
that has been reported in individuals with HD and in HD mouse models (Kudo et al., 2011;
Loh, Kudo, Truong, Wu, & Colwell, 2013; Morton, 2013; Morton et al., 2005). These potential
mechanisms are complex and interrelated and require further investigation.
The reduction in hypothalamic grey matter volume in individuals with premanifest HD was
significantly associated with morning cortisol release. This relationship was not observed in
healthy controls. Conversely, the association between hypothalamic volume and evening
melatonin concentrations observed in healthy controls was absent in individuals with
premanifest HD. Both the group by cortisol output and the group by melatonin output
interaction effect on hypothalamic grey matter volume occurred across regions encompassing
the SCN and the PVN. Despite significantly reduced habitual sleep efficiency and an increase
in the number of awakenings and time spent awake after sleep onset in individuals with
premanifest HD, which aligns with previous reports of sleep disturbances in premanifest HD
(Lazar et al., 2015), hypothalamic volume was not significantly associated with habitual sleep
outcomes. The lack of consistent associations between hypothalamic volume and habitual sleep
outcomes was unexpected, especially considering the known role of the hypothalamus in
regulating the sleep-wake cycle via the SCN and its connections with the ventrolateral preoptic
nucleus and the lateral area within the hypothalamus (Bartlett et al., 2016; Saper et al., 2005).
While inconsistent relationships were observed between hypothalamic volume and habitual
sleep outcomes, further studies should assess the impact of reduced hypothalamic volume on
changes in the underlying sleep electroencephalogram, which is reported to be altered in HD
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mouse models and in individuals with HD (Fisher et al., 2013; Fisher et al., 2016; Kantor,
Szabo, Varga, Cuesta, & Morton, 2013; Lazar et al., 2015; Piano et al., 2017). Such analyses
would allow further characterisation of the impact of hypothalamic changes on sleep outcomes
in HD.
Despite observing differences in the relationships between hypothalamic grey matter volume
and cortisol and melatonin in the premanifest HD cohort compared to healthy controls, no
differences in morning cortisol or evening melatonin release were observed between the two
groups, which is contradictory to previous reports (Kalliolia et al., 2014; van Duijn et al., 2010).
It is important to note that a large proportion of our premanifest HD cohort were females
(65.6%). This is of relevance as sex-specific differences in circadian rhythm dysfunction have
been reported in HD mouse models (Kuljis et al., 2016). In particular, female HD mice exhibit
less severe or delayed changes in activity levels and behavioural fragmentation compared to
male HD mice (Kuljis et al., 2016). Therefore, the lack of differences in cortisol and melatonin
release between individuals with premanifest HD and healthy controls may be related to sexspecific effects.
Conceivably, the right side of the hypothalamus, or indeed other structures involved in the
release of cortisol and melatonin, such as the pituitary or pineal glands, may be able to
compensate for the reduced hypothalamic volume during the premanifest stages of the disease
and thereby maintain normal regulation of cortisol and melatonin release. This is supported by
emerging evidence indicating the presence of compensatory neural functions in individuals
with HD (Gregory et al., 2017; Scheller, Minkova, Leitner, & Kloppel, 2014). This theory
nevertheless requires further validation in larger longitudinal studies.
This study is not without limitations. Firstly, current imaging methods are not yet sensitive
enough to capture the individual nuclei within the hypothalamus; however, parcellation
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approaches that rely on anatomic landmarks visible on MR images (e.g. Makris et al., 2013)
allow the distinction of the different hypothalamic regions, which affords some insight into
which structures may be affected. Secondly, this study evaluated cortisol and melatonin
regulation using saliva sampling, which is known to be more variable than blood sampling.
However, salivary cortisol and melatonin sampling was preferred to blood sampling as
previous studies indicate that blood sampling elevates cortisol levels (Weckesser et al., 2014).
Thirdly, this study included a large proportion of females with HD, which may have influenced
our ability to find significant differences in cortisol/melatonin release between individuals with
premanifest HD and healthy controls. Discrepancies in cortisol and melatonin findings between
this study and others may also reflect differences in measurement protocols (i.e., frequency of
sampling time points), patient characteristics or seasonal differences (Kalliolia et al., 2014;
Stothard et al., 2017; van Duijn et al., 2010). A lack of concordance also existed between the
habitual sleep measures, potentially due to differences in reporting methods (i.e. subjective
versus objective). No evidence of elevated stress, anxiety or depression was noted, indicating
that mood disorders did not impact on markers of circadian rhythm or habitual sleep. Future
studies should assess the relationship between hypothalamic pathology and sleep architecture
in individuals with premanifest HD using polysomnography.
In summary, our findings show that individuals with premanifest HD exhibit leftward biased
hypothalamic pathology that is differentially associated with markers of circadian rhythm, but
not consistently associated with habitual sleep-wake deficits, when compared to healthy
controls. However, the lack of differences in concentrations of markers of circadian rhythm
between the two groups suggests the possibility of neural compensation, facilitated by the right
hemisphere of the hypothalamus or by other brain structures involved in the circadian and sleep
cycles, as a mechanism involved in maintaining the regulation of the circadian rhythm and
habitual sleep-wake function in individuals with premanifest HD. Larger, longitudinal studies
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are required to further investigate the role of hypothalamic pathology in circadian rhythm and
habitual sleep-wake disturbances in HD as the disease course lengthens.
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3.10 Supplementary Data
Acquisition of MRI Data

Scans were obtained at two locations: 49 participants were scanned at Perth Radiological Clinic
using a 3T GE Healthcare Discovery MR750w MRI scanner with a 24-channel head coil using
an IR-SPGR sequence (TA = 9 m 59 s, TR = 3 s, TE = Min, TI = 400 ms, flip angle = 11˚, field
of view = 256 mm, image matrix = 256 x 256, 1 mm3 isotropic voxels); 12 participants were
scanned at Monash Biomedical Imaging in Melbourne using a 3T Siemens Skyra MRI scanner
with a 32-channel head coil using an MP-RAGE sequence (TA = 9 m 14 s, TR = 2.3 s, TE =
2.96 ms, TI = 900 ms, flip angle = 9˚, field of view = 256 mm, image matrix = 256 x 256).

Pre-Processing of MRI Data

Images were pre-processed according to a SPM12 pipeline (http://www.fil.ion.ucl.ac.uk/spm)
running on MATLAB R2015a (MathWorks Inc., USA). Segmentation of the T1-weighted
images into grey and white matter tissue was performed (Ashburner & Friston, 2005) and then
registered through Diffeomorphic Anatomical Registration through Exponentiated Lie algebra
(DARTEL) (Ashburner, 2007). The resulting study-specific template was registered to
Montreal Neurological Institute (MNI) space. The normalisation procedure included
modulating the grey matter tissue probability maps by the Jacobian determinants of the
deformation field. As the analysis focused on the hypothalamus, the normalised grey matter
images were smoothed with a 6 mm full width at the half maximum Gaussian kernel, which is
more appropriate for small structures (Salmond et al., 2002).

MRI Site Consistency Analysis

To ensure consistency of MR imaging across scanning sites, we evaluated a range of
morphometric and volumetric measurements across three participants scanned twice at both
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sites. First, we obtained an estimate of individual hypothalamic volume per participant from
images pre-processed according to the voxel-based morphometry pipeline described above.
The estimate of hypothalamic volume corresponded to the average intensity across all voxels
in

a

hypothalamus

mask

(from

the

WFU

Pick

Atlas—

http://fmri.wfubmc.edu/software/pickatlas—dilated by 3 mm) (Breen et al., 2016). In addition,
grey and white matter volumes were also calculated (in mm3) with SPM12’s Tissue Volumes
tool form the output of the Segment routine. Volumes for caudate, putamen, pallidum, brain
stem, thalamus and hippocampus were also obtained (in mm3) after segmentation with
FMRIB’s Integrated Registration and Segmentation Tool from the raw T1-weighted images
(Patenaude, Smith, Kennedy, & Jenkinson, 2011). All segmentations were visually inspected
to ensure their accuracy.

As a further quality assurance procedure, whole-brain, voxel-based morphometry analysis was
carried out to ascertain baseline group differences in grey matter volume between premanifest
Huntington’s disease and healthy control participants. Spatial pre-processing was the same as
before except that images were smoothed with an 8 mm full width at the half maximum
(FWHM) Gaussian kernel.

Three participants were scanned twice in Perth and Melbourne (i.e., we obtained two structural
images from each participant at each site). Parcellation of the T1-weighted images into grey
and white matter tissue was performed with the Segment routine in SPM12 (Ashburner &
Friston, 2005). Grey and white matter volume was then calculated with SPM12’s Tissue
Volumes tool. We then used voxel-based morphometry to extract a measure of grey matter
volume from the hypothalamus. Grey and white matter tissue images resulting from the
Segment routine were co-registered through DARTEL (Ashburner, 2007). The resulting studyspecific template was registered to MNI space. The normalisation procedure included
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modulating the grey matter tissue probability maps by the Jacobian determinants of the
deformation

field.

A

hypothalamus

mask

from

the

WFU

Pick

Atlas

(http://fmri.wfubmc.edu/software/pickatlas) was used (dilated by 3mm; Figure S1) to obtain
an estimate of individual hypothalamic volume per participant (the average intensity across all
voxels in the mask) (Breen et al., 2016). Grey matter volume in the region of interest was
calculated using the FMRIB Software Library (FSL) tool “fslstats” within FSL version 5.0.9
(www. fmrib.ox.ac.uk).

Figure S3.2. Hypothalamus mask (in red). Slice labels are displayed on top. L, left

Segmentation of other subcortical structures (comprising caudate, putamen, pallidum, brain
stem, thalamus and hippocampus) was performed with FMRIB’s Integrated Registration and
Segmentation Tool (FIRST) from the raw T1-weighted images. All segmentations were
visually inspected to ensure their accuracy.

We then calculated, for all measurements (whole-brain grey and white matter, hypothalamus,
caudate, putamen, pallidum, brain stem, thalamus and hippocampus), the average percent
absolute difference within each participant across both sites as well as the average percent
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absolute difference across participants between both sites. Measurements as well as within and
between site differences are displayed in Figures S3.3 and S3.4.

Results show a high level of consistency across within and between site measurements of all
structures. In addition, discrepancies between within and between site differences did not
reveal a consistent pattern (i.e., between site differences were not consistently larger than
within site differences or vice versa).

Figure S3.3. Volume measurements for three participants scanned twice at each site.
Shades of blue indicate scans from Perth and shades of orange denote scans from
Melbourne. Lighter shades (of blue or orange) represent first scan, darker shades
designate second scan. Measurements from subjects 1, 2 or 3 are grouped across plots
A-D as indicated in plot D. Measurements in plot D correspond to arbitrary VBM units.
GM, grey matter; WM, white matter.
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Figure S3.4. Average within and between sites differences across volume
measurements.

Whole-Brain, Voxel-Based Morphometry Analysis

Whole-brain, voxel wise statistical analysis was carried out to ascertain baseline group
differences in grey matter volume between the 33 premanifest HD and 29 control participants.
The premanifest HD sample in this analysis included one extra participant not included in the
main paper as they contributed incomplete sleep data (results were almost identical including
or excluding the extra participant. Here we report the full sample). Spatial pre-processing
followed the same SPM12 pipeline as all other voxel-based morphometry analyses in this paper
(except for the smoothing kernel used = FWHM 8 mm). Images from premanifest HD and
controls were then contrasted using a two sample t-test and cluster correction at FWE p = 0.05
(with a cluster defining threshold p = 0.001 and a voxel extent threshold k = 20). Sex, site and
age were included as covariates of no interest.

Results revealed significant grey matter loss in the striatum in premanifest HD compared to
controls (Figure S3.5). This is as expected for individuals at this stage of the disease, consistent
with previous studies (i.e., Tabrizi et al., 2009). The well-known caudo-rostral and dorsoventral gradient of striatal neurodegeneration is apparent (Douaud et al., 2006; Kassubek et al.,
2004).
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Figure S3.5. VBM analysis of striatal grey matter volume
Results from VBM analysis showing statistically significant grey matter loss in the
striatum in premanifest HD compared to controls. Peak activation voxel on the right,
MIN 13 -5 19, t = 6.22; and on the left, MNI -11 -5 19, t = 5.95. Slice labels are
displayed on top. L, left

Salivary Cortisol and Melatonin Collection and Analysis

To avoid contamination of saliva samples, participants were asked to refrain from consuming
alcohol 12 hours prior and avoid eating, drinking (with the exception of water) and brushing
their teeth one hour prior to sampling. For melatonin sampling, participants were also instructed
to wear sunglasses and remain in a dim lit room during the three-hour sampling timeframe to
avoid suppressive effects of light on melatonin rise. Based on these criteria, a questionnaire
was devised to monitor participant compliance. Saliva samples were transported on dry ice
from Melbourne to Perth and were stored at -80˚C until analysis at Edith Cowan University,
Western Australia. Salivary cortisol and melatonin concentrations were then measured in
duplicate using salivary cortisol and melatonin ELISA kits (Salimetrics) according to
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manufacturer’s instructions. The limit of detection of the cortisol and melatonin ELISAs was
reported to be 70 pg/mL and 1.37 pg/mL, respectively.

Physical Activity

Metabolic equivalents (MET) were calculated using recorded physical activity levels, the
Compendium of Physical Activities database and estimated resting metabolic rate (RMR) with
the following formula:

Corrected MET value = MET value (from Compendium code) X 3.5 ml.kg/Harris-Benedict
RMR (ml.kg.min)

RMR was calculated using the Harris-Benedict equation seen below:
Male = 66.4730 + 5.0033 (Height cm) + 13.7516 (Weight kg) – 6.7550 (Age yr)
Female = 655.0955 + 1.8496 (Height cm) + 9.5634 (Weight kg) – 4.6756 (Age yr)

Statistical Analyses
Hypothalamic Volume

The hypothalamus mask (dilated by 3 mm) from the WFU Pick Atlas was used to restrict
analysis to this area (Breen et al., 2016). Results are reported in MNI space with a voxel size
of 1 mm isotropic and displayed on the ch256 anatomical template available as part of
MRIcroGL (http://www.mccauslandcenter.sc.edu/mricrogl/). To illustrate the group by
continuous covariate interactions in relevant scatterplots and to estimate the strength of the
relationship we used the MarsBaR SPM12 tool box (Brett, Anton, Valabregue, & Poline, 2002)
to extract parameter estimates from relevant contrasts (grey matter average of all significant
voxels in the relevant contrast).
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The interaction model used to assess differences in the association between hypothalamic
volume and cortisol/melatonin output in individuals with premanifest HD compared to healthy
controls included group regressors, one for each group, and regressors modelling cortisol or
melatonin, one for each group. Gender, site, age and Perceived Stress Scale, ESS and PSQI
scores were included as covariates of no interest. In premanifest HD, we adjusted also for CAG
Age Product score (CAPs). Covariates of interest in the above models were mean centred
across both groups. Furthermore, to determine whether hypothalamic volume was associated
with measures of subjective sleep quality (PSQI), behavioural sleep/wake data (Consensus
Sleep Diary; sleep onset latency, number of awakenings, sleep efficiency) and stress (Perceived
Stress Scale), we used a categorical by continuous covariate interaction model, adjusting for
evening melatonin, gender and age, as well as CAPs in premanifest HD. Although
measurements across sites were found to be consistent and whole-brain differences between
premanifest HD and controls were as expected, we also included site as a covariate of no
interest in all statistical analyses to remove any residual site effects.

Contrasts modelled positive and negative associations between each group and cortisol or
melatonin ([0 0 1 0], [0 0 -1 0], [0 0 0 1], and [0 0 0 -1]) as well as group differences in these
associations ([0 0 1 -1] and [0 0 -1 1]); that is, the group by cortisol/melatonin output interaction
effect.

Salivary Cortisol and Melatonin

The intra- and inter-assay coefficients of variation were below 10% for all cortisol and
melatonin ELISAs. One sample was removed due to suspected blood contamination. Samples
were taken on two consecutive days, with each time point on day 1 correlating significantly
with its counterpart on day 2 (r = 0.891, p < 0.001). Area under the curve with respect to
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ground (AUCG) was calculated using the trapezoid rule for morning cortisol and evening
melatonin output on the two consecutive days (Dijk et al., 2012; van Duijn et al., 2010).
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4.1 Abstract
Objective: Hypothalamic pathology has been reported in Huntington’s disease (HD) a decade
prior to predicted clinical onset and has been proposed to contribute to circadian rhythm and
habitual sleep disturbances. Currently, no therapies exist to combat hypothalamic changes, nor
circadian rhythm and habitual sleep disturbances in HD. Therefore, we aimed to assess whether
multidisciplinary rehabilitation could reduce the loss of hypothalamic volume and improve
circadian rhythm and habitual sleep outcomes in individuals with premanifest HD.
Methods: Eighteen individuals with HD (ten premanifest and eight prodromal) undertook a
nine-month multidisciplinary rehabilitation intervention (intervention group) and were
compared to a community sample of eleven individuals with premanifest HD receiving
standard care (control group). Hypothalamic volume, blood-based BDNF, salivary cortisol and
melatonin concentrations, subjective sleep quality, daytime somnolence, habitual sleep-wake
patterns and stress, anxiety and depression symptomatology were evaluated.
Results: A significant decrease in hypothalamic grey matter volume loss was observed in the
intervention group compared to the control group. This was accompanied by a maintenance of
BDNF levels in the intervention group, whereas BDNF levels in the control group decreased
significantly. Daytime somnolence and anxiety and depression symptomatology were also
significantly reduced in the intervention group relative to controls. Both the intervention and
control groups exhibited decreases in cortisol and melatonin concentrations following the ninemonth study period.
Conclusion: This study provides preliminary evidence that multidisciplinary rehabilitation can
significantly reduce the rate of hypothalamic volume loss, maintain peripheral BDNF levels
and improve sleep and mood outcomes in premanifest HD, but does not have a robust effect
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on markers of circadian rhythm. Larger, randomised controlled trials are required to confirm
these findings.
4.2 Introduction
Hypothalamic pathology, particularly grey matter volume loss and microglial activation, has
been reported as early as a decade prior to clinical manifestation of Huntington’s disease (HD)
(Politis et al., 2008; Soneson et al., 2010). Degeneration within the hypothalamus, particularly
the suprachiasmatic nucleus (SCN), which is responsible for generating the circadian rhythm,
is believed to underpin circadian rhythm and habitual sleep disturbances in individuals with
HD (Aziz et al., 2010; Bartlett et al., 2016; Moore, 1995; Morton et al., 2005; Saper et al.,
2005).
Disturbances in circadian rhythm and sleep are documented in HD mouse models, as well as
in humans (Kudo et al., 2011; Lazar et al., 2015; Morton, 2013). Circadian changes appear to
commence during the premanifest stages of HD and worsen as the course of the disease
lengthens. In particular, early changes in the circadian regulation of cortisol and melatonin and
a sleep phase delay have been noted in individuals with premanifest HD (Aziz et al., 2010;
Aziz, Pijl, Frölich, Schroder-van der Elst, et al., 2009; Aziz, Pijl, Frölich, van der Graaf, et al.,
2009; Kalliolia et al., 2014; van Duijn et al., 2010). Furthermore, studies in the R6/2 HD mouse
model have revealed altered night-day activity ratios and this altered night-day activity is
recapitulated in individuals with manifest HD (Morton et al., 2005). These alterations in
circadian rhythm could potentially mediate sleep deficits that have been reported in HD (Lazar
et al., 2015). Lazar et al (2015) reported early changes in sleep architecture, particularly
increased sleep fragmentation, prior to clinical onset of HD. Given that the onset of circadian
rhythm and disturbances occur during the premanifest phase of HD, early treatments aimed at
reducing or ameliorating degeneration of the hypothalamus or targeting circadian rhythm and
habitual sleep disturbances are warranted.
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Evidence from animal models and other clinical populations suggests that interventions
comprising exercise have the potential to improve circadian rhythm and sleep outcomes
(Cuesta et al., 2014; Nascimento et al., 2014), although it is not known if these improvements
are mediated by changes in the hypothalamus. In patients with HD, our team has previously
shown that multidisciplinary rehabilitation, involving exercise and cognitive training, enhances
brain volume in the striatum and prefrontal cortex and improves cognition and motor function
(Cruickshank et al., 2015; Thompson et al., 2013). The exact mechanism by which
multidisciplinary rehabilitation improves brain volume in these areas is not yet known. A
possibility is that multidisciplinary rehabilitation exerts its effects on the brain by upregulating
levels of brain derived neurotrophic factor (BDNF), since BDNF is vital for neurogenesis
following environmental enrichment in animal models (Rossi et al., 2006). This is supported
by studies in HD mouse models, in which BDNF levels were rescued following environmental
enrichment, as well as by research into other neurodegenerative and clinical populations,
whereby increases in BDNF levels have been reported following intervention paradigms
comprising an exercise component (Cotman & Berchtold, 2002; Frazzitta et al., 2014; Spires
et al., 2004).
In the present study, we aimed to examine the effects of a nine-month multidisciplinary
rehabilitation intervention on BDNF levels, hypothalamic volume, circadian rhythm, and
habitual sleep outcomes in individuals with premanifest HD. In line with findings suggesting
an increase in BDNF levels following multimodal exercise paradigms (Nascimento et al., 2014)
and with the proposed role of the hypothalamus in circadian rhythm disturbances in HD (Aziz
et al., 2008; Bartlett et al., 2016), we hypothesised that multidisciplinary rehabilitation would
increase BDNF levels, attenuate hypothalamic volume loss and improve circadian rhythm and
habitual sleep outcomes in individuals with premanifest HD.
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4.3 Materials and Methods
4.3.1 Study Design
The present investigation was a controlled exploratory study on the effects of nine months of
multidisciplinary rehabilitation on hypothalamic volume, blood-based BDNF, markers of
circadian rhythm and habitual sleep-wake outcomes in individuals with premanifest HD.
Subjective sleep quality, daytime somnolence and stress, anxiety and depression
symptomatology were also examined. Study participants were allocated to receive nine months
of either multidisciplinary rehabilitation (intervention group) or standard care (control group).
The length of the intervention was informed by our previous work (Cruickshank et al., 2015;
Thompson et al., 2013).
4.3.2 Study Approval and Patient Consent
All aspects of the study were conducted in accordance with the declaration of Helsinki. Ethical
approval for study procedures was granted by the North Metropolitan Area Mental Health
Service (2009_16), Edith Cowan University (13145), Monash University (CF15/1172015000058) and Deakin University (2015-052) human research ethics committees at Perth
and Melbourne study sites. All participants provided written informed consent.
4.3.3 Participants
Twenty-seven premanifest HD and eight prodromal HD individuals were recruited in Perth and
Melbourne through ENROLL-HD, existing study databases, clinicians and HD community
organisations. Inclusion criteria were as follows: 1) Unified Huntington’s Disease Rating Scale
(UHDRS) Diagnostic Confidence Level (DCL) of ≤ 2 and 2) a UHDRS Total Motor Score
(UHDRS-TMS) of < 5 for premanifest or > 5 for prodromal HD (Reilmann et al., 2014).
Exclusion criteria included: 1) concomitant neurological, cardiovascular, musculoskeletal,
endocrine, metabolic or sleep disorders, 2) shift work, 3) recent or ongoing substance abuse,
and 4) the inability to understand written and verbal English.
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4.3.4 Multidisciplinary Rehabilitation Intervention
The multidisciplinary rehabilitation intervention was designed and implemented by an
experienced team of clinical exercise physiologists, strength and conditioning experts,
cognitive training specialists and neuroscientists. The intervention was fully supervised and
consisted of autoregulated periodised aerobic and resistance training, computerised cognitive
training, dual task training and social events. Periodised aerobic and resistance training was
performed twice weekly for one hour (thirty minutes for each mode of exercise) and comprised
resistance, endurance and high-intensity interval training (Harries, Lubans, & Callister, 2015;
Jimenez & Paz, 2011). Supervised computerised cognitive training was informed by a metaanalysis and by previous investigations (Lampit, Ebster, & Valenzuela, 2014; Lampit, Hallock,
Moss, et al., 2014; Lampit, Hallock, Suo, Naismith, & Valenzuela, 2015; Lampit, Hallock, &
Valenzuela, 2014). Computerised cognitive training was performed three times weekly for one
hour using NeuroNation (Synaptikon, Berlin, Germany) and Captain’s Log MindPower
Builder (BrainTrain Inc., Richmond, VA) software (30 minutes each program) and targeted
working memory, visual scanning, processing speed, attention, planning, problem solving and
task switching cognitive domains. Cognitive-motor interference training was performed once
weekly for one hour and consisted of combined aerobic and resistance training and cognitive
exercises (Fritz, Cheek, & Nichols-Larsen, 2015; Yogev-Seligmann, Giladi, Brozgol, &
Hausdorff, 2012). Intervention sessions were conducted in small groups (2-4 participants per
session) and social events were organised every twelve weeks to encourage social engagement,
which is thought to be a zeitgeber that acts to modulate the circadian rhythm (Foster et al.,
2013).
4.3.5 MRI Data Acquisition and Pre-processing
T1-weighted structural images of the brain were obtained from each participant in Perth and
Melbourne using a GE Healthcare Discovery or a Siemens Skyra 3T MRI scanner, respectively.
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In Perth, images were acquired with a 24-channel head coil using an IR-SPGR sequence (TA
= 9 m 59 s, TR = 3 s, TE = Min, TI = 400 ms, flip angle = 11˚, field of view = 256 mm, image
matrix = 256 x 256, 1 mm3 isotropic voxels). In Melbourne, acquisition took place with a 32channel head coil and an MP-RAGE sequence (TA = 9 m 14 s, TR = 2.3 s, TE = 2.96 ms, TI =
900 ms, flip angle = 9˚, field of view = 256 mm, image matrix = 256 x 256). Images were
acquired using consistent methodology across both sites according to the Alzheimer’s Disease
Neuroimaging Initiative protocols for multi-site imaging (Jack et al., 2008). Three participants
also underwent additional scans at both sites to ensure reproducibility. Image pre-processing
was conducted according to Breen et al. (2016) using a hypothalamus mask from the WFU
Pick Atlas (http://fmri.wfubmc.edu/software/pickatlas), dilated by 3mm to restrict analysis to
this area and for displaying results. Results are reported in MNI space with a voxel size of 1
mm isotropic and displayed on the ch256 template. We also used the MarsBaR SPM12 tool
box (Brett et al., 2002) to extract parameter estimates from relevant contrasts (average of all
significant voxels in the relevant contrast).
4.3.6 Blood-based BDNF Analysis
Blood was collected from participants via venepuncture into serum gel separator tubes
(Vacuette, Greiner Bio-one) one hour following awakening. Blood was collected at the same
time prior to and following the study period to minimise the potential effects of circadian
variation on BDNF levels (Piccinni et al., 2008). The blood was left to clot for at least 30
minutes and then centrifuged at 1800 x g for 10 minutes. Serum was then aliquoted and stored
at -80ºC until analysis in duplicate using BDNF Emax ELISA kits (Promega, Madison, WI)
according to the manufacturer’s instructions (Ciammola et al., 2007).
4.3.7 Salivary Cortisol and Melatonin Analysis
Saliva samples were collected by participants in their own homes. Participants were instructed
to passively drool into four separate polypropylene collection tubes (SSI Bio) at four time
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points in the morning at 15, 30, 45 and 60 minutes following awakening for morning cortisol
analysis and at four time points across the evening at one hour intervals from two hours before
their usual bedtime (T1) until one hour after their usual bedtime (T4) for melatonin analysis
(van Duijn et al., 2010; Voultsios et al., 1997). To avoid contamination of samples, participants
were instructed to refrain from consuming alcohol 12 hours prior and to avoid eating, drinking
(with the exception of water) and brushing their teeth within the hour prior to sampling (van
Duijn et al., 2010). For melatonin sampling, participants were also instructed to wear
sunglasses and to remain in a dimly lit room during the three-hour sampling timeframe to avoid
suppressive effects of light on melatonin rise (Voultsios et al., 1997). Based on these criteria,
a questionnaire was devised to monitor participant compliance. Saliva samples were stored at
-80ºC until analysis in duplicate using salivary cortisol and melatonin ELISA kits (Salimetrics,
USA) according to the manufacturer’s instructions.
4.3.8 Subjective Sleep Assessments
Sleep questionnaires were used to measure habitual sleep/wake timing, sleep quality and
daytime somnolence, as used previously (Bartlett et al., 2019 [Chapter 3]). Habitual sleep wake
timing was measured using the Consensus Sleep Diary (CSD) (Carney et al., 2012), which was
devised to standardise the measurement of habitual sleep parameters. Subjective sleep quality
was assessed using the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989). The PSQI
comprises seven components relating to subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleep medication and daytime dysfunction.
Scores are summated to provide a global PSQI score, of which a score of greater than five
indicates poor sleep quality. Daytime somnolence was assessed using the Epworth Sleepiness
Scale, with a score of greater than 10 indicating excessive daytime sleepiness (Johns, 1991).
The PSQI and Epworth Sleepiness Scale have been used previously in HD research (Aziz et
al., 2010; Lazar et al., 2015).
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4.3.9 Mood Measures
Psychological stress over the previous month was measured using the 14-item Perceived Stress
Scale (Cohen et al., 1983) and anxiety and depression symptomatology were measured using
the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983). Both scales
are deemed valid for use in HD research (De Souza et al., 2010; Downing et al., 2011).
4.3.10 Statistical Analysis
Data from the premanifest (prior to onset of motor signs) and prodromal HD (slight, but no
overt, motor signs) intervention groups were combined. This was based on preliminary
analyses that showed no differences between any of the primary or secondary outcome
measures at baseline between the premanifest and prodromal intervention groups (data on
groups separated can be viewed in supplementary files). Data from the combined intervention
group was compared to the premanifest HD community sample. To control for clinical
differences, UHDRS-TMS was included as a covariate in analyses.
Missing saliva sampling data points were imputed to avoid removing the participant from
analyses and to maintain sample size (van Duijn et al., 2010). Area under the curve with respect
to ground (AUCG) was calculated using the trapezoid rule for morning cortisol and evening
melatonin output (Dijk et al., 2012; van Duijn et al., 2010).
Shapiro -Wilk tests were used to test normality assumptions. Baseline group differences were
assessed using independent t-tests and Mann-Whitney U tests. Within-group and betweengroup differences were assessed using a mixed model analysis of variance (ANOVA), with
age, gender, CAG repeat and baseline values of the variable of interest included as covariates.
To assess voxel-wise differences in hypothalamic volume change between baseline and ninemonth follow-up between intervention and control groups, grey matter Jacobian change images
from each respective group were compared using a two-sample t-test, with sex and age included
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as covariates of no interest. Using the same grey matter Jacobian change images, we also
investigated group differences in the association between change in hypothalamic volume and
change in cortisol and/or melatonin output in the intervention compared to the control group,
using a categorical by continuous covariate interaction model (see supplementary data for
details of this model). Given the exploratory nature of this study and our a priori interest in the
hypothalamus, all results are reported at α = 0.05.
4.4 Results
4.4.1 Participant Demographic and Clinical Characteristics
Two participants withdrew from the study prior to baseline testing, two withdrew following
baseline testing and a further two participants did not provide complete data at follow-up. Ten
premanifest HD and eight prodromal HD participants underwent a nine-month
multidisciplinary rehabilitation intervention (intervention group). Eleven premanifest HD
participants receiving standard care served as a reference group for this study (control group).
Demographic and clinical characteristics for the intervention and control groups are presented
in Table 4.1. Age differed significantly between the intervention group and the control group,
but no significant differences were observed in gender, CAG repeat number, disease burden
score, CAP score, body mass index (BMI), smoking status, alcohol consumption or use of
psychotropic medication between the groups. No participants reported changes in the use of
sleep medications using the PSQI at baseline or following the nine-month study period. Higher
UHDRS-TMS and diagnostic confidence level scores were observed in the intervention group
compared to the control group (Table 4.1 and Supplementary Table S4.4) due to the inclusion
of individuals with prodromal HD in the intervention group.
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Table 4.1. Demographic and clinical characteristics of premanifest plus prodromal HD
intervention group and control group at baseline
Intervention
group (n=18)

Control
Group (n=11)

p-value

40.89 ± 11.73

50.55 ± 9.49

0.029*

6 (33)

4 (36)

0.868

CAGn, mean ± SD

43.67 ± 3.28

41.91 ± 2.02

0.123

DCL, mean ± SD

0.67 ± 0.84

0.00 ± 0.00

0.000*

UHDRS-TMS, mean ± SD

7.56 ± 8.56

0.09 ± 0.30

0.000*

309.52 ± 91.87

309.36 ± 61.51

0.996

CAPs, mean ± SD

0.89 ± 0.22

0.93 ± 0.13

0.598

BMI, mean ± SD

26.60 ± 3.85

25.29 ± 1.99

0.303

Smoker, n (%)

6 (33)

1 (9)

0.172

High alcohol consumption, n (%)

2 (11)

0 (0)

0.394

Psychotropic medication, n (%)

2 (11)

3 (27)

0.264

Demographic Characteristics
Age, mean ± SD
Male, n (%)
Clinical Characteristics

Disease burden score, mean ± SD

*Values are significant at p ≤ 0.05.
CAGn= cytosine-adenine-guanine repeat number; DCL= diagnostic confidence level; UHDRS-TMS=
Unified Huntington’s Disease Rating Scale- Total Motor Score; CAPs= CAG-age product score; BMI=
body mass index.

4.4.2 Hypothalamic Volume
Voxel-wise analysis revealed significantly less right hypothalamic grey matter volume loss in
the intervention group compared to the control group following the nine-month study period
(Table 4.2 and Figure 4.1). The observed differences corresponded to a large effect size
(Cohen’s d = 1.1, computed from associated parameter estimates) and suggest that
multidisciplinary rehabilitation slows the rate of grey matter loss in the right hypothalamus.
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Table 4.2. Results from voxel-based morphometry analysis.

Peak Voxel
Side

k

T-score

p-value

MNI Coordinates
(mm)
x

y

z

Group Effect
Control group vs intervention group

R

321

2.90

0.004

5

2

-7

R

305

2.47

0.012

6

-4

-10

R

86

2.36

0.014

8

-2

-14

Group x Cortisol Interaction Effect
Control group vs. intervention group
Group x Melatonin Interaction Effect
Control group vs. intervention group

Results are significant at p < 0.05, uncorrected.
k = No. of voxels; MNI = Montreal Neurological Institute; R = right.

Figure 4.1. Effects of nine months of multidisciplinary therapy on hypothalamic grey matter
(GM) volume.
(A) Group effect on GM volume and bar graphs illustrating the effect. Values in the bar graphs
correspond to the mean volume change in each group (after averaging across voxels in each
participant). (B) Group by cortisol output change interaction effect on GM volume (control
group outliers excluded from the analysis are in cross-hatching). (C) Group by melatonin
output change interaction effect on GM volume. Scatterplots in (B) and (C) illustrate the
respective interaction effects (a.u., arbitrary units). Heat maps correspond to T-scores
thresholded at p < 0.05, uncorrected. The maps are displayed at x = ~8 (MNI) and are scaled
to the peak T-score for the relevant analysis (see Table 4.2).
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4.4.3 Blood-Based BDNF Analysis
Serum BDNF did not significantly differ at baseline between the intervention and control
groups, however, when comparing the two groups at follow-up, a significant difference in
BDNF levels was observed (p = 0.030; Table 4.3 and Supplementary Table S4.5). Post-hoc
analysis revealed a significant decrease in serum BDNF levels in the control group (p = 0.008),
while serum BDNF levels were maintained in the intervention group over the study period (p
= 0.869), suggesting that multidisciplinary rehabilitation facilitates the maintenance of serum
BDNF levels in premanifest HD.
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Table 4.3. Mean salivary cortisol and melatonin concentrations, subjective sleep outcomes and affective symptomatology outcomes in the
premanifest HD intervention and control groups.

Serum BDNF (pg/mL)

Within-Group Differences
Intervention group (n=18)
Baseline
Follow-Up
p-value
Effect
Baseline
Size
27634.53 ±
27587.55 ±
0.869
0.009
29384.49 ±
5870.90
4969.02
6699.71

Control group (n=11)
Follow-Up
p-value
22812.15 ±
3486.14

0.008*

Effect
Size
1.230

Between-Group Differences
Follow-Up
Observed Partial Eta p-value
Power
Squared
0.483
0.533
0.165
0.030*

Baseline
p-value

Cortisol (nmol/L)
Awakening (hh:mm)
Time of sample relative to
awakening:
+15 mins
+30 mins
+45 mins
+60 mins
AUCG
Melatonin (pg/mL)
Bedtime (hh:mm)
Time of sample relative to
bedtime:
-2 hrs
-1 hr
+0 hrs
+1 hr
AUCG
CSD
Total time in bed (min)
Total sleep time (min)
Sleep onset latency (min)
WASO (min)
Number of awakenings
Sleep efficiency (%)
Restorative quality of sleep
PSQI Global Score
Epworth Sleepiness Scale

06:16 ± 01:01

06:11 ± 00:52

0.355

0.088

05:53 ± 00:58

06:43 ± 01:03

0.091

0.826

0.393

0.692

0.223

0.020*

11.43 ± 3.82
14.43 ± 4.41
13.99 ± 3.20
12.49 ± 3.05
40.37 ± 9.69

9.15 ± 3.33
11.59 ± 4.18
12.12 ± 3.74
11.15 ± 3.75
33.86 ± 9.50

0.012*
0.003*
0.034*
0.053
0.004*

0.636
0.661
0.537
0.392
0.678

11.12 ± 4.68
13.69 ± 4.22
14.06 ± 3.14
12.73 ± 4.05
39.68 ± 9.46

9.03 ± 2.11
10.06 ± 2.13
11.62 ± 2.28
9.99 ± 2.53
31.20 ± 5.75

0.173
0.022*
0.024*
0.028*
0.018*

0.576
1.086
0.889
0.811
1.083

0.844
0.662
0.953
0.852
0.851

0.050
0.297
0.177
0.389
0.290

0.000
0.088
0.048
0.118
0.086

0.985
0.151
0.295
0.093
0.156

22:02 ± 00:41

22:03 ± 00:37

0.901

0.026

22:00 ± 00:57

21:46 ± 00:56

0.356

0.248

0.891

0.171

0.048

0.306

13.29 ± 8.99
15.89 ± 11.44
22.50 ± 13.20
25.79 ± 16.89
55.48 ± 32.00

9.29 ± 13.43
9.34 ± 8.83
14.48 ± 11.79
15.77 ± 13.37
36.34 ± 31.03

0.012*
0.000*
0.000*
0.000*
0.002*

0.350
0.641
0.641
0.658
0.607

10.65 ± 8.25
11.19 ± 8.29
13.50 ± 7.72
14.17 ± 6.93
36.65 ± 21.31

6.20 ± 4.37
5.22 ± 3.23
6.60 ± 4.18
7.35 ± 4.59
18.64 ± 10.39

0.098
0.013*
0.030*
0.011*
0.075

0.674
0.949
1.111
1.160
1.074

0.393
0.126
0.055
0.116
0.053

0.059
0.051
0.057
0.052
0.052

0.004
0.001
0.003
0.001
0.001

0.768
0.906
0.793
0.903
0.895

430.59 ± 57.26
383.83 ± 55.45
23.20 ± 26.12
22.00 ± 28.25
1.72 ± 1.48
89.48 ± 9.29
3.63 ± 0.76
6.00 ± 2.94
5.76 ± 3.31

422.50 ± 48.46
379.69 ± 46.27
20.75 ± 23.05
11.91 ± 20.30
1.31 ± 1.12
90.31 ± 9.20
3.70 ± 0.88
5.06 ± 3.15
4.71 ± 3.02

0.509
0.711
0.641
0.306
0.347
0.756
0.522
0.107
0.017*

0.153
0.081
0.099
0.410
0.312
0.090
0.085
0.309
0.331

435.15 ± 51.54
390.10 ± 55.55
8.85 ± 4.37
7.65 ± 18.71
0.60 ± 1.41
90.15 ± 12.50
3.7 ± 1.03
5.18 ± 3.12
4.18 ± 4.21

497.90 ± 98.54
449.03 ± 65.94
10.58 ± 8.37
6.40 ± 9.51
1.30 ± 1.70
91.37 ± 9.60
4.00 ± 0.78
5.18 ± 2.68
4.64 ± 2.91

0.026*
0.015*
0.878
0.600
0.248
0.646
0.168
1.000
0.603

0.798
0.967
0.259
0.084
0.448
0.109
0.328
0.000
0.127

0.839
0.782
0.183
0.102
0.026*
0.562
0.833
0.505
0.136

0.644
0.857
0.227
0.067
0.099
0.072
0.161
0.055
0.244

0.230
0.336
0.083
0.008
0.088
0.011
0.051
0.002
0.073

0.025*
0.008*
0.218
0.688
0.474
0.649
0.323
0.837
0.200
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Perceived Stress Scale
HADS total score
Anxiety
Depression

18.35 ± 7.57
9.00 ± 5.30
6.22 ± 3.35
2.78 ± 2.69

15.29 ± 8.32
6.17 ± 3.75
4.94 ± 3.08
1.22 ± 1.11

0.134
0.004*
0.034*
0.009*

0.385
0.616
0.398
0.758

16.18 ± 4.49
5.55 ± 3.59
3.73 ± 2.65
1.82 ± 1.66

16.18 ± 6.32
6.00 ± 3.87
4.82 ± 3.19
1.18 ± 1.47

1.000
0.654
0.221
0.161

0.000
0.121
0.372
0.408

0.400
0.068
0.046*
0.519

0.205
0.300
0.263
0.122

0.060
0.089
0.077
0.028

Data are presented as mean ± standard deviation. Baseline differences between groups were assessed using independent t-tests for parametric and Mann-Whitney U tests for
non-parametric data. Mixed model analysis of variance (ANOVA) was used to test within-group and between-group differences at follow-up. Partial η2, 0.01, 0.06 and 0.14
are defined as small, medium and large effects, respectively.
*Values are significant at p < 0.05
CSD= Consensus Sleep Diary; WASO= wake after sleep onset; PSQI= Pittsburgh Sleep Quality Index; HADS= Hospital Anxiety and Depression Scale.
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0.249
0.148
0.180
0.426

4.4.4 Salivary Cortisol and Melatonin Analysis
Cortisol and melatonin measures did not significantly differ at baseline between the
intervention and control groups. Moreover, both the intervention and control groups exhibited
a significant decrease in cortisol AUCG following the study period (p < 0.05; Table 4.3 and
Supplementary Table S4.5) and the magnitude of change was not different between the groups.
Following the nine-month study period, the intervention group exhibited a decrease in
melatonin levels at all time points and in total melatonin output (p < 0.05; AUCG, Table 4.3).
Melatonin levels in the control group also significantly decreased within the hour leading up
to usual bedtime, at usual bedtime and the hour following the usual bedtime, with a trend
towards a decrease in total melatonin output. Comparison of the two groups following the ninemonth study period revealed no differences in cortisol or melatonin concentrations at any of
the sampling time points, suggesting that the multidisciplinary rehabilitation program does not
have a robust effect on morning cortisol or evening melatonin release.
4.4.5 Subjective Sleep Assessments
At baseline, the intervention group exhibited a significantly higher number of awakenings
(identified using the CSD) than the control group. When comparing the groups following the
nine-month study period, a significantly later awakening time and increased total time in bed
and total sleep time was observed in the control group compared to the intervention group.
Within group analyses revealed that sleep timing, as measured using the CSD, did not
significantly change over the nine-month study period in the intervention group, however the
total time in bed and total sleep time significantly increased in the control group (Table 4.3).
No other differences were observed in CSD outcomes or subjective sleep quality (PSQI) within
the intervention or control group following the nine-month study period.
Daytime somnolence significantly decreased in the intervention group, but did not differ in the
control group (Table 4.3).No other differences were observed in habitual sleep/wake timing
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(CSD), subjective sleep quality (PSQI scores) or daytime somnolence (ESS scores) at baseline
or follow-up between any of the groups (Table 4.3 and Supplementary Table S4.5). These
results suggest that multidisciplinary rehabilitation does not significantly alter subjective sleep
quality, but does reduce daytime somnolence and facilitates the maintenance of sleep/wake
timing.
4.4.6 Affective Symptoms
There were no significant differences between groups at baseline for depression and perceived
stress outcomes (Table 4.3 and Supplementary Table S4.5). Anxiety symptomatology was
significantly higher in the intervention group compared to the control group at baseline;
however, it is important to note that anxiety and depression scores on the HADS were
subthreshold (< 8) for both groups, indicating no clinically meaningful anxiety
symptomatology for both groups (Zigmond & Snaith, 1983). Following the intervention period,
a significant decrease in anxiety and depressive symptomology, but not perceived stress, was
observed in the intervention group, but not the control group.
4.4.7 Correlative Results Between Change in Hypothalamic Volume and Change in Cortisol
and Melatonin Output
A significant interaction effect was observed between group (intervention or control) and
change in cortisol output (Table 4.2 and Supplementary Table 4.6). Parameter estimates for
this interaction were used to generate a scatterplot with fitted lines for each group. Visual
inspection revealed a positive slope for the relationship between change in hypothalamus
volume and change in cortisol output in the control group (Figure 4.1B). Associated correlation
coefficients in the control group, computed from parameter estimates extracted from the
relevant areas, were r = -0.73, in the right, and r = -0.57, in the left. A group by cortisol output
change interaction effect on hypothalamus grey matter volume loss was also observed
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bilaterally (right, k = 368, t = 2.54, p = 0.01, MNI = 7 0 -12; left, k = 29, t = 2.11, p = 0.024,
MNI = -9 -8 -4; Figure 4.1B).
A group by melatonin output change interaction effect on grey matter volume loss was
observed in the right hypothalamus when comparing the intervention group to the control group
(Figure 4.1C, Table 4.2 and Supplementary Table S4.6). Parameter estimates revealed the
association between nine-month right hypothalamus grey matter volume loss and change in
evening melatonin output was positive in the intervention group (r = 0.47) and negative in the
control group (r = -0.51).
These results suggest a shift towards a positive association between right hypothalamic grey
matter volume and evening melatonin output in the intervention group. Interestingly, the
location of this particular finding was in the basal hypothalamus, a region that contains the
suprachiasmatic nucleus.
4.5 Discussion
Pathological disturbances in circadian rhythmicity and sleep are debilitating features of HD,
thought to occur primarily due to degeneration within the hypothalamus. To date, no proven
therapies exist to treat circadian rhythm and habitual sleep disturbances in individuals with HD.
Here we show, for the first time, that multidisciplinary rehabilitation significantly attenuates
grey matter volume loss within the hypothalamus, coinciding to a small extent with changes in
cortisol and melatonin and reduced symptoms of daytime somnolence, anxiety and depression
in individuals with premanifest HD.
Studies by our team and others show that individuals with premanifest and prodromal HD have
significantly reduced grey matter volume in the hypothalamus as early as ten years prior to
predicted clinical disease onset (Bartlett et al., 2016; Bartlett et al., 2019 [Chapters 2 and 3];
Soneson et al., 2010). Results from the present study indicate that multidisciplinary
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rehabilitation significantly reduces hypothalamic grey matter volume loss, suggesting that
multidisciplinary rehabilitation may act to preserve the hypothalamus. To the authors’
knowledge, this is the first study to document a significant reduction in grey matter volume
loss in the hypothalamus following multidisciplinary rehabilitation in individuals with HD.
This promising finding builds upon previous work by our team, where multidisciplinary
rehabilitation was found to significantly increase grey matter volume in the caudate and
dorsolateral prefrontal cortex (Cruickshank et al., 2015). Together, these findings provide
compelling evidence that adds to the growing body of preclinical and clinical evidence
suggesting

that

lifestyle

approaches,

particularly

environmental

enrichment

and

multidisciplinary rehabilitation, have neuroprotective effects capable of preserving grey matter
in brain structures vulnerable to neurodegeneration in HD (Lazic et al., 2006; Nithianantharajah
& Hannan, 2006; Spires et al., 2004).
The biological mechanisms mediating the attenuation of hypothalamic volume loss after
multidisciplinary therapy are not known. However, it is possible that preservation of BDNF
levels observed in the intervention group may have contributed. BDNF plays a crucial role in
the protection and plasticity of neurons (Bemelmans et al., 1999). Our results demonstrate that
nine months of multidisciplinary rehabilitation attenuates the loss of serum BDNF
concentrations and this coincides with a reduction in the loss of hypothalamic grey matter
volume. Studies using animal models have shown that BDNF crosses the blood-brain barrier
(Pan, Banks, Fasold, Bluth, & Kastin, 1998; Pan, Banks, & Kastin, 1998; Pan & Kastin, 1999),
however this is yet to be confirmed in humans. This, together with evidence showing that
BDNF is required for neurogenesis (Bekinschtein, Oomen, Saksida, & Bussey, 2011; Rossi et
al., 2006), suggests that maintenance of serum BDNF levels as a result of regular exercise and
cognitive training could contribute to the support and preservation of the hypothalamus
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(reviewed in Bartlett et al., 2016). However, additional research is required to support this
supposition.
Significant attenuation of grey matter volume loss in the hypothalamus following
multidisciplinary rehabilitation was positively associated with changes in cortisol and
melatonin release; however, contrary to our expectations, this was not associated with
improvements in habitual sleep quality following multidisciplinary rehabilitation, as has been
reported in Parkinson’s and Alzheimer’s disease (Nascimento et al., 2014). We did, however,
observe reduced daytime somnolence in the group receiving the multidisciplinary rehabilitation
intervention, which was accompanied by a reduction in anxiety and depression
symptomatology, though it should be noted that affective symptomology in this population was
subthreshold. Given the known role of the hypothalamus in the modulation of sleep (Saper et
al., 2005), we expected attenuation of hypothalamic volume loss to positively coincide with
habitual sleep outcomes. However, accumulating evidence indicates that multiple brain
structures are responsible for regulating the sleep/wake cycle, including the thalamus and locus
coeruleus (Fuller, Gooley, & Saper, 2006; Saper et al., 2005). While beneficial for the
hypothalamus, multidisciplinary rehabilitation may not have widespread positive effects on
other structures necessary for the regulation of circadian rhythm and sleep. Therefore, future
studies should assess the effects of multidisciplinary rehabilitation on other structures
regulating the sleep/wake cycle and perhaps use objective measures to assess the effects of
multidisciplinary rehabilitation on sleep architecture rather than the subjective measures used
here.
A number of limitations are associated with this study. The small sample size and nonrandomised structure of the trial limits the generalisations that can be made to the wider HD
community. Nevertheless, this study provides proof-of-concept data on the neuroprotective
effects of multidisciplinary rehabilitation for the hypothalamus, which can be used to inform
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sample size estimations for future randomised controlled trials. It is also important to note that
this study used sleep questionnaires to evaluate habitual sleep, which are often prone to
subjective bias. Future studies should assess the effects of multidisciplinary rehabilitation on
habitual sleep outcomes, as well as sleep architecture using polysomnography in a laboratory
setting in individuals with premanifest HD.
In summary, this study provides novel, preliminary evidence that multidisciplinary
rehabilitation reduces hypothalamic grey matter volume loss, possibly due to preservation of
basal serum BDNF levels, and decreases daytime somnolence in individuals with premanifest
HD. Larger randomised controlled trials are nevertheless required to confirm these preliminary
findings, as well as further explore the effects of multidisciplinary rehabilitation on circadian
rhythm and habitual sleep outcomes in individuals with premanifest HD.
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4.6 Supplementary Data
MRI Data Pre-Processing
Voxel-based morphometry (Ashburner & Friston, 2000) was performed in SPM12 (v6225,
http://www.fil.ion.ucl.ac.uk/spm) following the same longitudinal VBM spatial pre-processing
protocol as in Eshaghi et al. (2014). First, the pairwise longitudinal registration toolbox was
used to register baseline and follow-up images to a within-subject mid-point average to avoid
asymmetric treatment of time-points. Next, a Jacobian change rate map was generated for each
participant that encodes the contraction or expansion of each voxel between time points. The
Segment routine was then used to extract grey matter, white matter and cerebrospinal fluid
probability maps from each of the mid-point average images (Ashburner & Friston, 2005;
Streitbürger et al., 2014). The resulting grey and white matter maps of all participants were
nonlinearly transformed to a customized template in standard MNI space using a diffeomorphic
registration algorithm [DARTEL; (Ashburner, 2007)]. Following from this, grey matter
Jacobian change images were computed by multiplying the grey matter probability map by the
Jacobian change rate map for each of the participants in native space. Flow fields from the
DARTEL step above were used to normalize the grey matter Jacobian change images to MNI
space with Gaussian smoothing. As the analysis focused on the hypothalamus, the normalised
grey matter images were smoothed with a 6 mm full width at the half maximum (FWHM)
Gaussian kernel, which is more appropriate for small structures (Salmond et al., 2002). No
modulation was applied as this may induce multiplicative noise related to inter-subject
variability of brain shape (Eshaghi et al., 2014). In addition to the grey matter Jacobian change
images, we also generated grey matter Jacobian determinant images for each time point. The
aim of this was to compare the associations between changes in hypothalamus volume and
changes in cortisol, melatonin and sleep measures following the nine-month study period.

103

Statistical Analysis
The continuous covariate interaction model used to assess the differences in associations
between hypothalamic volume and cortisol/melatonin between the intervention and control
groups included group regressors, one for each group, and regressors modelling change in
cortisol or melatonin output, one for each group. Contrasts modelled the interaction between
group and change in cortisol or melatonin output ([0 0 1 -1] and [0 0 -1 1]). Two-sample t-tests
were used to evaluate the statistical significance of these contrasts. Covariates of interest in the
above models (i.e., cortisol and melatonin) were mean centred across both groups. Sex and age
were included as covariates of no interest.
Table S4.4. Demographic and clinical characteristics of premanifest HD and prodromal HD
intervention groups and premanifest HD control group at baseline
Premanifest HD
Intervention
group (n=10)

Prodromal HD
Intervention
Group (n=8)

Premanifest
HD Control
Group (n=11)

pvalue

37.2 ± 8.7

45.5 ± 13.9

50.5 ± 9.5

0.027*

4 (40.0)

2 (25.0)

4 (36.4)

0.790

CAGn, mean ± SD

43.6 ± 2.9

43.8 ± 4.0

41.9 ± 2.0

0.402

DCL, mean ± SD

0.1 ± 0.3

1.4 ± 0.7

0.0 ± 0.0

0.000#†

UHDRS-TMS, mean ± SD

1.3 ± 1.8

15.4 ± 6.9

0.1 ± 0.3

0.000#†

290.35 ± 82.6

333.5 ± 102.7

309.4 ± 61.5

0.545

CAPs, mean ± SD

0.83 ± 0.21

1.00 ± 0.20

0.93 ± 0.13

0.306

BMI, mean ± SD

27.6 ± 3.9

25.4 ± 3.7

25.3 ± 2.0

0.221

Smoker, n (%)

2 (20)

1 (12.5)

1 (9.1)

0.074

High alcohol consumption, n (%)

2 (20)

0 (0)

0 (0)

0.217

Psychotropic medication, n (%)

2 (20)

0 (0)

3 (27.3)

0.287

Demographic Characteristics
Age, mean ± SD
Male, n (%)
Clinical Characteristics

Disease burden score, mean ± SD

Values are significant at p ≤ 0.05.
*Significant differences between premanifest intervention and premanifest control groups
#Significant differences between premanifest intervention and prodromal intervention groups
†Significant differences between prodromal intervention and premanifest control groups
CAGn= cytosine-adenine-guanine repeat number; DCL= diagnostic confidence level; UHDRS-TMS= Unified
Huntington’s Disease Rating Scale- Total Motor Score; CAPs= CAG-age product score; BMI= body mass index.
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Table S4.5. Mean salivary cortisol and melatonin concentrations, subjective sleep outcomes
and affective symptomatology outcomes in premanifest HD intervention and control groups.

BDNF

Premanifest HD Intervention group
(n=10)
Baseline
Follow-Up
26976.62 ±
28694.70 ±
6213.40
4569.96

Prodromal HD Intervention Group
(n=8)
Baseline
Follow-Up
28456.92 ±
26203.61 ±
5716.52
5401.19

Premanifest HD Control group
(n=11)
Baseline
Follow-Up
29384.49 ±
22812.15 ±
6699.71
3486.14*

Cortisol (nmol/L)
Awakening (hh:mm)
6:20 ± 0:58
6:18 ± 0:52
6:12 ± 01:09
6:03 ± 0:54
5:53 ± 0:58
6:43 ± 1:03
Time
of
sample
relative to awakening:
+15 mins
11.28 ± 3.84
9.05 ± 4.17
11.63 ± 4.05
9.26 ± 2.13
11.12 ± 4.68
9.03 ± 2.11
+30 mins
13.41 ± 3.97
11.35 ± 5.08
15.69 ± 4.87
11.90 ± 3.03*
13.69 ± 4.22
10.06 ± 2.13*
+45 mins
13.56 ± 2.81
11.72 ± 3.47*
14.53 ± 3.76
12.61 ± 4.25
14.06 ± 3.14
11.62 ± 2.28*
+60 mins
11.96 ± 2.52
10.38 ± 2.80
13.14 ± 3.67
12.11 ± 4.70
12.73 ± 4.05
9.99 ± 2.53*
*
AUCG
38.59 ± 8.42
32.78 ± 10.46
42.61 ± 11.26
35.20 ± 8.66
39.68 ± 9.46
31.20 ± 5.75*
Melatonin (pg/mL)
Bedtime (hh:mm)
21:50 ± 0:45
22:00 ± 0:43
22:20 ± 0:30
22:07 ± 0:30
22:00 ± 0:57
21:46 ± 0:56
Time
of
sample
relative to bedtime:
-2 hrs
11.76 ± 7.74
6.11 ± 5.38*
15.20 ± 10.57
13.26 ± 19.20
10.65 ± 8.25
6.20 ± 4.37
-1 hr
12.89 ± 4.77
6.54 ± 5.33*
19.63 ± 16.12
12.83 ± 11.30*
11.19 ± 8.29
5.22 ± 3.23*
+0 hrs
20.78 ± 9.51
12.27 ± 6.83*
24.66 ± 17.25
17.24 ± 16.18*
13.50 ± 7.72
6.60 ± 4.18*
*
*
+1 hr
24.48 ± 15.29
13.73 ± 8.68
27.43 ± 19.65
18.32 ± 18.01
14.17 ± 6.93
7.35 ± 4.59*
*
AUCG
51.45 ± 19.57
28.73 ± 15.44
60.53 ± 44.07
45.86 ± 42.97
36.65 ± 21.31
18.64 ± 10.39
CSD
Total time in bed 430.59 ± 57.26
422.50 ± 48.46
415.00 ± 84.63
389.17 ± 45.65
435.15 ± 51.54
497.90 ± 98.54
(min)
Total sleep time 383.83 ± 55.45
379.69 ± 46.27
370.67 ± 73.28
359.17 ± 47.24
390.10 ± 55.55
449.03 ± 65.94
(min)
Sleep onset latency
23.20 ± 26.12
20.75 ± 23.05
18.75 ± 21.67
16.67 ± 16.33
8.85 ± 4.37
10.58 ± 8.37
(min)
Wake after sleep
22.00 ± 28.25
11.91 ± 20.30
25.00 ± 38.47
10.00 ± 14.58
7.65 ± 18.71
6.40 ± 9.51
onset (min)
Number
of
1.72 ± 1.48#
1.31 ± 1.12
1.00 ± 0.95
0.92 ± 0.74
0.60 ± 1.41
1.30 ± 1.70
awakenings
Sleep efficiency (%)
89.48 ± 9.29
90.31 ± 9.20
89.89 ± 9.25
92.64 ± 7.32
90.15 ± 12.50
91.38 ± 9.60
Restorative quality
3.63 ± 0.76
3.70 ± 0.88
3.50 ± 0.84
3.90 ± 0.89
3.70 ± 1.03
4.00 ± 0.78
of sleep
PSQI Global Score
6.00 ± 2.94
5.06 ± 3.15
5.14 ± 2.85
5.57 ± 4.50
5.18 ± 3.13
5.18 ± 2.68
Epworth Sleepiness
5.76 ± 3.31
4.71 ± 3.02*
5.29 ± 3.64
4.14 ± 2.85
4.18 ± 4.21
4.64 ± 2.91
Scale
Perceived
Stress
19.90 ± 7.37
14.60 ± 8.50*
16.14 ± 7.84
16.29 ± 8.62
16.18 ± 4.49
16.18 ± 6.32
Scale
HADS total score
8.90 ± 5.82
6.10 ± 4.41*
9.13 ± 4.97
6.25 ± 3.01
5.55 ± 3.59
6.00 ± 3.87
Anxiety
6.30 ± 3.71
5.20 ± 3.68
6.13 ± 3.09
4.63 ± 2.33
3.73 ± 2.65
4.82 ± 3.19
Depression
2.60 ± 2.72
0.90 ± 0.99*
3.00 ± 2.83
1.63 ± 1.19
1.82 ± 1.66
1.18 ± 1.47
Data are presented as mean ± standard deviation. Baseline differences between groups were assessed using independent t-tests for
parametric and Mann-Whitney U tests for non-parametric data. Within group differences at follow-up were assessed using paired t-tests
for parametric and Wilcoxon Signed Rank tests for non-parametric data. Analysis of covariance (ANCOVA) was used for betweengroup analyses at follow-up. Non-parametric data were log-transformed prior to ANCOVA analysis. Values are significant at p ≤ 0.05.
*
Significant differences compared to baseline values
#
Significant differences compared to premanifest HD control group baseline values
†
Significant differences compared to prodromal HD intervention group baseline values
‡
Significant differences compared to premanifest HD control group follow-up values
⁑
Significant differences compared to prodromal HD intervention group follow-up values
CSD= Consensus Sleep Diary; PSQI= Pittsburgh Sleep Quality Index; HADS= Hospital Anxiety and Depression Scale.
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Table S4.6. Results from voxel-based morphometry analysis.
Peak Voxel
Side

k

T-score

p-value

MNI Coordinates
(mm)
x

y

z

Group Effect
Premanifest HD control vs. premanifest HD
intervention

R

284

2.94

0.004

11

1

-5

Premanifest HD control vs. prodromal HD
intervention

R

266

2.78

0.005

6

1

-4

L

87

1.97

0.030

-8

-5

-4

Premanifest HD control vs. combined
premanifest and prodromal HD intervention

R

321

2.90

0.004

5

2

-7

Premanifest HD control vs. premanifest HD
intervention

R

531

3.65

0.001

7

-5

-9

Premanifest HD control vs. prodromal HD
intervention

R

95

2.59

0.010

6

3

-16

Premanifest HD control vs. combined
premanifest and prodromal HD intervention

R

305

2.47

0.012

6

-4

-10

Premanifest HD control vs. prodromal HD
intervention

R

233

2.31

0.016

8

-2

-15

Premanifest HD control vs. combined
premanifest and prodromal HD intervention

R

86

2.36

0.014

8

-2

-14

Group x Cortisol Interaction Effect

Group x Melatonin Interaction Effect

Results are significant at p < 0.05, uncorrected.
k = No. of voxels; MNI = Montreal Neurological Institute; L = left; R = right.
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5.1 Abstract
Objective: Disturbances in sleep architecture arise early in the course of Huntington’s disease
(HD) and worsen as the disease course lengthens. The aim of this exploratory study was to
determine if multidisciplinary rehabilitation could improve sleep architecture and memory
consolidation in individuals with premanifest HD.
Methods: Sixteen individuals with premanifest HD completed a nine-month multidisciplinary
rehabilitation intervention, consisting of three, two hour sessions per week of cognitive,
exercise and dual-task training with social interaction. Outcome measures included
polysomnography and sleep-dependent memory consolidation.
Results: A significant increase in the percentage of total sleep time spent in rapid eye
movement (REM) sleep, a decrease in the percentage of stage N1 sleep and a decreased time
to reach REM sleep were observed following the nine-month intervention. Significant
increases in total sleep time and total time in bed were also observed and accompanied by a
significantly earlier bed time. No significant differences were observed in memory
consolidation after the intervention, as measured by the delayed recall component on the
Hopkins Verbal Learning Test-Revised.
Conclusion: This exploratory study provides preliminary evidence that multidisciplinary
rehabilitation can improve sleep architecture in individuals with premanifest HD, however
these changes were not associated with improvements in memory consolidation. Large
randomised controlled trials are however required to confirm and expand on these preliminary
findings in individuals with premanifest and manifest HD.
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5.2 Introduction
Sleep disturbances are a well-recognised feature of Huntington’s disease (HD) that present
several years prior to estimated clinical diagnosis and worsen as the disease course lengthens
(Lazar et al., 2015; Morton, 2013). Alterations in sleep architectures are particularly apparent
in individuals prior to clinical disease onset and include an increased number of awakenings, a
reduction in rapid eye movement (REM) and slow wave sleep, decreased sleep efficiency and
insomnia (Arnulf et al., 2008; Lazar et al., 2015; Morton, 2013; Videnovic, Leurgans, Fan,
Jaglin, & Shannon, 2009).
Disturbances in sleep have been proposed to exacerbate cognitive impairments, particularly
memory deficits, in individuals with HD (Lazar et al., 2015; Walker, 2008). Studies indicate
that sleep is integral to memory processing and consolidation (Genzel et al., 2015; Hobson &
Pace-Schott, 2002). Investigations in healthy individuals have reported that, although each
sleep stage is involved in memory consolidation, REM and slow wave sleep are crucial (Louie
& Wilson, 2001; Peigneux et al., 2004; Stickgold, 2005). Treatments aimed at improving or
attenuating sleep disturbances may therefore have a positive impact on memory consolidation
in individuals with HD.
There are currently no proven strategies for treating sleep disturbances in individuals with HD.
Recent evidence indicates that multidisciplinary rehabilitation improves self-reported sleep
quality in individuals with Parkinson’s disease (Frazzitta, Maestri, Ferrazzoli, et al., 2015). The
effects of multidisciplinary rehabilitation on sleep outcomes in HD individuals is yet to be
investigated. However, previous work by our team has shown that multidisciplinary
rehabilitation improves verbal learning memory in manifest HD individuals (Cruickshank et
al., 2015). While tentative, it is plausible that multidisciplinary rehabilitation enhances verbal
learning and memory in individuals with HD by improving sleep quality and architecture.
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The purpose of this exploratory study was twofold. Firstly, this study sought to examine, for
the first time, whether multidisciplinary rehabilitation improves sleep architecture and sleepdependent memory consolidation in individuals with premanifest HD. Secondly, this study
sought to investigate the role of sleep on memory consolidation in individuals with premanifest
HD. It is believed that the implementation of multidisciplinary rehabilitation prior to extensive
neuronal loss (during the premanifest stage) would provide maximum benefit for gene positive
HD individuals.

5.3 Materials and Methods
5.3.1 Study Design
The aim of this exploratory study was to assess the effects of a nine-month multidisciplinary
rehabilitation program on sleep architecture and memory consolidation in individuals with
premanifest HD. Outcome measures included polysomnography and memory consolidation
measures. Ethical approval for study procedures was granted by the Human Research Ethics
Committees at Edith Cowan University (13145), the University of Western Australia and the
North Metropolitan Area Mental Health Service (2009_16). All participants provided written
informed consent.
5.3.2 Participants
A subset of twenty participants from a concurrently running study with confirmed positive HD
gene status, a Unified Huntington’s Disease Rating Scale Total Motor Score (UHDRS-TMS)
of <15 and a diagnostic confidence level of <2, no concomitant neurological or cardiovascular
disease and no shift work were approached to participate.
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5.3.3 Outcome Measures
Polysomnography
Polysomnography was conducted at the Centre for Sleep Science at the University of Western
Australia. Polysomnography set-up included electroencephalography (EEG; C4/M1, C3/M2,
F4/ M1, F3/M2, O1/M2, O2/M1), electrooculography, submental and bilateral anterior tibial
electromyography,

electrocardiography,

pulse

oximetry

and

respiratory

inductive

plethysmography in accordance with the American Academy of Sleep Medicine (AASM)
recommendations. Signals were acquired and displayed using the Grael system
(Compumedics). Sleep stages were scored manually according to the AASM scoring criteria
Version 2.1 (Berry et al., 2012).
Memory Consolidation
The Hopkins Verbal Learning Test (HVLT-R) was used to examine immediate and delayed
recall. Participants were read a list of words on the evening of the sleep study and were asked
to repeat the words in three consecutive trials. Participants were then asked to repeat the same
words the following morning for the delayed recall component of the test. The total number of
words recalled and retained were recorded for each participant using the delayed recall
component and the highest score from the immediate recall component of the test. The HVLTR has previously been shown to be a sensitive and reliable measure of memory in individuals
with premanifest HD (Solomon et al., 2007).
5.3.4 Multidisciplinary Rehabilitation Intervention
Details on the multidisciplinary rehabilitation intervention are described elsewhere (Bartlett et
al., 2018 [Chapter 4]). Briefly, participants completed three, two hour supervised
multidisciplinary rehabilitation sessions, comprising exercise, computerised cognitive training
(NeuroNation, Synaptikon, Germany and Captain’s Log, BrainTrain, USA), dual task training
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and social events, per week for nine months in small groups (3-4 participants per session).
Training sessions were administered by clinical exercise physiologists.
5.3.5 Statistical Analysis
Normality assumptions were tested using a Shapiro-Wilk test. Within-group comparisons were
conducted using paired sample t-tests and Wilcoxon signed-rank tests. A Bonferroni correction
was applied to the data to account for multiple comparisons. Hedge’s g was calculated to
determine effect sizes for each outcome, where a small, medium and large effect size is
considered 0.2, 0.5 and 0.8 respectively. Pearson correlation coefficients were calculated to
assess the potential associations between sleep outcomes and sleep-dependent memory
consolidation outcomes. Results are reported as mean ± standard deviation (unless stated
otherwise) and were considered significant at p<0.05. Statistical analyses were performed
using SPSS version 24 (IBM Corp., Armonk, NY, USA).
5.4 Results
5.4.1 Baseline Demographic and Clinical Characteristics
Four participants withdrew from the study prior to follow-up testing. Therefore, data from
sixteen individuals with premanifest HD were used for analyses. Participant demographics and
clinical characteristics are presented in Table 5.1.
5.4.2 Sleep Measures
Following the intervention, significant improvements were observed in bed time, total time
spent in bed, REM latency and percentage of the total sleep time spent in stage N1 and REM
(Table 5.2). These improvements corresponded to moderate to large effect sizes, suggesting
that nine-months of multidisciplinary rehabilitation can reduce the time taken to reach REM
sleep, as well as increase the percentage of the total sleep time spent in REM sleep. No other
reportable effects were observed in sleep outcomes following the intervention.
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Table 5.1. Demographic and clinical characteristics of premanifest HD participants (n=16)

Demographic Characteristics
Age
Male, n (%)
Clinical Characteristics
CAGn
DBS
CAPs
DCL
UHDRS-TMS
BMI
Smoker, n (%)
High alcohol consumption, n (%)†
Psychotropic medication, n (%)

Baseline

Follow-Up

p-value

Effect
size (g)

40.31 ± 12.29
5 (31.3)

-

-

-

43.69 ± 3.50
302.50 ± 93.53
0.87 ± 0.23
0.69 ± 0.87
7.56 ± 9.09
26.13 ± 3.82
4 (25.0)
2 (12.5)
2 (12.5)

0.75 ± 0.86
6.31 ± 9.24
26.26 ± 2.98
3 (18.8)
-

0.739
0.306
0.501
-

0.069
0.136
0.038
-

Categorical variables were analysed using a chi-squared test. Data was tested for normality using a
Shapiro-Wilk test. Within group differences were analysed using paired t-tests (for parametric data) and
Wilcoxon matched-pairs signed rank tests^ (for non-parametric data). Bonferroni correction was applied
for multiple comparisons. Data are presented as mean ± standard deviation unless otherwise stated.
Values are significant at p ≤ 0.05*.
CAGn= cytosine-adenine-guanine repeat number, DCL= diagnostic confidence level, UHDRS-TMS=
Unified Huntington’s Disease Rating Scale Total Motor Score, DBS= disease burden score, CAPs= CAG
age product score, BMI= body mass index.
†High

alcohol consumption is described as consumption of more than 14 alcoholic beverages per week.

5.4.3 Memory Consolidation (Hopkins Verbal Learning Test)
A large effect size was observed in the total number of words recalled using the HVLT-R
following multidisciplinary rehabilitation. No significant differences were observed however,
in delayed recall or word retention components of the HVLT-R (Table 5.2). Upon assessment
of correlation values between sleep and memory outcomes, significant positive correlations of
moderate strength were observed between the change in sleep efficiency and changes in
delayed recall (d = 0.50, p = 0.049) and retention of words (d = 0.50, p = 0.050), indicating that
an increase in sleep efficiency is moderately associated with a greater propensity to recall
words from memory. However, the lack of significant change in sleep efficiency and delayed
recall or retention of words following the intervention period somewhat limits the conclusions
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that can be drawn from these findings. No other significant correlations were identified
between sleep and memory outcomes.

Table 5.2. Sleep and memory consolidation outcomes following a nine-month
multidisciplinary rehabilitation intervention (n=16).

Polysomnography
Bed time, hh:mm
Time of awakening, hh:mm
Total Sleep Time, min
Total Time in Bed, min
Sleep Efficiency, %
Number of Awakenings
WASO, min
Sleep Latency, min
REM Latency, min
Stage N1 (%)
Stage N2 (%)
Stage N3 (%)
REM (%)
Number of arousals
Arousal Index
Apnoea/Hypopnoea Index
PLM Index, per hour
Sleep-Dependent Memory
Consolidation
HVLT-R Total Recall
HVLT-R Delayed Recall
HVLT-R Retention (%)

Baseline

Follow-Up

p-value

Effect
size (g)

22:38 ± 00:18
06:07 ± 00:41
350.88 ± 63.46
448.81 ± 44.91
77.90 ± 10.34
22.13 ± 8.75
74.81 ± 39.18
21.72 ± 18.04
199.66 ± 77.68
17.35 ± 9.52
46.74 ± 7.32
18.76 ± 7.28
17.16 ± 6.91
108.13 ± 43.21
14.51 ± 5.61
6.70 ± 6.08
2.71 ±4.67

22:01 ± 00:37
06:13 ± 00:26
390.31 ± 65.76
492.56 ± 40.67
79.16 ± 11.48
25.13 ± 8.25
68.22 ± 40.30
26.81 ± 22.95
117.53 ± 44.57
12.75 ± 7.10
44.36 ± 7.94
17.52 ± 4.93
25.38 ± 8.35
128.94 ± 48.61
15.76 ± 6.05
6.30 ± 5.77
4.11 ± 3.92

0.001*
0.356
0.010*
0.001*
0.501
0.129
0.406
0.776
0.004*
0.043*
0.287
0.387
0.002*
0.074
0.304
0.408
0.182

1.315
0.175
0.610
1.021
0.115
0.353
0.166
0.247
1.297
0.548
0.312
0.199
1.073
0.452
0.214
0.067
0.325

24.63 ± 4.88
7.25 ± 2.52
71.40 ± 19.46

27.69 ± 6.04
7.31 ± 4.27
65.48 ± 35.03

0.018*
0.617
0.366

0.557
0.017
0.209

Data was tested for normality using a Shapiro-Wilk test. Within group differences were analysed using
paired t-tests (for parametric data) and Wilcoxon matched-pairs signed rank tests^ (for non-parametric
data). Bonferroni correction was applied for multiple comparisons. Data are presented as mean ± standard
deviation unless otherwise stated. Values are significant at p ≤ 0.05 *.
WASO= wake after sleep onset, REM= rapid eye movement, N1= stage 1 of non-REM sleep, N2= stage
2 of non-REM sleep, N3= stage 3 of non-REM sleep, TST= total sleep time, PLM= periodic limb
movement, HVLT-R= Hopkins Verbal Learning Test- Revised.
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5.5 Discussion
Sleep disturbances are an early feature of HD that worsen as the disease course lengthens
(Lazar et al., 2015; Morton, 2013). Disturbances in sleep are known to impair cognitive
function (Lowe, Safati, & Hall, 2017; Walker, 2008) and have even been purported to hasten
neurodegenerative processes (Musiek & Holtzman, 2016). Despite the disabling consequences
of sleep disturbances, particularly on the cognition of patients, no treatment options have been
developed to alleviate sleep disturbances in individuals with HD. In this exploratory study, we
evaluated the effects of multidisciplinary rehabilitation on sleep quality and architecture and
memory consolidation in individuals with premanifest HD.
Previous studies show that individuals with HD have an increase in REM latency and a
decrease in REM sleep (Arnulf et al., 2008). In the current study, increases in the percentage
of REM sleep and decreases in REM latency were observed following the intervention. To the
authors’ knowledge, this is the first study to find significant improvements in REM sleep in
individuals with premanifest HD after a non-pharmaceutical intervention. Our findings suggest
that multidisciplinary rehabilitation may favourably modulate sleep architecture, which is of
clinical interest, especially considering the known role of sleep in the maintenance of brain
structures and function (Malhotra & Desai, 2010); however, controlled studies are required to
determine the extent to which multidisciplinary rehabilitation may impact on sleep architecture.
REM sleep has been proposed to have functions in the reorganisation of memories (Genzel et
al., 2015). Therefore, it is possible that an improvement in REM sleep could have beneficial
implications for memory consolidation. Cognitive decline, including impairments in learning
and memory, have been reported in individuals with HD (Stout et al., 2012). Previous work by
our team has shown that multidisciplinary rehabilitation improves verbal learning and memory
in individuals with manifest HD. Together with the improvements in REM sleep following
such an intervention in premanifest HD, it was anticipated that memory consolidation outcomes
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would improve following the nine-month intervention. However, contrary to expectation, the
results presented here demonstrate that, although improvements in REM sleep and verbal
learning and memory were observed, these two outcomes were not associated. Furthermore,
no improvements in the delayed recall or retention components of the memory consolidation
tasks were noted. This suggests that the improvements in REM sleep may not be a mediating
factor in the improvement of verbal learning and memory following multidisciplinary
rehabilitation. However, it is important to note that the present study used the delayed recall
and retention components of the HVLT-R to assess memory consolidation after sleep, whereas
previous studies assessing memory consolidation have typically utilised a paired word
association test (Genzel, Dresler, Wehrle, Grözinger, & Steiger, 2009; Mander, Rao, Lu,
Saletin, Lindquist, et al., 2013). While both tests have the capacity to measure memory
consolidation, it is possible that the paired word association test is more sensitive to changes
than the HVLT-R. Nevertheless, larger randomised controlled studies are required to confirm
these preliminary findings and further assess the clinical sensitivity of these tests for assessing
memory consolidation in individuals with HD.
While the results of the study appear promising, a number of limitations exist within this
exploratory study. The small sample size and lack of control group limits the generalisability
of these results to the wider HD population. Additionally, participants spent only one night in
the sleep laboratory, which has been suggested to not be sufficient for acclimatisation, which
is essential for good sleep (Toussaint et al., 1995). While significant changes in sleep timing
occurred following the intervention, it is important to note that changes in sleep timing may
have occurred as a result of laboratory practices (i.e. termination of sleep studies by laboratory
staff) and should therefore be interpreted with caution. Finally, alcohol consumption and
medication use have been reported to impact on sleep architecture, including REM sleep and
REM latency (Garcia & Salloum, 2015). While alcohol consumption and medication use were
116

not measured at follow-up in this study, significance was maintained for REM sleep percentage
and REM latency after removal of individuals that reported high alcohol consumption and
medication use at baseline, indicating that the use of medications and alcohol did not have a
large effect on REM latency and REM sleep percentage. Nevertheless, future studies should
include medication use and alcohol consumption as a confounding factor in studies assessing
sleep.
Despite these methodological shortcomings, this study offers preliminary evidence on the
positive effects of multidisciplinary rehabilitation on sleep architecture and provides impetus
for further studies assessing the effects of multidisciplinary rehabilitation on sleep architecture
and quality and associated effects on clinical outcomes in individuals with HD.
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Chapter 6
6.1 General Discussion
Huntington’s disease (HD) is a rare, autosomal dominant neurodegenerative disease caused by
an expansion in the number of cytosine-adenine-guanine (CAG) repeats in exon one of the
huntingtin gene (The Huntington's Disease Collaborative Research Group, 1993). While the
classic triad of features includes motor, cognitive and mood disturbances, circadian rhythm and
sleep disturbances are becoming increasingly recognised as features of HD that require
treatment (Aziz et al., 2010; Lazar et al., 2015; Morton, 2013; Morton et al., 2005). Recent
evidence suggests that sleep disturbances emerge together with cognitive deficits during the
premanifest stage of HD and worsen as the disease course lengthens (Lazar et al., 2015; Morton
et al., 2005), suggesting that both features are related. This supposition is supported by
preclinical evidence, where disturbances in circadian rhythmicity and sleep/wake activity have
been shown to cause cognitive, metabolic, psychological and cardiovascular consequences
(Briançon-Marjollet et al., 2015; Morton et al., 2005), and have been purported to occur as a
result of hypothalamic pathology. Despite this supposition, only one study to date has examined
the neurobiological underpinnings of sleep disturbances in HD (Baker et al., 2016), using the
sleep component of a depression questionnaire. Understanding the mechanisms that mediate
circadian rhythm and sleep disruption will enable identification of potential avenues for
therapeutic targets. Furthermore, identifying such mechanisms during the premanifest stage of
HD will allow for the implementation of therapies prior to extensive neuronal damage,
potentially leading to greater benefits.
The hypothalamus contains the SCN, which is responsible for generating and regulating the
circadian rhythm. The direct and indirect connections between the SCN and other key
hypothalamic nuclei control the circadian timing of cortisol and melatonin release and the
sleep-wake cycle. The impact of degenerative processes on these nuclei could therefore
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facilitate disintegration of the circadian release of hormones and sleep-wake timing. However,
the implications of hypothalamic degeneration have not yet been extensively studied.
Several studies have reported disintegration of circadian rhythm and sleep parameters in
individuals with premanifest HD compared to healthy controls (Aziz et al., 2010; Aziz, Pijl,
Frölich, Schroder-van der Elst, et al., 2009; Lazar et al., 2015; Morton, 2013; Morton et al.,
2005) and these differences in circadian rhythm and sleep have been purported to be mediated
by hypothalamic pathology as reviewed in Chapter 2 (Bartlett et al., 2016). Despite this
supposition, no studies have attempted to assess the relationship between hypothalamic volume
and biological markers of circadian rhythm and sleep. One study to date has assessed the
relationship between hypothalamic volume and subjective sleep, in individuals with
premanifest and manifest HD (Baker et al., 2016). This study did not report a relationship
between hypothalamic volume and subjective sleep outcomes, however this study used
questions on sleep quality from a depression inventory, highlighting the need for further studies
aimed at assessing the relationship between hypothalamic volume and circadian rhythm and
habitual sleep.
The study conducted as part of this thesis (Chapter 3) suggests that even during the premanifest
stages of HD individuals present with reduced hypothalamic grey matter volume compared to
age- and gender-matched healthy controls. This finding aligns with previous reports of
hypothalamic pathology in individuals with premanifest HD, including reduced grey matter
volume and increased microglial activation in the hypothalamus (Politis et al., 2008; Soneson
et al., 2010). In our study, the nature of this reduced hypothalamic volume was leftward biased.
Interestingly, leftward biased atrophy has also been reported in the striatum in individuals with
HD (Thieben et al., 2002). The exact reason for this is unknown, however studies postulate that
this could merely be due to cumulative lifetime activity (Jenkins et al., 1998; Mühlau et al.,
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2007). It is possible that leftward biased degeneration of the hypothalamus is the first sign of
hypothalamic degeneration in individuals with premanifest HD.
The pathological mechanisms responsible for reduced hypothalamic volume in individuals
with HD are not yet entirely understood. Evidence from post-mortem investigations and studies
in mouse models provides some insight into the pathological mechanisms mediating
hypothalamic changes, as well as the mechanisms by which these changes could impact on
circadian rhythm and habitual sleep outcomes. Neuronal inclusions of mutant huntingtin in
suprachiasmatic nucleus (SCN) tissue at post-mortem (Aziz et al., 2008), may directly mediate
changes in the functioning of the SCN. These neuronal inclusions of mutant huntingtin within
the SCN could result in the reduction in the number of vasoactive intestinal polypeptide and
arginine vasopressin expressing neurons, which are crucial in the regulation of SCN activity
(Aton et al., 2005; Hofman & Swaab, 1994), as well as post-transcriptional changes in these
neuropeptides, which have been reported in HD (van Wamelen et al., 2013). This, together
with the loss of orexin-releasing neurons in the lateral hypothalamus that has been reported in
individuals with HD at post-mortem and in mouse models of HD (Aziz et al., 2008; Petersén
et al., 2005), could result in impaired functioning of the hypothalamic nuclei and lead to the
disruption of the circadian rhythm and sleep-wake cycle, however this supposition needs to be
investigated in greater detail.
Despite observing reduced hypothalamic volume in individuals with premanifest HD, no
differences in circadian regulated hormones were noted (Chapter 3). Morning cortisol and
evening melatonin levels remained similar to those in healthy controls. The reduced
hypothalamic grey matter volume in individuals with premanifest HD, taken together with the
lack of differences in cortisol and melatonin output, suggest that neural compensatory networks
may exist to maintain neuroendocrine output. Alternatively, the lack of differences in cortisol
and melatonin output between individuals with premanifest HD and healthy controls could be
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explained by a sex-dependent loss of circadian rhythmicity in HD. Evidence from mouse
models of HD, which recapitulate the circadian rhythm disturbances observed in individuals
with HD (Kudo et al., 2011; Morton et al., 2005), shows that female HD mice exhibit a delayed
or less severe circadian phenotype compared to male HD mice (Kuljis et al., 2016). As the
cohort presented in Chapter 3 consisted primarily of females (64.4%), it is possible that
circadian deficits were not yet apparent and may manifest later in the disease course. Further
studies are required to examine this tentative speculation.
Although individuals with premanifest HD exhibited habitually reduced sleep efficiency and
increased awakenings compared to healthy controls, no consistent relationships were observed
between habitual sleep outcomes and hypothalamic volume. This was contrary to expectations;
it was anticipated that hypothalamic volume would be associated with sleep outcomes,
particularly as the hypothalamus contains key nuclei that regulate the sleep-wake cycle (Saper
et al., 2005). However, it is important to acknowledge that other brain structures, such as the
thalamus and the locus coeruleus, are also involved in regulating the sleep-wake cycle and
perhaps provide a compensatory role for the hypothalamus when pathologically affected.
Despite intense scientific efforts, the treatment of HD remains symptomatic, with currently
approved medications indicated for the treatment of motor or psychiatric features of the
disease, often with only partial relief (Dominguez & Munoz-Sanjuan, 2014; Mason & Barker,
2016; Pidgeon & Rickards, 2013). While a number of studies have identified potential
therapeutic interventions to treat circadian rhythm and sleep disturbances in other clinical
populations, none have been trialled to date in individuals with HD (Paus et al., 2007; Rutten
et al., 2012; H.-B. Wang et al., 2017). However, evidence from HD mouse models suggests
that treatment of circadian rhythm and sleep disturbances prior to clinical onset of HD could
have beneficial outcomes on other disease features, particularly motor deficits, and could even
delay the progression of the disease (H.-B. Wang et al., 2018; H.-B. Wang et al., 2017). These
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studies suggest that early intervention is crucial to effectively treat circadian rhythm and sleep
disturbances in HD.
Preclinical studies in HD mouse models have shown that behavioural therapy, particularly
bright light therapy and voluntary wheel running, delays the progression of circadian
dysfunction and restores synchronisation of the light-dark cycle in the R6/2 mouse model
(Cuesta et al., 2014). Temporally scheduled feeding and blue light therapy have also been
shown to favourably modulate the circadian rhythm and improve motor features in the Q175
and BACHD mouse models of HD (H.-B. Wang et al., 2018; H.-B. Wang et al., 2017).
Together, this data suggests that the circadian rhythm can be entrained in HD by means of
targeting various zeitgebers, including physical activity, indicating that environmental
interventions could improve circadian rhythm outcomes in HD. Furthermore, multidisciplinary
rehabilitation, an environmental intervention comprising physical and cognitive training, has
been shown to improve sleep outcomes in individuals with Parkinson’s and Alzheimer’s
disease (Nascimento et al., 2014). These findings provide impetus for the investigation of the
therapeutic effects of multidisciplinary rehabilitation as a strategy for treating circadian rhythm
and sleep disturbances in individuals with HD, particularly in those with premanifest HD.
Previous studies conducted by our team have demonstrated that multidisciplinary rehabilitation
can improve brain volume and clinical outcomes in individuals with manifest HD. In particular,
increases in the striatum and dorsolateral prefrontal cortex were observed following a ninemonth multidisciplinary rehabilitation intervention, which coincided with improvements in
verbal learning and memory, strength, fat-free mass, mood and quality of life outcomes
(Cruickshank et al., 2015; Thompson et al., 2013). The data presented in Chapter 4 of this thesis
adds weight to these studies and confirms that multidisciplinary therapy has positive effects on
brain volume. In our more recent study, we provide evidence of significant hypothalamic
degeneration over a nine month period in individuals with premanifest HD. Furthermore, we
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show that following nine-months of multidisciplinary rehabilitation, a reduced loss of
hypothalamic grey matter volume was observed in individuals with premanifest HD
(intervention group) when compared to a cohort of individuals with premanifest HD receiving
standard care (control group). Taken together, this suggests that multidisciplinary rehabilitation
has the potential to maintain, and even improve, grey matter volume in the hypothalamus of
individuals with premanifest HD. Furthermore, preliminary studies show increases in volume
in other brain regions in premanifest HD (Cruickshank et al., submitted 2018) and in manifest
HD (Cruickshank et al., 2015) following multidisciplinary rehabilitation.
Understanding the mechanisms mediating the maintenance or increases in grey matter volume
after multidisciplinary rehabilitation will enable further optimisation of these programs in the
future treatment for individuals with HD. The mechanisms underpinning maintenance or
increases in brain volume following multidisciplinary rehabilitation are yet to be determined.
Studies conducted in mice have demonstrated that brain-derived neurotrophic factor (BDNF)
is essential for neurogenesis following interventions comprising exercise (Bekinschtein et al.,
2011; Rossi et al., 2006). Our results demonstrate that nine months of multidisciplinary
rehabilitation attenuates the loss of serum BDNF concentrations and this coincides with a
reduction in the loss of grey matter volume in the hypothalamus (Chapter 4). BDNF is known
to cross the blood-brain barrier (Pan, Banks, Fasold, et al., 1998; Pan, Banks, & Kastin, 1998;
Pan & Kastin, 1999) in animal models and our observed increases in BDNF in the intervention
group may indicate that BDNF mediated the neuroprotective effects in the present study,
however these findings require confirmation.
In addition to improving brain outcomes, environmental interventions, particularly those
encompassing exercise training, have been shown to regulate the circadian rhythm in animal
models of HD (Cuesta et al., 2014) and improve subjective sleep quality in individuals with
Alzheimer’s disease and Parkinson’s disease (Nascimento et al., 2014). Based on initial studies
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using subjective sleep assessments (Chapter 4), no changes in sleep outcomes were identified
in the intervention group compared to the control group. However, when objective sleep
measures were used to assess sleep outcomes following the intervention, significant differences
were observed in REM latency, the percentage of total sleep time spent in REM and in stage
N1 sleep (Chapter 5). It is possible that individuals have no perceived deterioration in habitual
sleep despite pathological alterations in sleep architecture, a phenomenon which has previously
been reported in individuals with HD (Goodman et., 2011). Therefore, objective assessment of
sleep using polysomnography should be conducted in future studies to provide further insight
into these features in premanifest HD.
Compared to healthy controls, individuals with HD exhibit a decrease in the percentage of total
sleep time spent in REM and an increase in REM latency (Arnulf et al., 2008). In the study
presented in Chapter 5, increases in the percentage of REM sleep and decreases in REM latency
were observed following the intervention period, suggesting that multidisciplinary
rehabilitation can improve sleep outcomes in individuals with premanifest HD. Furthermore,
given that REM sleep has been proposed to be a key mediator of the neuroplasticity associated
with reorganisation of memories (Genzel et al., 2015), it is possible that an increase in REM
could have beneficial implications for memory consolidation. However, the results presented
here demonstrate that, although increases in REM sleep were observed, no improvements in
the delayed recall or retention of words were noted, indicating that the improvements in REM
did not mediate improvements in memory consolidation in this group. It should be noted that
the sample size in this study was relatively small. In addition, the measure used to quantify
memory consolidation in this study may not be sufficiently sensitive to detect small changes.
Larger studies are therefore required, with more robust measures, to comprehensively assess
the effects of increased REM sleep on memory consolidation.
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Although speculative, it is possible that the effects of multidisciplinary rehabilitation on grey
matter volume could be mediated by improved sleep regulation. Recent studies suggest that
prolonged sleep disturbances could exacerbate neurodegenerative processes (Musiek, 2015;
Musiek & Holtzman, 2016). The mechanisms by which sleep disturbances could drive
neurodegenerative processes are yet to be robustly examined, however it has been suggested
that oxidative damage as a result of circadian dysregulation could contribute to
neurodegeneration (Musiek, 2015). Furthermore, while studies are yet to be conducted in
humans regarding the effects of treating sleep disturbances on clinical outcomes, evidence from
animal models suggest that treating sleep disturbances can also have a favourable impact on
clinical features of the disease (Kudo et al., 2011). It is therefore plausible that the
improvements in clinical outcomes observed following multidisciplinary rehabilitation in
individuals with HD could be mediated by improvements in sleep. Further studies are required
to assess this hypothesis in individuals with HD.
There are several limitations to the research presented in this thesis. Firstly, the studies
presented in Chapters 4 and 5 were not randomised. Together with the small sample size, this
limits the generalisability of the studies to the wider HD community. Secondly, the studies
were conducted in individuals with premanifest HD, limiting the translation of the intervention
to other, more severe disease stages. Additional studies in manifest populations are required
for translation to this disease stage. Finally, a washout period was not included, preventing the
assessment of the residual effects of multidisciplinary rehabilitation. Future studies should
include a wash out period to determine the length of duration of the effects of multidisciplinary
rehabilitation in HD.
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6.2 Future Directions
The work presented in this thesis is the first to assess the neurobiological underpinnings of
circadian rhythm and habitual sleep disturbances in premanifest HD. It is also the first to
evaluate the effects of multidisciplinary rehabilitation on circadian rhythm and sleep in
individuals with premanifest HD. Findings from this thesis show that hypothalamic pathology
and sleep disturbances are key features of HD and are remediable to multidisciplinary
rehabilitation. Following multidisciplinary rehabilitation, individuals with premanifest HD had
significant improvements in sleep architecture and attenuated grey matter volume loss in the
hypothalamus. This adds to the growing body of evidence supporting the use of
multidisciplinary rehabilitation as a strategy to improve neurobiological and clinical outcomes
in HD (Cruickshank et al., 2015; Piira et al., 2013; Thompson et al., 2013; Veenhuizen et al.,
2011; Zinzi et al., 2007). Further studies are nevertheless required to build upon this
preliminary data.
Chapter 3 of this thesis details the association between hypothalamic volume and circadian
markers in individuals with premanifest HD. The hypothalamus contains the circadian
pacemaker, the SCN, which is responsible for mediating the circadian rhythm. However, there
are multiple structures that are involved in the release of cortisol and melatonin (Bartlett et al.,
2016; Saper et al., 2005). Future studies should therefore consider imaging other structures
involved in the release of cortisol and melatonin. Furthermore, cortisol and melatonin are
subject to variation due to various environmental factors. The inclusion of additional indicators
of circadian rhythm, such as thermoregulation, heart rate and blood pressure, would provide a
more holistic view of circadian rhythm in premanifest HD (Bellosta Diago et al., 2017;
Cagnacci, Elliott, & Yen, 1992). In addition, while the studies presented in this thesis assessed
melatonin levels around the participants’ usual bedtime, future studies should assess the dim
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light melatonin onset as an additional measure of circadian rhythm changes in individuals with
HD (Pandi-Perumal et al., 2007).
Circadian rhythm and sleep disturbances are common features amongst neurodegenerative
disease and have recently been purported to drive neurodegenerative processes (Musiek, 2015;
Musiek & Holtzman, 2016; Pillai & Leverenz, 2017). Despite this knowledge, the associations
between circadian rhythm and sleep disturbances and brain volume in individuals with HD are
yet to be robustly investigated. Future studies should longitudinally assess the relationship
between circadian rhythm and sleep disturbances and brain volume in individuals with HD.
While improvements were observed in sleep architecture following the nine-month
intervention, future studies should assess the inclusion of bright light therapy into the
multidisciplinary rehabilitation model, with the aim to improve circadian rhythm. Light therapy
has been shown to improve the rest-activity profile in HD mouse models (H.-B. Wang et al.,
2017), sleep, mood and motor symptoms in individuals with Parkinson’s disease (Paus et al.,
2007; Rutten et al., 2012) and sleep-wake cycles in individuals with Alzheimer’s disease
(Ancoli-Israel, Gehrman, et al., 2003; Burns, Allen, Tomenson, Duignan, & Byrne, 2009;
Lyketsos, Lindell Veiel, Baker, & Steele, 1999; McCurry et al., 2011). Bright light therapy has
the potential to improve circadian rhythmicity in individuals with HD and should therefore be
assessed for inclusion into the multidisciplinary rehabilitation model.
Circadian rhythm and sleep disturbances arise early in HD and worsen as the disease course
lengthens. Chapter 5 of this thesis demonstrates that multidisciplinary rehabilitation can
improve sleep architecture in individuals with premanifest HD. Multidisciplinary rehabilitation
has previously been shown to be feasible and beneficial in individuals with manifest HD. It is
plausible that multidisciplinary rehabilitation could improve sleep outcomes in individuals with
manifest HD. Therefore, future studies should assess the effects of multidisciplinary
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rehabilitation on sleep outcomes in individuals with manifest HD. Evidence from HD mouse
models suggests that behavioural interventions, such as restricted feeding and light therapy,
improve circadian rhythm and sleep outcomes, as well as motor outcomes (H.-B. Wang et al.,
2018; H.-B. Wang et al., 2017). However, it is not known if the improvements in circadian
rhythm and sleep mediate the improvements in motor outcomes. Future studies should assess
the relationship between improved sleep as a result of multidisciplinary rehabilitation and
motor outcomes in individuals with manifest HD.
The results presented in this thesis also provide impetus for the evaluation of multidisciplinary
rehabilitation in other neurodegenerative diseases. For example, a recent study by Breen et al
(2016) reported hypothalamic volume loss in individuals with Parkinson’s disease.
Furthermore, individuals with Parkinson’s disease exhibit reduced REM density (Schroeder et
al., 2016). Given that multidisciplinary rehabilitation reduces the loss of hypothalamic volume
and increases REM in individuals with HD, it is plausible that similar effects could be seen in
individuals with Parkinson’s disease.
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6.3 Conclusion
In conclusion, individuals with premanifest HD exhibit reduced hypothalamic volume
compared to healthy controls. Contrary to expectation, hypothalamic volume was not strongly
associated with the output of circadian-regulated hormones, cortisol and melatonin in the
population studied here. However, it is possible that the circadian rhythm is maintained by
compensatory mechanisms, until these mechanisms are overcome, after which circadian
dysregulation ensues.
The research presented in this thesis provides preliminary evidence to suggest that
multidisciplinary rehabilitation can reduce the loss of hypothalamic grey matter volume in
individuals with premanifest HD. The mechanisms underpinning this reduced loss of volume
are yet to be determined, however the reduced loss of hypothalamic volume coincided with
maintenance of BDNF levels. It is plausible that hypothalamic volume is somewhat preserved
by maintenance of BDNF levels in premanifest HD. Furthermore, significant improvements in
sleep architecture, but not in subjective sleep outcomes or circadian release of hormones, were
observed in individuals with premanifest HD following nine months of multidisciplinary
rehabilitation. It is possible that these improvements in sleep architecture also contribute to the
maintenance of grey matter volume observed following multidisciplinary rehabilitation in HD,
but not improvements in memory consolidation. However, these findings need to be confirmed
in a larger cohort of individuals with premanifest HD. Future studies should assess the effects
of multidisciplinary rehabilitation on sleep and circadian rhythm outcomes in a larger,
randomised controlled trial in individuals with premanifest HD.
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Appendix 1: Information Letter and Consent Form for Individuals with HD

HEROs (Huntington’s disease Exercise Rehabilitation
Optimisation study):
The Effects of Multidisciplinary Rehabilitation Therapy on Clinical Measures of
Disease Progression and Quality of Life for Patients with Huntington’s Disease.
PARTICIPANT INFORMATION SHEET
Prof Mel Ziman, Dr Travis Cruickshank, Mrs. Maggie Speirs, Prof Nellie GeorgiouKaristianis, Prof Brian Power, Prof Anthony Hannan, Prof Andrew Churchyard, Dr Wei
Peng Teo, Ms Linda Hoult, Ms Danielle Bartlett, Ms Niamh Mundell, Mr Andrew Govus,
Mr Timothy Pulverenti and Ms Catarina Kordsachia, Prof Peter Eastwood, Dr Juan
Dominguez, Dr Kirk Feindel, Ms Sophia Quick, Dr Alpar Lazar, Dr Amit Lampit
Please take time to read the following information carefully and discuss it with your friends,
family and clinician if you wish. Ask us any question if some part of the information is not clear
to you or if you would like more information. Please do this before you sign this consent form.

Who is funding this study and where will it be conducted?
This study has been supported by a grant from Lotterywest, Huntington’s WA (Inc.) and Edith
Cowan University. This project will be conducted at Edith Cowan University, Monash
University and Deakin University as well as at clinical exercise centres and in participant’s
homes.
Contact persons: Should you have any questions about the study please contact:
Dr Travis Cruickshank, Ph: 6304 3416 Email: t.cruickshank@ecu.edu.au;
Mrs Maggie Speirs, Ph: 9346 7599 Email: maggie@huntingtonswa.org.au;
Prof Mel Ziman, Ph: 63043640 Email: m.ziman@ecu.edu.au
Prof Nellie Georgiou-Karistianis:
karistianis@monash.edu

Phone

9905

1575

Email:

nellie.georgiou-

All study participants will be provided with a copy of the Participant Information Sheet and
Participant Consent Form for their personal records. You may decide to provide or not provide
your consent for the prospective study. Your decision will not lead to any penalty or affect your
regular medical care or any benefit to which you are entitled.
What is the purpose of this study?
The purpose of this study is to examine the clinical utility of multidisciplinary therapy
compared to standard care in HD gene positive individuals. This is a pilot study. The study will
involve allocation to a multidisciplinary therapy (Perth) or standard care group (Melbourne).
The multidisciplinary therapy program encompasses cognitive, psychological, physical and
social exercises aimed at slowing disease progression, enhancing neural stimulation, functional
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independence and quality of life. Participants allocated to the multidisciplinary therapy group
will be required to commit to a four hour program of multidisciplinary therapy every week for
12 months. The therapy will be delivered as a three times weekly supervised therapy at a
clinical exercise centre. The researchers aim to advance multidisciplinary therapy for
individuals with Huntington’s disease in collaboration with teams locally, nationally and
internationally.
Why was I selected to take part in this study?
This study is suitable for individuals diagnosed as gene positive (either presymptomatic or
symptomatic) for Huntington’s disease.
Do I have to participate?
There is no obligation and or requirement to participate in this study. Declining to participate
in this research project will not influence your regular medical treatment in any way.
What will happen if I decide to participate in this research project?
Prior to commencement of the study you will be required to sign a consent form.
As a participant you will be asked to participate in two assessment periods, one at baseline and
one after 12 months. We will organise a suitable time and place for your assessments. At these
periods you will be assessed using neurological (Unified Huntington’s Disease Rating Scale
Total Motor Score (UHDRS-TMS)), physical, cognitive, psychological, physiological and
quality of life assessments. The neurological assessment (UHDRS) will be performed to ensure
that participants fulfil the inclusions criteria. The results of this neurological examination will
not be disclosed to participants and will only be used for research purposes. You will be asked
to undergo magnetic resonance imaging (MRI) to assess brain volume and Dual Energy X-Ray
Absorptiometry (DEXA) scans to assess body composition. You will also be asked to provide
saliva, hair and a small 36 ml blood sample for acute and chronic assessment of biological
measures.
Physical methods of assessment will include fine and gross motor movements, your balance
and walking and your strength. Maximum physical capacity will be examined using reliable
and clinically valid measurements.
Cognitive methods of assessment will involve a variety of tests that measure your problem
solving capability and your memory and emotional recognition. Psychological assessments
will be used to assess your anxiety and depression levels. Physiological methods of assessment
will measure your body composition, your sleep, your body temperature control, exercise
capacity, and your brain volume by MRI.
The results of these assessments will not be disclosed to participants and will only be used for
research purposes.
After baseline assessment, individuals who decide to participate will undertake a
multidisciplinary therapy intervention (Perth) or maintain their standard care (Melbourne). The
multidisciplinary therapy intervention will require you to participate in both physical and
mental exercises every week for 12 months. Supervised multidisciplinary therapy (physical
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and mental) will require you to attend a specific clinical gym for 60-90 minutes three times a
week.
Participant attendance at gym sessions will be monitored by clinical exercise specialists.
After 12 months you will be required to once again undertake a neurological examination
(UHDRS), as well as physical, cognitive, psychological and physiological assessments as
indicate above.
There may be a video recording of one of your clinical assessments and you will be informed
of this so you can provide your consent for this to take place.
What are the costs to me?
Travel costs and time taken to perform the assessments and multidisciplinary therapy
intervention are the only costs involved in the prospective study.
What are the potential benefits associated with participating in this study?
The proposed multidisciplinary therapy may exert positive therapeutic changes in physical,
cognitive, social, psychological and/or physiological functioning. If successful, the research
program may be routinely implemented for individuals with Huntington’s disease worldwide.
What are the potential disadvantages and or risks of taking part in this study?
Please read carefully the following sections for MRI, DEXA (dual energy x-ray
absorptiometry) scan, maximum physical capacity and donation of a blood sample for more
detailed information. There are time commitments and travel commitments associated with
the study.
What information do I need to know about having an MRI scan?
As a participant you will be required to have an MRI scan. MRI stands for magnetic resonance
imaging. An MRI scanner is a machine that can take clear pictures of the inside of the body.
The machine uses an electric field and a strong magnet to produce electromagnetic radiation
and radio waves which are not harmful. The pictures taken by the machine are called MRI
scans. Prior to the scanning two healthy volunteers will undergo scans to ensure the safety and
reliability of the MRI procedures. The machine uses an electric field and a strong magnet to
produce electromagnetic radiation and radio waves which are not harmful. The pictures taken
by the machine are called MRI scans. The scan will take 20 for one scan or up to 60 minutes
for three different kinds of scans and you will be informed at the time we make your
appointment whether you are required for one or three scans. There is no special preparation
and you can eat and drink as normal before the scan and you can take your normal medications.
We will ask you to lie on a table and this will be moved backwards into the MRI scanner. The
scanner will record information about your brain. It is very important that you keep very still
during the scanning. When you lie on the table, we will make sure you are as comfortable as
possible. The scanner makes loud tapping noises and we can give you some earphones to reduce
the noise.
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Some people (approximately 3-5%) experience symptoms of claustrophobia in the scanner. If
you experience discomfort at any time during the scan, you will be able to alert staff by pressing
on a call button provided to you.
Because a large magnet is used we will ask you if you have any metal implanted in your body,
such as a pacemaker or metal pins and to remove any metal items such as watches, jewellery,
hairpins, dentures etc.
Very occasionally (in approximately 2% of cases), the images of normal participants may show
anatomical abnormalities. It may be necessary to do further tests to establish whether an
abnormality is truly present. Some findings may have no negative implications for your health,
and are called incidental. However, in about 1% of scans, the imaging abnormality may
represent a risk to your health, and is called an adverse finding. In many cases, there are
effective treatments available for adverse findings, but sometimes there are adverse findings
for which no effective treatment is currently available.
Before your scan, you will be asked to indicate whether you wish to be informed about (i) all
incidental findings; or (ii) only those adverse findings that would usually lead directly to
treatment. You will also be asked whether you would like any incidental and/or adverse
findings to be discussed with you by your usual General Practitioner (GP), another doctor of
your choice, or by the MBI radiologist. You are entitled to be informed of the results of the
scan but we understand that you may not wish to receive the report yourself.
You may consent to copies of the report being released to the research team, and/or to a doctor
of your choice. Further investigation and treatment of adverse findings is unable to be funded
by Monash Biomedical Imaging or by the researchers conducting the study. Knowledge of an
incidental finding may also have implications for your private health insurance.
We will use these brain scans to compare your brain volume before and after the intervention
which will increase our understanding of how the intervention affects your mental and physical
symptoms of Huntington’s disease.
What information do I need to know about performing tests of my maximum physical
capacity?
In order for us to test your maximal physical capacity, you will be asked to complete an
incremental exercise test on a cycle ergometer until self-perceived exhaustion. The test will
begin at an easy workload of 60-80 watts and thereon increase after every minute by 20 watts
until self-perceived exhaustion. During the test you will be required to wear a mouthpiece that
is attached to a gas analyser. This analyser measures gas exchange and how much oxygen you
consume. Your heart rate will also be measured using a wireless strap around your chest. In
addition, changes in haemoglobin concentration will be measured non-invasively in the front
part of your brain using near infrared resonance spectroscopy. Finally, blood lactate will be
measured before and after the test using a Lactate Pro 2.
You will also be asked to perform 3 maximal isometric foot extensions against a rigid foot
platform on an isokinetic dynamometer. During the maximal isometric foot extensions your
muscle activity will be assessed using non-invasive electrodes placed on the front and back of
your lower limbs.
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These maximal physical assessments will enable us to measure:
•

Gas exchange using a mouthpiece connected to a gas analyser

•

Blood lactate levels before and after exercise using the Lactate Pro 2

•

Haemoglobin concentration changes in the front part of your head
Muscle activity using non-invasive electrodes placed on your lower limbs



What are the potential risks? Will you experience any discomfort or inconvenience?
• Pain and discomfort from shaving, abrading and cleaning with alcohol before applying the
electrodes.
• During the incremental cycling performance test there is a rare chance (1 in 100000) of
cardiovascular complications. However, if the ECG test, or the test by your GP, or medical
questionnaires shows any potential risks against maximal exercise, you will be excluded from
this testing procedure.
• Maximal muscle contractions during the strength measurement may lead to muscle soreness
directly after or in the days that follow the test.
What information do I need to know about having a DEXA scan?
As a participant in this project you will be required to have a DEXA scan which takes
approximately 15 minutes to determine your body composition, such as your bone density and
muscle mass.
The DEXA scan will expose you to a very small amount of radiation. As part of everyday
living, everyone is exposed to naturally occurring background radiation and receives a dose of
about 2 millisieverts (mSv) each year. The effective dose from this research project is about
0.001 mSv/year. At this dose level, no harmful effects of radiation have been demonstrated,
as any effect is too small to measure. Therefore, the risk from radiation as a result of this
project is believed to be minimal.
However, it is important for the researchers to know if you have received any other doses of
ionising radiation during your medical care as cumulative doses may be harmful.
What information do I need to know about giving a blood sample?
Some possible disadvantages and risks associated with blood testing include bruising, bleeding,
fainting, dizziness, haematoma, and infection. We need to ask you to provide a sample of
blood for this research project as we would like to measure genetic sequences that may be
associated with disease progression or your ability to respond to multidisciplinary therapy. We
would also like to measure the levels of biological markers in your blood sample such as
hormones and antioxidants.
Your blood and DNA sample will not have your name on it. It will be stored in a locked freezer
in a secure research facility, and will only be accessed by staff connected to this study.
Your genetic and biochemical material and de-identified information will not be released for
other uses without your prior consent, unless required by law.
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With your consent your de-identified genetic and biochemical sample may be used for future
research projects looking at multidisciplinary therapy and / or Huntington’s disease. Your
samples will be kept for a maximum of seven years after completion of this project. If however
you decline to allow us to use your DNA and biochemical samples for future research we will
destroy them seven years after the completion of this research.
A small portion of your blood sample (sufficient for a genetic test) may be transferred to
Monash University for genetic testing and we will keep a portion here in Perth to assess other
gene sequences. Although we cannot be directly responsible for the samples once they have
left our facility, Monash University has confirmed with us that your samples will not be sold
or shared with anyone else.
In addition, your sample will not be utilised for any genetic test other than stated above or for
any test that determines the health risk of your family and will not be disclosed to insurance or
employment companies.
What information do I need to know about having polysomnography sleep assessment?
Stress and sleep disturbances have been reported in premanifest HD individuals and these
factors have been shown to impact on brain function and even reduce volume of certain brain
structures. As these factors can be manipulated through an individual’s environment, it is likely
that multidisciplinary therapy will regulate stress and sleep patterns in these individuals.
In order to assess changes in stress outcomes and sleep quality in premanifest HD individuals
as a result of the multidisciplinary therapy intervention, we will require the participants to
provide morning and evening saliva samples via passively drooling into a tube and a 36mL
blood sample in the morning as well as providing 20 strands of hair. These measures will
provide a biological indication of changes in stress and sleep hormonal patterns.
The participants will also be required to complete short questionnaires regarding self-perceived
stress levels, as well as questionnaires detailing their sleep patterns and perception of daytime
sleepiness in order to assess clinically relevant outcomes of the intervention on stress and sleep
patterns.
Finally, to further analyse the effects of the intervention on sleep patterns, participants will be
asked to undertake polysomnography, the gold standard measure of sleep architecture and
quality. This will be accompanied by the use of actigraphy wrist monitors to observe sleep
patterns of participants in their own homes to avoid any confounding effects of sleeping in a
new environment.
Polysomnography studies will require the participant to stay overnight in a sleep clinic facility.
The UWA Centre for Sleep Science is a specialised research facility with 5 separate bedrooms.
Each participant will have their own bedroom. The rooms are all air-conditioned and have
temperature control. Participants are encouraged to bring their own pillow and anything they
would prefer to sleep with (apart from a bed partner). It is advised that participants wear
pyjamas of loose, light fabric- something that is comfortable to sleep in. Participants will arrive
at 7pm and will go about their normal evening routine before going to bed around their usual
bedtime. In order to measure breathing patterns, heart rate, oxygen levels and brain activity
during sleep, wires and electrodes will need to be attached to the body and then connected to a
computer. These are to measure and record electric impulses generated by your body; the
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electrodes themselves do not create any electricity. These electrodes are required for:
electroencephalography (EEG, which measures brain activity), electromyography (EMG,
which measures skeletal muscle movement), electrocardiography (ECG, which measures heart
rhythm) and electrooculography (EOG, which measures eye movements).
A sleep technician will ensure the following are attached:











Six electrodes and wires attached to the scalp using medical paste (easily removed in
the morning upon having a shower)
One stick-on electrode behind each ear, one next to each eye, three under the chin and
two on the upper chest
A band around the chest and another around the abdomen to measure breathing
Tape on one finger to measure oxygen saturation
A soft wire and tubing under the nose and an airflow sensor to measure breathing
Two electrodes on each leg to record movement
A microphone to record sound
Two activity monitors- one around the wrist and one soft belt around the hips to record
movement
A video camera to record movements whilst asleep (turned on once you are settled and
it is dark. This is an infra-red camera and does not record details)
All of these leads will be connected to one box that can be easily unhooked and taken
with you, should you want to get up during the night

This set up process takes approximately 45 minutes. A sleep technician will be in the office
next door to your bedroom all night and you will be able to communicate with this technician
through an intercom system next to your bed. Although most people think it will be difficult to
fall asleep in a different place whilst being hooked up to machines, generally, almost everyone
falls asleep relatively quickly. The following morning you will be given the results of your
sleep patterns and sleep quality.
These techniques are required to assess participants for sleep abnormalities. All these measures
will be repeated both before and after the intervention and will provide a holistic insight into
any changes in stress and sleep patterns of these individuals following the intervention.

What happens when the research study stops?
Your regular medical treatment will continue as normal. We will advise you of the general
study outcomes by newsletter, websites and public seminar. We also intend to publish our
results in medical research journals and present them at research conferences locally, nationally
and internationally. We may also provide general information to participating individuals if
they wish to receive it. Please note that your name or any other identifying information will not
be included in any of the publications or presentations.
What will happen to my data, blood sample and DNA samples?
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Your biological samples will be stored in locked freezers in secure laboratories for a maximum
of seven years after the end of the project. These samples will be permanently destroyed by
chemical and heat treatments.
Your data will be stored on password protected computers for a maximum of seven years then
the data will be permanently destroyed.
Will my taking part in this research project be kept confidential?
If it is relevant you will be asked to provide consent for researchers to access your clinical
information for use in this study. The information that we wish to access, is your CAG
(cytosine, adenine guanine – DNA) repeat number, UHDRS (United Huntington’s Disease
Rating Scale) score, your disease duration and your age at diagnosis.
The clinical information along with your study data will be available to the researchers only
and will be securely stored in ECU locked filing cabinets for analysis. Electronic and recorded
data obtained will be transferred onto ECU computers and stored on password protected hard
drives. All data will be entered into a solitary excel database where it will be encrypted and
only available to individuals working on this project. All data obtained from you will be deidentified for use in publications.
Researchers / clinicians will be monitoring changes in physical and mental health as a result of
the disease or multidisciplinary therapy. Changes which indicate that the participant’s safety
is at risk will be reported to their treating physician or the Neurosciences Unit so that
appropriate treatment can be provided.
What if I would like extra information or independent advice about participation in
research?
The contact details for the project staff, Huntington’s WA staff, Edith Cowan University
(ECU), Monash University and North Metropolitan Health Service Mental Health (NMHS
MH) review bodies are included at the end of this information sheet.
What if new information regarding multidisciplinary therapy becomes available
throughout the study?
Sometimes during the course of a research project, new information becomes available about
the treatment that is being studied. If this happens, we will tell you about it and discuss with
you whether you want to continue in the research project. If you decide to withdraw your
regular health care will continue.
What if I decide to no longer participate?
You may withdraw from the study at any time without prejudice and do not need to provide a
reason. There will be no changes to your routine medical treatment.
What will happen to the results upon conclusion of the study?
The results of the study will be written in medical and scientific literature and presented at
research seminars and forums. If you so desire, you may be given a report of your personal
results.
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Who has reviewed the study?
Approval to conduct this research has been provided by the Human Research Ethics
Committees of Edith Cowan University (ECU), Monash University, Deakin University and the
North Metropolitan Mental Health Service Research Ethics and Governance Office (NHMS
MH REGO) in accordance with their ethics review and approval procedures. Any person
considering participation in this research project, or agreeing to participate, may raise any
questions or issues with the researchers at any time.
If you have any questions or require further information about the research, please contact:
Mrs Maggie Speirs: 9346 7599 Email maggie@huntingtonswa.org.au
Dr Travis Cruickshank: Phone 6304 3416 Email t.cruickshank@ecu.edu.au
Prof Mel Ziman: Phone 6304 3640 Email m.ziman@ecu.edu.au
Prof Nellie Georgiou-Karistianis:
karistianis@monash.edu

Phone

9905

1575

Email:

nellie.georgiou-

In addition, any person not satisfied with the response of researchers may raise ethics issues or
concerns, and may make any complaints about this research project by contacting either the
Human Research Ethics Office at ECU on (08) 6304 2170 or research.ethics@ecu.edu.au.
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HEROS (HUNTINGTON’S DISEASE EXERCISE
REHABILITATION OPTIMISATION STUDY):
PARTICIPANT CONSENT FORM
1. I (the participant) have read the information above and any questions I have asked have
been answered to my satisfaction. I understand that my participation is voluntary and that
I may withdraw at any time without penalty or affect to my regular medical care.
2. I understand that the information I provide will be kept in the strictest confidence by the
researchers, unless obliged to release this information by law.
3. I understand that the study involves the following procedures:
a. I will be asked to attend gym sessions three times per week
b. I may be asked to give a blood, saliva and hair sample for biochemical analysis.
c. I will be asked to perform a variety of non-invasive neurological (UHDRS), physical,
cognitive and psychological tests and to answer questionnaires and I understand that
some of the tests may be video-recorded for analysis purposes.
d. I agree to my carer or partner participating in this research project by completing
questionnaires about my health status, and give permission for them to do so
e. I understand that I may be asked to undertake an MRI brain scan and / or a DEXA scan.
f. I understand I may be required to undertake an overnight stay at a sleep clinic and wear
an actigraphy bracelet to measure sleep quality.
g. I understand that I will be required to undertake a maximal aerobic and strength test. I
understand that my skin will be prepared to record muscle activity throughout the
strength test. I understand that my heart rate, gas exchange, blood lactate and
haemoglobin concentration changes will be measured throughout the aerobic test.
h. I understand that the maximal strength measurements and cycling exercises may lead
to muscle soreness if I am unaccustomed to the mode and intensity of the exercise
performed.
4. I agree the research data gathered for this study may be published provided my name and
any other identifying information is not used

Y

Y

5. I agree to allow this project to access my CAG (cytosine, adenine guanine – DNA) repeat
number, and where relevant my UHDRS (United Huntington’s Disease Rating Scale) score,
disease duration and my age at diagnosis which is held in my case notes at the
Neurosciences Unit.

Y

6. I agree that data gathered as part of this study can be used in future research projects that
have approval from the appropriate Institutional Ethics Committees, as long as my name or
any other identifying information is not made available to these projects.

Y

7. I confirm that I do not suffer from any neurological condition other than HD, or any
physical or mental condition that would affect my ability to participate in this study and I
provide permission for the researchers to contact my treating physician or the
Neurosciences Unit to arrange appropriate treatment if they identify any physical or mental
health concerns before or during the study.

166

Y

8. I wish to be informed about
Y

a. all incidental findings; or
b.

only those adverse findings that would usually lead directly to treatment.

Y

9. Would you like any incidental and/or adverse findings to be discussed with
a. your usual General Practitioner,

Y

b. another doctor of your choice,

Y

c. or by the radiologist.

Y

10. Are you currently participating in any other research project?

Name of Participant (please print) ______________________________________________
Signed _________________________________Date __________________
Phone _____________
Investigator (Name, please print) ________________________________________________
Signed _________________________________ Date _______________________________
Approval to conduct this research has been provided by the Human Research Ethics
Committees of Edith Cowan University (ECU) and the North Metropolitan Mental Health
Service Research Ethics and Governance Office (NHMS MH REGO) in accordance with their
ethics review and approval procedures. Any person considering participation in this research
project, or agreeing to participate, may raise any questions or issues with the researchers at any
time.
Any questions concerning the project entitled “HEROs: The effects of Multidisciplinary
Therapy on clinical measures of disease progression and quality of life for patients with
Huntington’s disease” can be directed to:
Prof Mel Ziman; Phone: 6304 3640, Email: m.ziman@ecu.edu.au;
Linda Hoult; Phone: 6304 3401, Email: l.hoult@ecu.edu.au
Dr Travis Cruickshank; Phone: 6304 3416, Email: t.cruickshank@ecu.edu.au
Huntington’s WA: Maggie Speirs; Phone: 9346 7599, Email: maggie@huntingtonswa.org.au
In addition, any person not satisfied with the response of researchers may raise ethics issues or
concerns, and may make any complaints about this research project by contacting either the
Human Research Ethics Office at ECU on (08) 6304 2170 or research.ethics@ecu.edu.au or
The NMHS MH REGO Executive Officer on (08) 9347 6502 or
NMAHSMHREGO@health.wa.gov.au.
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Appendix 2: Information Letter and Consent Form for Healthy Controls

HEROs (Huntington’s disease Exercise Rehabilitation
Optimisation study):
The effects of multidisciplinary rehabilitation therapy on clinical measures of disease
progression and quality of life for patients with Huntington’s disease.
PARTICIPANT INFORMATION SHEET
Prof Mel Ziman, Dr Travis Cruickshank, Ms Linda Hoult, Ms Danielle Bartlett, Mr
Andrew Govus, Mr Timothy Pulverenti, Mr Tim Ball
Please take time to read the following information carefully and discuss it with your friends,
family and clinician if you wish. Ask us any question if some part of the information is not
clear to you or if you would like more information. Please do this before you sign this consent
form.
Who is funding this study and where will it be conducted?
This study has been supported by a grant from Lotterywest, Huntington’s WA (Inc.) and Edith
Cowan University. This project will be conducted at Edith Cowan University and at participant
homes.
Contact persons:
Prof Mel Ziman, Ph: 6304 3640, Email: m.ziman@ecu.edu.au
Dr Travis Cruickshank, Ph: 6304 3416, Email: t.cruickshank@ecu.edu.au
Ms Linda Hoult, Ph: 6304 3401, Email: l.hoult@ecu.edu.au
Ms Danielle Bartlett, Ph: 6304 3568, Email: d.bartlett@ecu.edu.au
All study participants will be provided with a copy of the Participant Information Sheet and
Participant Consent Form for their personal records. You may decide to provide or not provide
your consent for the prospective study. Your decision will not lead to any penalty or affect your
regular medical care or any benefit to which you are entitled.
What is the purpose of the study?
The purpose of this study is to assess healthy individuals using physical, cognitive and
biological measures. The data collected from these measures will be used to validate measures
in people with Huntington’s Disease (HD).
Why was I selected for this study?
This study is suitable for healthy individuals. Participation will assist in the validation of novel
motor, cognitive and biological measures for use in HD studies.
Do I have to participate?
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There is no obligation and or requirement to participate in this study. Declining to participate
in this research project will not influence your health or your regular medical treatment in any
way.

What will happen if I decide to participate in this research study?
Prior to the commencement of the study you will be required to sign a consent form.
As a participant you will be asked to perform assessments that assess your physical function,
exercise capacity, cognition and sleep quality. You will also be asked to provide a small hair
sample for biochemical analyses. All results are for the research project only and not for clinical
assessment.
Physical measures include fine and gross motor assessments. Balance, walking and strength
measures will also be used. Exercise capacity will be measured using a measure of selfperceived maximal exertion in a specialised exercise physiology lab. Cognitive methods of
assessments will involve a variety of tests that measure your problem solving capacity and
ability to recognise and perceive visual and auditory emotions. Your quality of sleep will also
be examined using actigraph wrist monitors and validated sleep questionnaires.
All assessments will be administered by trained specialists. The results of these assessments
will not be disclosed to individuals not involved with the research study and will only be used
for research purposes.
What are the costs to me?
Travel costs and time taken to perform the assessments are all that is involved.
What are the potential benefits associated with participating in this study?
The results of this study could be of interest to you, your family, acting clinicians and the HD
community at large. The findings of this study could lead to more specialised diagnostic and
prognostic assessment tools leading to more effective treatments for individuals suffering with
HD.
What are the potential disadvantages and or risks of taking part in this study?
Please read carefully the following sections for maximum physical capacity for more detailed
information. There are time commitments and travel commitments associated with the study.
Importantly, your hair and exercise data will be deidentified (not have your name on it), thereby
maintaining your privacy. This information will not be released for other uses without your
prior consent, unless required by law.

What information do I need to know about performing tests of my maximum physical
capacity?
In order for us to test your maximal physical capacity, you will be asked to complete an incremental
exercise test on a cycle ergometer until self-perceived exhaustion. The test will begin at an easy
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workload of 60-80 watts and thereon increase after every minute by 20 watts until self-perceived
exhaustion. During the test you will be required to wear a mouthpiece that is attached to a gas analyser.
This analyser measures gas exchange and how much oxygen you consume. Your heart rate will also be
measured using a wireless strap around your chest. In addition, changes in haemoglobin concentration
will be measured non-invasively in the front part of your brain using near infrared resonance
spectroscopy. Finally, blood lactate will be measured before and after the test using a Lactate Pro 2.
You will also be asked to perform 3 maximal isometric foot extensions against a rigid foot platform on
an isokinetic dynamometer. During the maximal isometric foot extensions your muscle activity will be
assessed using non-invasive electrodes placed on the front and back of your lower limbs.
These maximal physical assessments will enable us to measure:
•

Gas exchange using a mouthpiece connected to a gas analyser

•

Blood lactate levels before and after exercise using the Lactate Pro 2

•

Haemoglobin concentration changes in the front part of your head



Muscle activity using non-invasive electrodes placed on your lower limbs

What are the potential risks? Will you experience any discomfort or inconvenience?
• Pain and discomfort from shaving, abrading and cleaning with alcohol before applying the electrodes.
• During the incremental cycling performance test there is a rare chance (1 in 100000) of cardiovascular
complications. However, if the ECG test, or the test by your GP, or medical questionnaires shows any
potential risks against maximal exercise, you will be excluded from this testing procedure.

• Maximal muscle contractions during the strength measurement may lead to muscle soreness
directly after or in the days that follow the test.

What happens when the research study stops?
We will advise you of the general study outcomes by newsletter, websites and public seminar.
We also intend to publish our results in medical research journals and present them at research
conferences locally, nationally and internationally. We may also provide general information
to participating individuals if they wish to receive it. Please note that your name or any other
identifying information will not be included in any of the publications or presentations.
What will happen to my data and biochemical samples?
Your biological samples will be stored in locked freezers in secure laboratories for a maximum
of seven years after the end of the project. These samples will be permanently destroyed by
chemical and heat treatments.
Your data will be stored on password protected computers for a maximum of seven years then
the data will be permanently destroyed.
Will taking part in this research project be kept confidential?
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Your information along with your study data will be available to the researchers only and will
be securely stored in ECU locked filing cabinets for analysis. Electronic and recorded data
obtained will be transferred onto ECU computers and stored on password protected hard drives.
All data will be entered into a solitary excel database where it will be encrypted and only
available to individuals working on this project. All data obtained from you will be deidentified for use in publications.
What if I would like extra information or independent advice about participation in
research?
The contact details for the project staff and Edith Cowan University are included at the end of
this information sheet.
What if I decide to no longer participate?
You may withdraw from the study at any time without prejudice and do not need to provide a
reason.
What will happen to the results upon conclusion of the study?
The results of the study will be written in medical and scientific literature and presented at
research seminars and forums. If you so desire, you may be given a report of your personal
results.
Who has reviewed the study?
Approval to conduct this research has been provided by the Edith Cowan University (ECU)
Human Research Ethics Committee. Any person considering participation in this research
project, or agreeing to participate, may raise any questions or issues with the researchers at any
time.
If you have any questions or require further information about the research, please contact:
Dr Travis Cruickshank; Phone: 6304 3416, Email: t.cruickshank@ecu.edu.au
Prof Mel Ziman; Phone: 6304 3640, Email: m.ziman@ecu.edu.au
Ms Linda Hoult; Phone: 6304 3401, Email: l.hoult@ecu.edu.au
Ms Danielle Bartlett; Phone: 6304 3568, Email: d.bartlett@ecu.edu.au
In addition, any person not satisfied with the response of researchers may raise ethics issues or
concerns, and may make any complaints about this research project by contacting either the
Human Research Ethics Office at ECU on (08) 6304 2170 or research.ethics@ecu.edu.au.
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HEROS (HUNTINGTON’S DISEASE EXERCISE
REHABILITATION OPTIMISATION STUDY):
HEALTHY CONTROL PARTICIPANT CONSENT
FORM
11. I (the participant) have read the information above and any questions I have asked have
been answered to my satisfaction. I understand that my participation is voluntary and that
I may withdraw at any time without penalty.
12. I understand that the information I provide will be kept in the strictest confidence by the
researchers, unless obliged to release this information by law.
13. I understand that the study involves the following procedures:
i. I will be required to give hair samples for biochemical analysis.
j. I will be asked to perform a variety of non-invasive physical and cognitive tests and to
answer questionnaires
k. I will be asked to wear an actigraph monitor and complete questionnaires to monitor
sleep quality.
a. I will be required to undertake a maximal aerobic and strength test. I understand that
my skin will be prepared to record muscle activity throughout the strength test. I
understand that my heart rate, gas exchange, blood lactate and haemoglobin
concentration changes will be measured throughout the aerobic test.
b. I understand that the maximal strength measurements and cycling exercises may lead
to muscle soreness if I am unaccustomed to the mode and intensity of the exercise
performed.

Y

14. I agree the research data gathered for this study may be published provided my name and
any other identifying information is not used.

Y

15. I agree that data gathered as part of this study can be used in future research projects that
have approval from the appropriate Institutional Ethics Committees, as long as my name
or any other identifying information is not made available to these projects.

Y

16. I confirm that I do not suffer from any neurological condition or any physical or mental
condition that would affect my ability to participate in this study.

Y

17. I wish to be informed about
a. all incidental findings; or

Y

b.

Y

only those adverse findings that would usually lead directly to treatment.
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18. Would you like any incidental and/or adverse findings to be discussed with
a. your usual General Practitioner,

Y

b. another doctor of your choice,

Y

c. or by the radiologist.

Y

19. Are you currently participating in any other research project?
Name of Participant (please print) _______________________________________________
Signed _________________________________Date __________________
Phone _____________

Investigator (Name, please print) ________________________________________________
Signed __________________________________Date ___________________

Approval to conduct this research has been provided by the of Edith Cowan University (ECU)
Human Research Ethics Committee. Any person considering participation in this research
project, or agreeing to participate, may raise any questions or issues with the researchers at any
time.
Any questions concerning the project entitled “HEROs: The effects of Multidisciplinary
Therapy on clinical measures of disease progression and quality of life for patients with
Huntington’s disease” can be directed to:
Prof Mel Ziman, Phone: 6304 3640, Email: m.ziman@ecu.edu.au ;
Dr Travis Cruickshank, Phone: 63043416, Email: t.cruickshank@ecu.edu.au ;
Ms Linda Hoult, Phone: 6304 3401, Email: l.hoult@ecu.edu.au
Ms Danielle Bartlett, Phone: 6304 3568, Email: d.bartlett@ecu.edu.au
In addition, any person not satisfied with the response of researchers may raise ethics issues or
concerns, and may make any complaints about this research project by contacting either the
Human Research Ethics Office at ECU on (08) 6304 2170 or research.ethics@ecu.edu.au.
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Appendix 3: Salivary Sampling Instructions for Participants
Information for Participants- Biological Sampling and Questionnaires
Thank you for agreeing to provide us with biological samples for the HEROs 2.0 research
project. In this sample collection package, you will find:







2 x saliva sampling packs, each containing 4 red-capped tubes, 4 blue-capped tubes, 8
straws and 8 labels for tubes
1 x set of detailed instructions describing how to collect your saliva samples (below)
1 x set of picture instructions for providing saliva samples
1 x biological specimen storage bag to store your samples in before placing them in the
freezer
2 x saliva collection questionnaires to note down the time you went to bed, the time you
woke up and the time you provided your samples
1 x set of questionnaires to fill out at various stages of sampling (containing the
Perceived Stress Scale, the Epworth Sleepiness Scale, the Pittsburgh Sleep Quality
Index and the Consensus Sleep Diary)

Travis and Danielle will make an appointment to come to your home to carry out cognitive
testing. This will occur in the morning on two days that are suitable for you. During this time,
Danielle will also take 4 tubes of blood and pick up your saliva samples that you would have
already collected.
The night before our visit, we ask that you begin taking your night-time saliva samples. IT IS
ESSENTIAL THAT NIGHT TIME SALIVA SAMPLES ARE TAKEN IN DIM-LIGHT
CONDITIONS. PLEASE WEAR YOUR SUNGLASSES DURING NIGHT TIME
SALIVA SAMPLE COLLECTION BEGINNING FROM THE FIRST SAMPLE AND
FOR THE REMAINDER OF THE THREE HOUR SAMPLE COLLECTION PERIOD
AND REFRAIN FROM HAVING ANY LIGHTS ON DURING THIS TIME. LIGHT
WILL RESET THE RELEASE OF THE SLEEP HORMONE MELATONIN AND
WILL NOT PROVIDE AN ACCURATE INDICATION OF MELATONIN LEVELS.
PLEASE DO NOT FALL ASLEEP DURING THIS TIME AS THIS WILL AFFECT
HORMONE LEVELS. You may watch TV during this sampling period, provided you wear
your sunglasses and reduce the brightness of your TV using the settings menu.
The following morning, you will provide your morning saliva samples. You should also fill
out the Consensus Sleep Diary, Perceived Stress Scale, Pittsburgh Sleep Quality Index and
Epworth Sleepiness Scale. After you have provided your morning saliva samples, it is
recommended that you have something to eat and drink prior to your blood being taken. Each
of these processes will be repeated again on a second day. This ensures that the samples we
take are reliable. On this second day, we will also require a hair sample (20 strands).
The exact times of saliva collection and colour of the tube caps are critical for analysis of the
saliva samples. The blue-capped tubes will be for morning saliva and the red-capped tubes
for saliva before bed-time. It is important that we collect saliva in these tubes so that they can
be analysed appropriately. So, blue= morning and red= night-time.
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We ask that you collect your saliva in the tubes by drooling into them using the straws provided,
then label the tubes with the time and date the samples were collected and your full name
and then store them in your freezer in the biological sample bag provided until we come to
collect them.

Before providing your saliva sample, it is essential that you:







Avoid alcohol 12 hours prior to, and during, saliva sample collection
Do not brush your teeth before, and during, saliva sample collection
Avoid smoking within the hour leading up to, and during, sample collection
Do not eat or drink (except water) 60 minutes prior to providing a saliva sample and
during sample collection
If you need water, please ensure that it is consumed no less than 10 minutes before
collecting each of your saliva samples to avoid diluting the sample
Avoid strenuous exercise in the day leading up to and during sample collection

Day one of saliva sample collection:
The evening before our visit
Prior to going to bed, please drool into the red-capped tubes at the times indicated below
(again, please ensure you are wearing your sunglasses from the start of your sample collection
and during the remainder of the three hour sample collection period and that you refrain from
turning on any lights during this time):









2 hours before your normal bed time
1 hour before your normal bed time
At your normal bed time
1 hour after your normal bed time (we have to ask that you stay up an hour past your
usual bed time for this sample)
Please set an alarm for each of these time points to ensure the samples are taken at the
correct time
PLEASE REMAIN AWAKE DURING THIS TIME. You may watch TV, however
please ensure you wear your sunglasses and reduce the brightness of your TV using the
settings menu
Ensure all tubes are labelled with your full name, the time and the date and please fill
out the Saliva Sample Collection Questionnaire
Please ensure all tubes are placed in the freezer

On the morning of our visit
After you wake up, please drool into the blue-capped tubes at the following times:





15 minutes after awakening
30 minutes after awakening
45 minutes after awakening
60 minutes after awakening
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Please set an alarm for each of these time points to ensure the samples are taken at the
correct time
Ensure all tubes are labelled with your full name, the time and the date and please fill
out the Saliva Sample Collection Questionnaire
Please ensure all tubes are placed in the freezer

Whilst you are waiting between saliva sample collections in the morning, please fill out the
following questionnaires:
1.
2.
3.
4.

The Perceived Stress Scale
The Pittsburgh Sleep Quality Index
The Epworth Sleepiness Scale
The Consensus Sleep Diary

Travis and Danielle will schedule, in advance, a time to come to your house that same morning.
At this visit, Danielle will also take 36ml (4 tubes) of blood and 20 strands of hair and pick
up the saliva tubes. These samples will provide invaluable information regarding the benefits
of the intervention.
Day 2 of saliva sample collection:
This will be a repeat of the first day of saliva sampling. There will be no need to fill out the
Perceived Stress Scale, Epworth Sleepiness Survey or Pittsburgh Sleep Quality Index on the
second day. You will, however, need to fill out the Consensus Sleep Diary and the Saliva
Collection Questionnaire on the second day.
The evening before our visit
Prior to going to bed, please drool into the red-capped tubes at the times indicated below:








2 hours before your normal bed time
1 hour before your normal bed time
At your normal bed time
1 hour after your normal bed time (we have to ask that you stay up an hour past your
usual bed time for this sample)
Please set an alarm for each of these time points to ensure the samples are taken at the
correct time
Ensure all tubes are labelled with your full name, the time and the date and please fill
out the Saliva Sample Collection Questionnaire
Please ensure all tubes are placed in the freezer

Again, please ensure you are wearing your sunglasses from the start of your sample collection
and during the remainder of the three-hour sample collection period and that you refrain from
turning on any lights or falling asleep during this time. You may watch TV, however please
be sure to wear your sunglasses and reduce the brightness of your TV using the settings menu.
On the morning of our visit
After you wake up, please drool into the blue-capped tubes at the following times:




15 minutes after awakening
30 minutes after awakening
45 minutes after awakening
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60 minutes after awakening
Please set an alarm for each of these time points to ensure the samples are taken at the
correct time
Ensure all tubes are labelled with your full name, the time and the date and placed in
the freezer, and please fill out the Saliva Sample Collection Questionnaire

Whilst you are waiting between saliva sample collections in the morning, please fill out the
Consensus Sleep Diary questionnaire. Travis and Danielle will schedule, in advance, a time
to come to your house that same morning. At this visit, Danielle will also take 36ml (4 tubes)
of blood.
What happens if you forget/miss a sample?
We will send you a reminder text message/phone call the evening before our visit to remind
you to begin your sampling two hours before your bedtime. If you miss a sample, please DO
NOT provide a “make up” sample. Timing is essential in the analysis of these samples. If
you do miss a sample, we will send out more saliva collection tubes and we will ask you to
repeat the sampling on another day.

If you require further information, please contact Danielle Bartlett by email at
d.bartlett@ecu.edu.au or by phone on 6304 3568 or 0448 524 696.
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Appendix 4: Saliva Sampling Questionnaire
Saliva Sample Collection Questionnaire- Day 1
This questionnaire is designed to provide us with as much information as possible about the
saliva samples you are providing us so that we can analyse them in the appropriate manner.
Please be completely honest when completing this survey.
Please fill out directly after providing your night-time saliva samples:
1. What is your usual bedtime (UBT)? _______________________
2. What time did you provide your first saliva sample (2hrs before UBT)? _______ pm
3. What time did you provide your second saliva sample (1hr before UBT)? ______ pm
4. What time did you provide your third saliva sample (at UBT)? ______ pm
5. What time did you provide your fourth saliva sample (1 hr after UBT)? ______ pm
6. Did you wear your sunglasses during the three hour period of night time saliva
collection? Yes/No
7. Did you avoid turning on any lights during the three hour period of night time saliva
collection? Yes/No
8. How long before the first sample did you eat food? _________ hours
9. Did you avoid smoking in the hour leading up to the first sample collection, as well as
during the three hour sample collection period? (if non-smoker, please indicate)
_______ hours
10. Did you have a drink of any sort within the 10 minutes prior to each sample collected?
Yes/No

Please fill out directly after providing your morning saliva samples:
1. What time did you wake up this morning? _______ am
2. What time did you provide your first saliva sample (15 mins after waking)? _____ am
3. What time did you provide your second saliva sample (30 mins after waking)? ___am
4. What time did you provide your third saliva sample (45 mins after waking)? ____ am
5. What time did you provide your fourth saliva sample (60 mins after waking)? ___ am
6. Did you have a drink of any sort within the 10 minutes prior to each sample collected?
_____________________________________________________________________
7. Did you avoid brushing your teeth during morning saliva sample collection? Yes/No
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8. Did you avoid smoking during morning sample collection? (if non-smoker, leave
blank) ______________________
9. Have you participated in regular physical activity over the past month? Yes/No
If yes,
a. How many days per week?
_______________________________________________________________
b. What exercise did you mostly do?
_______________________________________________________________
c. How long did you participate in physical activity (at any one time)?
___ hrs ___mins
d. At what intensity?

10. Have you participated in physical activity this week? Yes/No
If yes,
a. How many days this week?
_______________________________________________________________
b. What exercise did you mostly do?
_______________________________________________________________
c. How long did you participate in physical activity (at any one time)?
___ hrs ___mins
d. At what intensity?

11. Did you participate in any physical activity yesterday? Yes/No
If yes,
a. What exercise did you mostly do?
_______________________________________________________________
b. How long did you participate in physical activity (at any one time)?
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___ hrs ___mins
c. At what intensity?

Thank you for taking the time to complete this questionnaire. If you have any queries, please
contact Danielle Bartlett by email at d.bartlett@ecu.edu.au or by phone on 6304 3568 or 0448
524 696.
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Saliva Sample Collection Questionnaire- Day 2
This questionnaire is designed to provide us with as much information as possible about the
saliva samples you are providing us so that we can analyse them in the appropriate manner.
Please be completely honest when completing this survey.
Please fill out directly after providing your night-time saliva samples:
11. What is your usual bedtime (UBT)? _______________________
12. What time did you provide your first saliva sample (2hrs before UBT)? _______ pm
13. What time did you provide your second saliva sample (1hr before UBT)? ______ pm
14. What time did you provide your third saliva sample (at UBT)? ______ pm
15. What time did you provide your fourth saliva sample (1 hr after UBT)? ______ pm
16. Did you wear your sunglasses during the three hour period of night time saliva
collection? Yes/No
17. Did you avoid turning on any lights during the three hour period of night time saliva
collection? Yes/No
18. How long before the first sample did you eat food? _________ hours
19. Did you avoid smoking in the hour leading up to the first sample collection, as well as
during the three hour sample collection period? (if non-smoker, please indicate)
_______ hours
20. Did you have a drink of any sort within the 10 minutes prior to each sample collected?
Yes/No

Please fill out directly after providing your morning saliva samples:
12. What time did you wake up this morning? _______ am
13. What time did you provide your first saliva sample (15 mins after waking)? _____ am
14. What time did you provide your second saliva sample (30 mins after waking)? ___am
15. What time did you provide your third saliva sample (45 mins after waking)? ____ am
16. What time did you provide your fourth saliva sample (60 mins after waking)? ___ am
17. Did you have a drink of any sort within the 10 minutes prior to each sample collected?
_____________________________________________________________________
18. Did you avoid brushing your teeth during morning saliva sample collection? Yes/No
19. Did you avoid smoking during morning sample collection? (if non-smoker, leave
blank) ______________________
20. Have you participated in regular physical activity over the past month? Yes/No
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If yes,
a. How many days per week?
_______________________________________________________________
b. What exercise did you mostly do?
_______________________________________________________________
c. How long did you participate in physical activity (at any one time)?
___ hrs ___mins
d. At what intensity?

21. Have you participated in physical activity this week? Yes/No
If yes,
a. How many days this week?
_______________________________________________________________
b. What exercise did you mostly do?
_______________________________________________________________
c. How long did you participate in physical activity (at any one time)?
___ hrs ___mins
d. At what intensity?

22. Did you participate in any physical activity yesterday? Yes/No
If yes,
a. What exercise did you mostly do?
_______________________________________________________________
b. How long did you participate in physical activity (at any one time)?
___ hrs ___mins
c. At what intensity?
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Thank you for taking the time to complete this questionnaire. If you have any queries, please
contact Danielle Bartlett by email at d.bartlett@ecu.edu.au or by phone on 6304 3568 or 0448
524 696.
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